

Proposed Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis (CAG-00413N)

Decision Summary

Given the totality of the currently available evidence, we propose that CMS not issue a national coverage determination at this time for Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis (CAG-00413N).

In order to maintain an open and transparent process, we are seeking comments on our proposal that no national coverage determination is appropriate at this time. We will respond to public comments in a final decision memorandum, consistent with the spirit of §1862(l)(3).

[Back to Top](#)

Proposed Decision Memo

TO: Administrative File: CAG # 00413N Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis

FROM: Louis B. Jacques, MD
Director, Coverage and Analysis Group

Tamara Syrek Jensen, JD
Deputy Director, Coverage and Analysis Group

James Rollins, MD, PhD
Division Director

Kimberly Long
Lead Analyst

Elizabeth Koller, MD
Lead Medical Officer

Proposed Decision Memorandum for CAG # 00413N

SUBJECT: Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis

[DATE]

DATE:

I. Proposed Decision

Given the totality of the currently available evidence, we propose that CMS not issue a national coverage determination at this time for Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis (CAG-00413N).

In order to maintain an open and transparent process, we are seeking comments on our proposal that no national coverage determination is appropriate at this time. We will respond to public comments in a final decision memorandum, consistent with the spirit of §1862(l)(3).

II. Background

In this section, we describe the technological developments that gave rise to recombinant erythropoietin and related erythrocyte stimulating agents (ESAs). We then describe the physiologic role of the kidneys, pathology of renal disease, and the demographics of renal disease. This is followed by a description of the types of anemia found in renal disease. Finally we describe how anemia management has changed over time. For purposes of this discussion, therapy for a medical condition includes treatment for the signs and symptoms of the underlying condition. Though we have tried to simplify the discussion for the lay reader, the topic is scientifically complex and we believe that an overly simplistic treatment would ultimately be detrimental to the understanding of our review. We caution the reader that the term “inulin” refers to a polysaccharide used to measure kidney function and should not be misread as the term “insulin.”

ERYTHROPOIETIN IN RENAL DISEASE

A. Biochemical Background

Erythropoietin is a 34-kDa glycoprotein hormone produced primarily, but not exclusively, in the kidney and to a lesser extent in the liver. (Miyake 1977) The native protein is a 193 amino acid peptide sequence from which a 27 amino acid peptide leader sequence is removed from the N-terminus. An arginyl residue at the carboxyl terminus also appears to be cleaved during post-translation processing. The mature protein consists of a 165 amino acid backbone with 2 disulfide bonds, three N-linked carbohydrate chains, and one O-linked carbohydrate chain. The major side chains, sialated tetra-antennary saccharides, contribute to *in vivo* stability. (Faults 1989)

As indicated above, production of this hormone is controlled via a feedback loop. (Bauer 1898, Erslev 1980) Anemia and/or hypoxia result in decreased oxygen tension at the tissue level. Via intermediate signaling, perhaps with hydrogen peroxide (H₂O₂) and hypoxia inducible factors (HIF), cells increase transcription of the erythropoietin gene and subsequent production of the processed protein hormone. Basal physiologic levels range from approximately 6 to 32 U/L. (Van Dyke 1961) Serum levels of the hormone may transiently increase by a thousand-fold.

Erythropoietin has multiple actions. (Bahlmann 2004, Rossert 2005) Its classic actions are well understood. Erythropoietin regulates erythrocyte production by stimulating progenitor cell proliferation and differentiation in the bone marrow. (Ingley 2004) It also decreases erythrocyte apoptosis (cell death). (Polenakovic 1996, Ratajczak 2001, Schwartz 1992) Less well understood are the roles erythropoietin may play either directly or indirectly in angiogenesis (blood vessel formation), e.g., wounds and the female reproductive tract (Haroon 2003, Yasuda 1998, Zvezdaryk 2007) and the increase in thrombogenic properties of vascular endothelium. (Fruste 2002) Even less well understood are the proliferative effects it has on other tissues such as the bone marrow (stroma parenchyma) and tumors. (Lai 2005, Shiozawa 2010)

Erythropoietin activity is mediated through the classic erythropoietin receptor and perhaps non-classic receptor(s). (Sawada 1987) Binding of the erythropoietin receptor by erythropoietin results in phosphorylation of Jak2 (Janus kinase 2), which in turn activates other intracellular pathways STAT (signal transducer and activator of transcription), PI₃K–Akt (phosphatidylinositol-3/Akt), and Ras/MAP (mitogen-activated protein) kinase. (Arcasoy 2005, Pfeifer 2008, Ratajczak 2001, Yamazaki 2004) The expression of erythropoietin receptors on erythroid progenitor cells is well known. (D'Andrea 1989, Jones 1990, Winkelman 1990) Less well appreciated is the presence of erythropoietin-binding receptors on other tissues including cardiac myocytes, macrophages, neurons, vascular endothelial cells (Anagnostou 1994, Digicaylioglu 1995, Haroon 2003, Masuda 1993, Wright 2004), and cancers/cancer cell lines (bone sarcoma, breast, cervical, colon, gastric, head-neck [squamous cell], hepatoblastoma, melanoma, ovarian, pediatric, renal, retinal, and uterine (Acs 2001, 2002, 2003, Arcasoy 2003, 2005, Batra 2003, Ribatti 2003, Selzer 2000, Westenfelder 2000, Yasuda 2001).

Several forms of recombinant human erythropoietin have been developed (Table 1). (Jelkmann 2010, NKF Position Paper 1989, OTA 1990, Schellekens 2009) They differ in their carbohydrate structure. The most common species are erythropoietin-alpha and beta. The pharmacokinetic half-life of these products is six to eight hours after IV injection (Halstenson 1991). Because the pharmacodynamic response on the bone marrow is prolonged, dosing regimens vary from three times weekly to once weekly. Dosing via the intravenous route may require ~ 10-25% more drug for the same hematologic effect compared to subcutaneous administration. (Besarab 1992, Kaufman 1998, Paganini 1995) The erythropoietin molecule has been modified by the addition of 2 N-linked carbohydrate chains to form darbepoietin. The additional sialic acid residues decrease pharmacokinetic clearance by the body and permit weekly and semi-weekly dosing. (Egrie 2001, MacDougall 1999)

More recently, the erythropoietin molecule has been modified by the addition of a methoxy-poly-ethylene glycol polymer chain (pegylation) via a succinimidyl butanoic acid linker (MacDougall 2005). These changes further decrease pharmacokinetic clearance by the body and permit weekly and even monthly dosing. (MacDougall 2005) Although the molecular modifications decrease the affinity of the compound for the erythropoietin receptor *in vitro*, the increased residence time results in increased exposure of the compound to the erythropoietin receptor and increased erythropoietin-type activity *in vivo*. (Agoram 2008, El-Komy 2011, MacDougall 2003-abstract, 2005)

Molecules that activate the erythropoietin receptor or downstream pathways are under development. (Bugelski 2008 A and B, Johnson 1998, MacDougall 2008, Perez-Ruixo 2009, Sathyanarayana 2009, Sytkowski 1998, 1999, Wrighton 1996, 1997; Patents including #5,767,078, #5,773,569, #5,830,851, and #5,986,047 and patent applications including #20100249032.) These may be fusion proteins, erythropoietin dimers, truncated erythropoietin molecules, mimetic antibodies, or other small molecular entities. Others, such as GATA, may activate the receptor itself along with other hemoglobin synthesis genes. (Chiba 1991, Gregory 1999) Still others may activate/inactivate related pathways involving hypoxia-inducible transcription factor or hematopoietic cell phosphatase. (Bernhardt 2007, Del Vecchio 2010, Liu 2007) Phase III studies (Emerald 1 and 2, Pearl 1 and 2) have been conducted with peginesatide (formerly hematide), a pegylated peptidic erythropoiesis stimulating agent. (Affymax Analyst Day Handout 12/12/2010, Macdougall 2008, 2009, Stead 2006, Woodburn 2010)

Table 1: Erythrocyte Stimulating Agents

Compound	Drug Names	Manufacturer	Production Site	Supplier	Distribution Sites
Erythropoietin- α	Epogen	Amgen	USA	Amgen	USA
Erythropoietin- α	Procrit	Amgen	USA	Ortho Biotech	USA
Erythropoietin- α (citrate buffer)	Erykine-cancer Epopit-kidney	Intas	India	-	-
Erythropoietin- α (w/o serum albumin)	Eporex Epypo Epopen Epoxitin Globuren	J&J subsidiary (Ortho Biologics)	Puerto Rico	Cilag Janssen	Europe, Canada (Some of these no longer distributed)
Erythropoietin- α	Abseamed		-	-	-

Compound	Drug Names	Manufacturer	Production Site	Supplier	Distribution Sites
Otherwise unspecified	Binocrit HEXAL	Rentschler Biotechnologie GmbH			
Erythropoietin- α Otherwise unspecified	Wepox	Wockhardt-India.	-	-	-
Erythropoietin- β	(Neo)Recormon	Roche	Germany	Roche	Europe Recormon no longer marketed
Erythropoietin- β	Erantin	-	-	Boehringer Mannheim (Spain), Roche (Spain)	Discontinued or no longer marketed
Erythropoietin- β	Epoch	Chugai	Japan	-	Under development
Erythropoietin- β	Betapoeitin	CinnaGen Zahravi	-	-	-
Erythropoietin- δ	Dynepo	Aventis Transkaryotic Therapies	-	Shire	Europe (not yet launched)

Compound	Drug Names	Manufacturer	Production Site	Supplier	Distribution Sites
In human cell lines	Gene Activated Erythropoietin				Patent issues
Erythropoietin- Ω	Epomax Hemax Hemax-Eritron	Baxter	-	Cryopharma (Mexico) Lek (Czech) Sidus (Argentina) Bio Sidus (Thailand) Biosintetica (Brazil)	Countries outside USA
Erythropoietin- Ω	Hemax EPOMAX HP-Epo	Elanex with Hindustan Antibiotics	-	-	-
Erythropoietin- ζ	Retacrit Silapo	Norbitec GmbH BIOCEUTICALS Arzneimittel AG	Germany?	Hospira STADA	European Union Germany
Erythropoietin-Unspecified	Ceriton	Ranbaxy	India	-	-
Erythropoietin-Unspecified	Epofer-cancer	Emcure	India	-	-

Compound	Drug Names	Manufacturer	Production Site	Supplier	Distribution Sites
	Vintor-kidney				
Erythropoietin-Unspecified	Epotin	Gulf /Julphar	UAE	-	-
Erythropoietin-Unspecified	Espogen	LG Life Sciences (India)	Korea	LG Life Sciences	Asia, Africa, Middle East
Erythropoietin-Unspecified	ReliPoietin	Reliance Life Sciences with Reliance Gene-Medix Plc	Ireland India	-	-
Erythropoietin-Unspecified	Shanpoietin	Shantha (Sanofi-Aventis)	India	Shantha	India Developing Countries
Erythropoietin-Unspecified	Zyrop	Zydus Cadila	India	-	-
Modified erythropoietin- α Darbepoietin	Aranesp	Amgen	USA	Amgen	USA, Europe
Modified erythropoietin- α	Nespo	Amgen	-	Dompé Biotec S.p.A.	Europe

Compound	Drug Names	Manufacturer	Production Site	Supplier	Distribution Sites
Darbepoietin					
Modified Erythropoietin- β	Mircera	Roche	-	Roche	USA, Europe
Continuous Erythropoietin Receptor Activator (Pegylation)					(patent issues affect distribution)

? = possibly
 Recommended starting doses of erythropoietin (50 U/kg) result in serum erythropoietin levels that are supraphysiologic for many hours to days (Figure 1). (Brockmoller 1992) The supraphysiologic exposure (area-under-the-curve above) is greater in patients dosed via the intravenous route than via the subcutaneous route (Figure 1). (Brockmoller 1992) The supraphysiologic exposure is greater with higher dosing (Figure 2). (McMahon 1989) There are similar findings with the starting dose of darbepoetin (0.45 mcg/kg) and pegylated erythropoietin (0.6 mcg/kg) although the residence time is longer and the peak serum levels occur later with subcutaneous dosing. (Allon 2002, FDA darbepoietin review-pharmacokinetic section, FDA pegylated erythropoietin review-pharmacokinetic section, Locatelli 2007)

Figure 1: Serum levels of erythropoietin after a single dose 50 U/kg by route of administration (Brockmoller 1992)
 Panel A Intravenous Dose Panel B Subcutaneous Dose

Figure 2: Serum levels of erythropoietin after a 300 U/kg intravenous dose on days 1 and 10 (McMahon 1989)

Basal physiologic levels of erythropoietin range from approximately 6 to 32 U/L.

B. Disease Summary

The kidneys are responsible for multiple aspects of physiologic homeostasis. They do this by maintaining acid-base balance, maintaining electrolyte balance, regulating whole body water content, filtering water soluble toxins, retaining/preventing the loss of re-usable biochemical entities, e.g., glucose and proteins including albumin, activating vitamin D to facilitate calcium absorption, and mitigating hypoxia. Renal disease may impair these functions.

Kidney damage may manifest itself with urinary protein loss, abnormal urinary sediment with casts and/or blood cell elements (erythrocyte or leukocytes), or structural changes present on medical imaging (scarring, size reduction, and/or cystic changes) even before decreased glomerular filtration is detected. (Levey 2009) In Stage 1 disease, the glomerular filtration rate (GFR) is normal or increased (≥ 90 mL/min/1.73 m²), but there are other chronic pathologic findings of damage. In Stage 2 disease, the glomerular filtration rate is minimally decreased (60-89 mL/min/1.73 m²) and there are other chronic pathologic findings of damage. In Stages 3 and 4, the glomerular filtration rates are minimally decreased to 30-59 mL/min/1.73 m² and 15-29 mL/min/1.73 m². In Stage 5 disease, the glomerular filtration rate is less than 15 mL/min/1.73 m² and/or dialysis is required for management of electrolytes, fluids, and/or uremic toxins. (For claims purposes, further distinction is made in patients with endstage renal disease via the ICD-9 codes: Stage 5 585.5 for those with a GFR less than 15 ml/min/1.73 m² and not on dialysis and Stage 6 585.6 for those on chronic dialysis.)

Symptoms, primarily attributable to uremia, reduced fluid clearance, urinary protein loss, and secondary hypertension may present when glomerular filtration is below 30 mL/min/1.73 m² and become more noticeable with further declines in renal function. Symptoms include alterations in sleep patterns, anorexia, bruising, chest discomfort, dysgeusia (abnormal taste), dyspnea, edema, fatigue, gastrointestinal bleeding, itching, impaired cognitive function, insomnia, muscle cramps, nausea, and changes in micturition patterns. With the progression of renal disease, patients may lose physical function and independence. Cross-sectional Medicare claims data reveal that use of assistive devices for walking (canes, walkers, wheelchairs) is 16.9% in the pre-dialysis chronic kidney disease population and 32.5% in the incident dialysis population. (USRDS 2008, 2009) The data also reveal that a walking disability (abnormal gait, difficulty walking, fall history) is present in 19.2% of incident dialysis patients and that 40.1% of incident dialysis patients go onto develop a new walking disability during the first year on dialysis. (USRDS 2008, 2009)

Chronic kidney disease (pre-dialysis and end-stage renal disease requiring dialysis) has become more common in the U.S over time. Cross-sectional laboratory data (persistent microalbuminuria [> 30 mg/g creatinine] and calculated glomerular filtration derived from serum creatinine values and the Modification of Diet in Renal Disease equation) from National Health and Nutrition Examination Surveys (NHANES) II (1988-1994) and III (1999-2004) revealed an increase in the prevalence of pre-dialysis kidney disease in the general adult (≥ 20 years) population. (Coresh 2007) The largest prevalence increases were found in patients with Stage 2 disease (2.7% to 3.2%) and Stage 3 disease (5.4% to 7.7%). Cross-sectional claims data revealed an increase in pre-dialysis kidney disease from 2.9% to 7.9% whereas data from the Medical Evidence form (2728) revealed an increase in end-stage renal disease (ESRD) requiring dialysis and/or transplantation from 0.8% to 1.1% in the general Medicare population from 1996 to 2006. (USRDS 2008)

The demographics of the end-stage renal disease population in the U.S. have changed over time. The adjusted incident rate for patients 19 years and under has remained relatively low and stable at 13-15/million from 1988 to 2006 (USRDS 2008, 2009). The adjusted incident rate for patients 20 to 44 years of age has increased minimally and gradually from 97/million to 127/million. By contrast the adjusted incident rate for older adults has increased significantly: a) almost double (363/million to 625/million) for patients 45 to 64 years of age, b) more than double (668/million to 1452/million) for patients 65 to 74 years of age, and c) tripled 517/million to 1744/million for patients 75 years and older.(USRDS 2008, 2009) By contrast, ESRD prevalence is highest for patients aged 45 to 64 years of age and the adjusted prevalence rate is highest for patients aged 65 to 74 years of age and reflects the overall mortality associated with age and increased mortality especially within the first year of dialysis respectively. (USRDS 2008, 2009)

The causes of end-stage renal disease in the U.S. have also changed over time. Although the major causes of ESRD (diabetes-related, hypertension, glomerulonephritis, and cystic kidney disease) have remained the same, their relative importance has changed. The incidence of diabetes-related and hypertension-related renal disease has increased markedly. Much of the increase in diabetes-related renal disease may reflect the underlying macrovascular disease and hypertension associated with the metabolic derangement of Type 2 diabetes (and not the classic microvascular renal disease associated with Type 1 diabetes). By contrast, glomerulonephritis was the most common cause of renal disease in the prevalent population in the early 1980s, and currently both glomerulonephritis and cystic kidney disease are disproportionately represented in the prevalent population when compared to the incident population. This reflects the increased mortality associated with diabetes-related renal disease and hypertension as well as the age-of-onset associated with these disorders.

The current end-stage renal disease population is currently older and has more co-morbid disease (especially antecedent hypertension, type 2 diabetes, and atherosclerosis-lipids dysfunction). (USRDS 2008, 2009, NKF Position Paper 1989) Annual mortality rates are higher for older patients. Mortality rates during the first year on dialysis have remained unchanged. (USRDS 2008, 2009) Survival in that first year is approximately 60% in the overall incident dialysis population and 40% in patients who are unable to walk. The five-year survival in the dialysis population is approximately 30%. (USRDS 2008, 2009) Cardiovascular-related mortality, which has fluctuated between 79 deaths/10³ patient-years in 1991, 94.1 deaths/10³ patient-years in 1999, and 72.1 deaths/10³ patient-years in 2006, is responsible for approximately 50% of overall mortality. (USRDS 2008, 2009)

Although the number of renal transplants has increased over time, both age and cause of renal disease are factors in whether a patient (with onset of ESRD less than 70 years of age) has received a renal transplant within three years of ESRD registration and these demographic features have changed little since 1991. (USRDS 2008, 2009) Patients with cystic kidney disease (~ 45-50%) and glomerulonephritis (~35-40%) are more likely to receive a transplant than those with hypertension and diabetes-related renal disease (~ 12-18%). Younger patients (aged < 20 years; ~70%) are more likely to receive a transplant than older patients (age 20-39 years; 47% declining to 31%; age 40-59 years; 25% declining to 18%, and age 60-69 years; 6% increasing to 9%).

Anemia in Renal Disease-Etiology

There are multiple causes of anemia in patients with renal disease. There is decreased red cell production and increased red cell loss. Uremia reduces erythrocyte survival and suppresses hematopoietic cell production in the bone marrow. (Delwiche 1986, Fukushima 1986, Radtke 1980) Uremia may cause hemorrhagic bleeding, often from the gastrointestinal tract. (Andrassy 1985, Kang 1990, 1993, 1999, Rabiner 1972, Schiller 1989) The hemodialysis procedure and the filters used result in frank blood loss and decreased red blood cell survival. (Handelman 2010) Because of anorexia and dietary restrictions, oral intake of important nutrients, e.g., iron (Fe), may be inadequate. (DeVita 2003, Donnelly 1990, Kotaki 1997, van Wyck 1989) Aluminum (Al), which may be used for phosphate binding and as an antacid to reduce occult bleeding, may have a direct toxic effect on hematopoiesis and an indirect effect impairing iron metabolism. (Bia 1989, Caramelo 1995, Donnelly 1990) Erythropoietin deficiency in many patients with renal disease reduces marrow stimulation of hematopoietic cells although endogenous production (made by the body) of erythropoietin is relatively preserved in some types of renal disease, e.g., polycystic kidney disease. Erythropoietin production and utilization by the body may also be decreased in the setting of other nutritional co-factors, e.g., iron and vitamins. (Altallah 2006 Amato 2005, DeVita 2003, Goicoechea 1998, Keven 2003, MacDougall 1995)

There may be resistance to erythropoietin, whether endogenous (made by the body) or exogenous (made outside the body) in the setting of dialysis inadequacy, dysplastic marrow, occult or frank inflammation, infection, anti-erythropoietin antibodies, putative receptor defects, and putative anti-erythropoietin receptor antibodies. (Boven 2005, Casadevall 1996, de la Chapelle 1993, Di Iorio 2003, Elliot 2009, Howman 2007, Ifudu 1996, Jacob 2005, Kalantar-Zadeh 2003, Kralovics 1997, MacDougall 1995, Markson 1956, Nassar 2002, Ryan 2006, Schellekens 2006, Schreiber 1996, Radtke 1981, Wallner 1981, Zappacosta 1982)

Hyperparathyroidism, usually present as a secondary phenomenon to hypocalcemia in renal disease, has been postulated to cause anemia via several mechanisms including specific type of marrow fibrosis (osteitis fibrosa cystica) impairing hematopoietic cell production. (Bhadada 2009, Gallieni 2000, Grutzmacher 1983, Massry 1983, McGonigle 1984, Rao 1993) Medications used in the management of renal disease, e.g., erythropoietic (erythropoiesis) stimulating agents may cause (semi-)reversible marrow fibrosis with different pathologic features. (Akada 2010, Bader 1992, Barosi 2005, Dokal 1989, Epogen label, Gallieni 2000, Kakumitsu 2005, Lacout 2006, Levine 2005, Reilly 1997, Shiozawa 2010, Tulliez 1989, Wernig 2006)

In addition, many patients with renal dysfunction have co-morbid conditions that are the underlying cause(s) of their anemia. For example, cytokines associated with the anemia of chronic disease may impair hematopoietic nutrient utilization, erythropoietin production, and erythropoietin efficacy. (Means 1992) The presence of a mild anemia in type 2 diabetes is only now being recognized and may be a variant of the anemia of chronic disease. (Thomas 2003)

Anemia can be attributed to renal dysfunction only when there is significant renal dysfunction (Figure 3). (Radtke 1979) Mild anemia (mean hematocrit ~ 37 volume %) may be present when the glomerular filtration rate is between 30 and 40 ml/min/1.73 m². It is more common (mean hematocrit ~ 33 volume %) when the clearance is between 20 and 30 ml/min/1.73 m². Modest anemia (mean hematocrit ~ 30 volume %) is present when the clearance is between 10 and 20 ml/min/1.73 m².

Longitudinal data demonstrate that hematocrit levels decline in the six months prior to the initiation of dialysis and rebound, without exogenous erythropoietin, in the months immediately subsequent to the initiation of dialysis (Figure 4; Panel A). (Erbes 1978, Radtke 1979) Concomitant longitudinal data show that endogenous erythropoietin levels rise in the 6 month prior to the initiation of dialysis and decline in the months immediately subsequent to the initiation of dialysis (Figure 4; Panel B). (Radtke 1979) In the six to twelve months after the initiation of dialysis, both hematocrit and endogenous erythropoietin levels decline and remain low in most patients-even when dialysis is adequate. (Radtke 1979) Select patients, including those with polycystic kidney disease, retain some erythropoietin-production capacity. (Brown 1980, Eckardt 1991, Koch 1979, Radtke 1977, Ross 1994, Zeier 1996) Such data suggest that the uremia is the primary underlying etiologic agent for anemia in the pre-dialysis patient and that the kidney (and extra-renal tissue) respond to the challenge of anemia with increased production of the erythropoietin hormone in the pre-dialysis patient. Consistent with classic hormone feedback loops, the removal/reduction of the anemia-causing toxins, via dialysis and other renal management measures, decreases the need for erythropoietin secretion. Then, with continued deterioration of the renal parenchyma over time, the functional capacity for both filtration and erythropoietin production is lost (for most patients). The hormonal feed-back loop ceases to function in patients with well-established chronic renal failure. At this stage, erythropoietin deficiency becomes a major underlying cause of anemia.

Figure 3: Hematocrit Level and Renal Function (Radtke 1979)

Figure 4: Hematocrit, Erythropoietin, and Renal Function (Radtke 1979)

Panel A Changes in Hematocrit in Response to Uremic State

Panel B Changes in Erythropoietin in Response to Hematocrit and Uremic State

Anemia in Renal Disease-Demographics Features

The severity of anemia in end-stage renal disease patients appears to have changed over time. Secular changes suggest that hemoglobin/hematocrit levels are currently higher in ESA-naïve patients. Data from the 2008 USRDS annual publication suggest that 51% of incident ESRD patients have hemoglobin levels < 10 g/dl (hematocrit ~ 30 volume%) (and 9% unknown) whereas 1990 Congressional-Office of Technology (OTA) data indicate that 74% had hematocrit levels < 30 volume % (hemoglobin ~10 g/dl) (Figures 5 and 6). Forty-one percent of these had hematocrit levels 25 to < 30 volume %; thirty percent had hematocrit levels from 20 to < 25 volume %; three percent had hematocrit levels under 20 volume %. These differences may reflect changes in patient management, patient composition, and/or some other unknown factor. (Eggers 2000)

Figure 5: Level of Anemia Prior to Significant ESA Use in U.S. **Figure 6: Level of Anemia in Current Pre-dialysis Patients in U.S. (Population not treated by a nephrologist. ESA use in 5.7%)**

Historical Treatment of Anemia

It was long presumed that anemia contributed to the fatigue and poor level of functioning in renal disease and that therapeutic intervention was warranted although the level at which anemia requires intervention is not well established. By tradition, patients have been transfused with packed red blood cells (PRBCs) at the hemoglobin level of 7 or 8 g/dl to avoid symptoms and physiologic complications. A transfusion of two or more units of PRBCs would result in an increase of at least 2 g/dl of hemoglobin (6 volume % units of hematocrit). Most of these practices, however, are based on empiric observations and not clinical trials. Anemia in renal disease prior to the development of ESAs was primarily treated with transfusions. In 1992, in the year post initiation of dialysis, approximately 19% of patients received a single transfusion, 8% received two transfusions, and 7% received three or more transfusions. (USRDS 2008). Other therapeutic interventions included androgens and nutrients, e.g., iron (oral or intravenous).

In 1906, erythropoietin was identified as a regulatory hormone for red cell production and, in 1957, its source identified as the kidneys. (Gurney 1957, Reissman 1960) Commercialization was limited by the availability of processes for extraction, replication, and purification of the protein. In the 1980s, with the advent of recombinant technology, several companies, e.g., Amgen and the Genetics Institute, attempted commercialization of a therapeutic product. Amgen and the Genetics Institute received Orphan Drug status from the FDA for their respective products, erythropoietin α and erythropoietin β . (Asbury 1991) Amgen partnered with Ortho Pharmaceutical Company. Amgen retained marketing rights for erythropoietin in the U.S. dialysis population. (Coster 1992, NKF Position Paper 1989) Genetics Institute partnered with Chugai (Japan) and Chugai-Upjohn with the latter holding the marketing rights to erythropoietin in the U.S. (Coster 1992, NKF Position Paper 1989) In 1989, the FDA approved recombinant erythropoietin α to manage anemia decrease transfusions in dialysis patients and in pre-dialysis patients in whom hemoglobin levels were less than < 10 g/dl. There was rapid penetration of ESA administration in the end stage renal disease population. Within one year of FDA approval, erythropoietin was used in 60% of in-center dialysis patients and 52% of all dialysis patients covered by the Medicare program. (Powe 1992) In 2001, darbepoetin alpha (α) was approved by the FDA to increase hemoglobin.

Over time, ESAs became used in a greater proportion of dialysis patients, a greater proportion of pre-dialysis patients, and in renal patients with less severe anemia (Figure 7). (USRDS 2008) The dose of ESAs has increased over time (Figure 8). (Collins 1997, USRDS 2008, 2009) Dosing in the U.S. differs from that of Europe, where dosing is approximately 50% less for equivalent hemoglobin levels (Tables 29, 30, and 31). (Burton 2000, Jacob 2005, Pisoni 2004, Richardson 2009)

Figure 8: Change in ESA Doses over Time

Figure 7: Change in Hemoglobin Levels and ESA Use over Time

III. History of Medicare Coverage

The end stage renal disease program in Medicare was established by the Social Security Amendments of 1972, Public Law 92-603, Section 2991 (1972). Medicare coverage of dialysis typically started during the fourth month of dialysis. Services and items covered by the program include dialysis procedures whether in-patient or out-patient, dialysis supplies, blood transfusions, transplantation, some transplantation-related costs, and drugs associated with dialysis, e.g., heparin and ESAs. These medications are paid under Medicare Part B.

There is no national coverage determination (NCD) concerning the use of ESAs in beneficiaries with renal disease treated with dialysis and beneficiaries with renal disease in pre-dialysis stages.

A. Current Request

On June 16, 2010 CMS accepted a formal request for a NCD with respect to Medicare coverage of ESAs for treatment of chronic kidney disease (CKD) and dialysis-related anemia from Mr. Dennis Cotter, President, Medical Technology & Practice Patterns Institute (MTPPI.) His letter is available at the following link: <http://www.cms.gov/DeterminationProcess/downloads/id245.pdf>.

B. Benefit Category

Medicare is a defined benefit program. An item or service must fall within a benefit category as a prerequisite to Medicare coverage §1812 (Scope of Part A); §1832 (Scope of Part B) and §1861(s) (Definition of Medical and Other Health Services) of the Act. ESAs fall within the benefits categories specified in §1861(s)(2)(O) of the Social Security Act.

IV. Timeline of Recent Activities

September 2009

CMS commissioned a technology assessment (TA) to search the literature for ESA clinical trials.

November 2009

CMS commissioned a TA that would describe ESA utilization in Medicare beneficiaries with renal disease. The information was presented at the March 24, 2010 MEDCAC.

June 16, 2010

CMS accepted a formal request for an NCA to evaluate erythropoiesis stimulating agents (ESAs) for treatment of anemia in adults with CKD including both patients on dialysis and patients not on dialysis. A tracking sheet was posted on the web site and the initial 30 day public comment period commenced. CMS commissioned a technology assessment to delineate the role and impact of blood transfusion on renal transplantation.

July 16, 2010

The initial 30 day public comment period ended. Nine timely comments were received.

January 19, 2011

CMS held a Medicare Evidence Development and Advisory Committee (MEDCAC) meeting to discuss the role and impact of blood transfusion on renal transplantation. (www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=57&bc=BAAQAAAAAAAA&; accessed January 21, 2011.)

V. FDA Status

A. In 1989, the FDA approved erythropoietin-alpha for the treatment of anemia in renal disease. It was the first erythropoiesis stimulating agent (ESA) approved by the FDA.

B. In 1993, the FDA approved erythropoietin-alpha for the management of the anemia due to myelosuppressive cancer chemotherapy of solid tumors.

C. On September 17, 2001, the FDA approved the long-acting erythropoietin analogue, darbepoetin, to increase hemoglobin in renal disease patients. (www.accessdata.fda.gov/drugsatfda_docs/applletter/2001/darbamg091701L.htm, www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080442.htm, www.accessdata.fda.gov/drugsatfda_docs/label/2001/darbamg091701LB.htm; accessed July 19, 2010.)

D. On July 19, 2002, the FDA approved darbepoetin for the management of the anemia due to concomitantly administered chemotherapy for non-myeloid cancer. See www.accessdata.fda.gov/drugsatfda_docs/applletter/2002/darbamg071902L.htm and www.accessdata.fda.gov/drugsatfda_docs/label/2002/darbamg071902LB.pdf. (Accessed July 19, 2010.)

E. In 1997, 2004, 2005, 2007, and 2008, ESA product labeling underwent substantial revisions. (Accessed July 19, 2010.)

1-Epogen/Procrit

www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080580.htm (revised pediatric use section for renal disease; 4 studies in dialysis patients (EPO 9118 single arm n = 74, EPO 8702 single arm n = 5, EPO 8905 double-blind n = 10, EPO 9902 double-blind n = 112)

http://www.accessdata.fda.gov/drugsatfda_docs/applletter/1999/epoamg072699L.pdf (request for literature on pharmacokinetic data in neonatal use)

www.accessdata.fda.gov/drugsatfda_docs/applletter/biologics/2004/103234-5033ltr.pdf (phase 4 commitment N93-004 to assess ESA effect on solid tumor growth completed; agreement made with 1993 approval; agreement to conduct survival/time to tumor progression study in metastatic breast cancer patients; update warnings and precautions sections for cancer patients; dear doctor letter.)

www.accessdata.fda.gov/drugsatfda_docs/nda/2004/103234s5033.pdf (review of BEST trial; advised recent proposed label changes not acceptable; request for information on thrombosis-vascular events, tumor progression, and cancer treatment response rates in randomized, placebo controlled studies with patients with a single tumor type and anti-cancer treatment regimen.)

www.accessdata.fda.gov/drugsatfda_docs/applletter/biologics/2004/103234_5053ltr.pdf (acknowledgement that study PR99- 11-034/044, a study of anemia and quality-of-life children with solid tumors, Hodgkin s disease, ALL, or NHL and undergoing myelosuppressive chemotherapy, has been completed, but not yet received for review; request for deferred studies in pediatric cancer patients five years and under)

www.accessdata.fda.gov/drugsatfda_docs/nda/2004/103234s5053.pdf (review of several studies in cancer patients for weekly dosing and hemoglobin, time to transfusion, and quality-of-life parameters; survival curve in PR98-27-008 appears to diverge after approximately 500 days and favors the placebo arm)

www.accessdata.fda.gov/drugsatfda_docs/label/2004/103234_5053_Epogen_lbl.pdf (alternative weekly dosing was added for cancer patients)

www.accessdata.fda.gov/drugsatfda_docs/applletter/2004/103234_5076ltr.pdf (acknowledgement of submission of literature search for pharmacokinetic information on use in neonates in response to a 1997 commitment)(use in children based on literature, renal: Campos 1992, Montini 1990, Offner 1990, Muller -Wiefel 1988, Sharer 1993; HIV: Mueller 1994, Zuccotti 1996; cancer: Beck 1995, Bennetts 1995.)

www.accessdata.fda.gov/drugsatfda_docs/nda/2004/103234s5076_AP_PKG.pdf (literature submitted: Kling and Widness 1992 case report of infant with urinary tract obstruction, Widness 1996 seven premature infants and ten adults)

www.accessdata.fda.gov/drugsatfda_docs/label/2004/103234_5076lbl.pdf (two studies above included in label)

www.accessdata.fda.gov/drugsatfda_docs/applletter/2005/103234s5093ltr.pdf (added information about pure red cell aplasia for renal disease section, update renal section of patient insert, distribute dear doctor letter to hematology-oncology care providers)

www.accessdata.fda.gov/drugsatfda_docs/nda/2005/103234s5093_AP_PKG.pdf (pure red cell aplasia case reports in system and packaging issues resulting in administration errors viewed)

www.accessdata.fda.gov/drugsatfda_docs/label/2005/103234s5093lbl.pdf (IV route recommended for hemodialysis patients to possibly reduce risk of pure red cell aplasia)

www.accessdata.fda.gov/drugsatfda_docs/applletter/2006/103234s5104_LTR.pdf (unspecified label and patient insert changes)

www.accessdata.fda.gov/drugsatfda_docs/label/2006/103234s5104_LBL.pdf (unspecified label changes)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/103234s5122ltr.pdf (increased warnings and precautions; removed quality of life claims, requested substantiation of any patient-related outcome (PRO) claims in accordance with the FDA guidance and to be received by June 15, 2007)

www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5122lbl.pdf (addition of boxed warning for increased risk of death, cardiovascular events, thrombo-embolic events, tumor progression; include information delineating increased risk with use in renal and HIV patients; remove quality of life claims; clarify dosing strategies)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/103234s5158ltr.pdf (strengthen box label warnings and send dear doctor letter)

www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5158lbl.pdf (cardiovascular-thrombotic risk for renal and surgical patients more clearly outlined in boxed warning)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/103234s5163ltr.pdf (typographical error in table 1 in warning section to be corrected)

www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5163lbl.pdf (addition of boxed warning for increased risk of death, cardiovascular events, thrombo-embolic events, tumor progression; include information delineating increased risk with use in renal and HIV patients; remove quality of life claims; clarify dosing strategies)

www.accessdata.fda.gov/drugsatfda_docs/label/2008/103234s5164lbl.pdf (unspecified changes in label and patient insert)

2-Darbepoetin

www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/103951_5069ltr.pdf (thrombosis and tumor progression; dear doctor letter)

www.accessdata.fda.gov/drugsatfda_docs/label/2004/103951_5069lbl.pdf (thrombosis and tumor progression; label change)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/103951s5096ltr.pdf (pure red cell aplasia; dear doctor letter)

www.accessdata.fda.gov/drugsatfda_docs/label/2005/103951s5096lbl.pdf (pure red cell aplasia; label change)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/103951s5088ltr.pdf (agreement to provide information on 20010145 in small cell lung cancer patients, DE 2001-0033 (PREPARE-CIA in chemotherapy patients, DE-2002-0015 (ARA-03) in breast cancer patients, SE-2002-9001 (DAHANCA-10) in head-and-neck cancer patients, FR-2003-3005 (GELA LNH-036B) large B-cell lymphoma patients, adverse events [12/2011])

www.accessdata.fda.gov/drugsatfda_docs/label/2006/103951s5088lbl.pdf (dosing regimen q3 weeks)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/103951s5139ltr.pdf (boxed label warning section for cardiovascular, thrombotic, and tumor growth potential; provide information on survival in cancer patients)

www.accessdata.fda.gov/drugsatfda_docs/label/2007/103951s5139lbl.pdf (increase severity of adverse event warnings in label)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/103951s5135ltr%20.pdf (allergic reactions with rubber stoppers for vials)

www.accessdata.fda.gov/drugsatfda_docs/label/2007/103951s5135LBL.pdf (allergic reaction; label change)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/103951s5164ltr.pdf (dear doctor letter with new label changes)

www.accessdata.fda.gov/drugsatfda_docs/label/2007/103951s5164lbl.pdf (change in label, package insert, patient information)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/103951s5169ltr.pdf (correction of typographical error in warning section)

www.accessdata.fda.gov/drugsatfda_docs/label/2007/103951s5169lbl.pdf (typographical error; label change)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/103951s5170ltr.pdf (includes data from DE 2001-0033 (PREPARE) and GOG191; dear doctor letter)

www.accessdata.fda.gov/drugsatfda_docs/label/2008/103951s5170lbl.pdf (label change to warnings and boxed warnings sections)

www.accessdata.fda.gov/drugsatfda_docs/label/2008/103951s5195PI.pdf (updated label)

www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/103951s5211ltr.pdf (pure red cell aplasia in setting of hepatitis C treated with ribavirin and HIV and ribavarin and interferon; dear doctor letter)

www.accessdata.fda.gov/drugsatfda_docs/label/2009/103951s5211Lbl.pdf (updated warnings section for red cell aplasia in label)

F. In 2004, the FDA reviewed results of the Breast Cancer Erythropoietin Trial (BEST) and Henke studies. On May 4, 2004, the FDA convened a meeting of the Oncologic Drugs Advisory Committee May 4, 2004 to discuss safety issue for ESAs. The briefing information and transcript for the meeting is available at www.fda.gov/ohrms/dockets/ac/cder04.html#Oncologic. Later that year, concerns regarding an increased rate of tumor progression and increased mortality were incorporated into the precautions section of product labeling. (Accessed July 19, 2010.)

G. In February, 2006, the FDA issued a draft guidance for patient report outcomes (PRO). See www.fda.gov/OHRMS/DOCKETS/98fr/06d-0044-gdl0001.pdf and www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm118795.pdf. (Accessed July 19, 2010.)

H. On January 26, 2007, the FDA issued a “Dear Doctor Letter” regarding the use of ESAs for anemia management in the absence of chemotherapy. See www.fda.gov/medwatch/safety/2007/safety07.htm#Aranesp. (Accessed July 19, 2010.)

I. On February 16, 2007, the FDA notified healthcare providers of increased mortality and no transfusion decrease in a study in darbepoetin using cancer patients not receiving chemotherapy. See www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152120.htm. (Accessed July 19, 2010.)

J. On March 9, 2007, the FDA notified healthcare providers of increased adverse events including death in four studies of cancer patients. The trials were studying ESA use in an off-label patient population, in an off-label dosing regimen, or with an unapproved ESA. See www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152120.htm. (Accessed July 19, 2010.)

K. In March 2007, the FDA sent Amgen a letter requesting that Amgen, in a post-marketing commitment, reassess the data used to make patient report outcomes (PRO) in ESA labels in concordance with the principles laid out in the FDA draft PRO guidance document. Amgen agreed to remove quality-of-life claims (e.g., happiness, life satisfaction, and well-being) from ESA labels. Claims that could be considered would be limited to health-related quality of life claims (physical, psychological, and social functioning that reflect the impact of a disease and its treatment). The sponsor was to provide the information by June 15, 2007.

The FDA noted that the instruments for PRO claims must have content validity (documentation that the test items are derived from patient input and are appropriate, clinically meaningful, well-defined, specific to the target population/indication, interpretable, and comprehensive), construct validity, reliability, and the ability to detect change. If instruments are altered or used in different patient populations, they require re-validation. PRO instruments will not provide meaningful information unless they are used in adequately designed studies with blinding and prospective statistical analysis plans. Plans to address missing data and drop-outs must be made.

L. On September 11, 2007, the FDA convened a joint meeting of the Cardio-Renal Drugs Advisory Committee (CRDAC) and Drug Safety and Risk Management Advisory Committee to discuss safety issue for ESAs. The briefing information and transcript for the meeting is available at www.fda.gov/ohrms/dockets/ac/cder07.htm#CardiovascularRenal. (Accessed July 19, 2010.)

The FDA determined that on the basis of the documents submitted to the FDA by July 2007 that the PRO claims made in the label for erythropoietin were not adequately substantiated. Documents submitted subsequent to July 2007 were to be reviewed after the CRDAC meeting date.

M. On November 8, 2007, the FDA notified healthcare professionals of ESA label changes including black box warnings. The warnings noted the tumor growth and shortened survival in study patients with advanced breast cancer, head and neck cancer, lymphoid cancer, and non-small cell cancer in which the ESA was dosed in an attempt to reach a hemoglobin of ≥ 12 g/dl. The warnings noted that ESAs, in the setting of cancer, should be used only when the anemia was due to the chemotherapy and should be discontinued with the cessation of chemotherapy. The notice provided information on management of poor responders to ESAs. See www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm152274.htm. (Accessed July 19, 2010.)

N. On November 8, 2007, the FDA notified healthcare professionals of ESA label changes including black box warnings. The warnings noted that maintaining hemoglobin levels higher than 12g/dl increased the risk of death and other adverse events in patients with chronic renal failure. The notice provided information on management of poor responders to ESAs.

O. On January 3, 2008, the FDA notified healthcare professionals of additional studies demonstrating tumor growth and shortened survival in patients with breast cancer (Preoperative Epirubicin Paclitaxel Aranesp Study [PREPARE]; Germany; n = 733) and cervical cancer (National Cancer Institute Gynecologic Oncology Group [COG-19] [sic GOG 191]; chemotherapy and radiation; 109 of 460 enrolled) after being notified by Amgen on November 30 and December 4, 2007 respectively. Enrollment was stopped early in the NCI study because of an imbalance in serious blood clots. Healthcare professionals were encouraged to review ESA risks with patients. See www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm152274.htm. (Accessed July 19, 2010.)

(PREPARE information filed to clinicaltrials.gov/ct2/show/NCT00544232 without subsequent change on October 15, 2007. GOG-191 recruitment closure filed to clinicaltrials.gov/archive/NCT00017004/2007_08_06 on August 6, 2007.) (Accessed July 19, 2010)

P. On August 14 and 15, 2008, the FDA convened a meeting of the Risk Communication Advisory Committee to discuss methods and procedures to effectively convey and reduce risk to patients. The briefing and transcript information is available at www.fda.gov/ohrms/dockets/ac/08/transcripts/2008-4377t1-01.pdf. (Accessed July 19, 2010.)

Q. On September 26, 2008, the FDA publically reported preliminary data from a German study in which an erythropoietin product not marketed in the U.S. (40,000 units daily for three days) and recombinant-tPA were used to treat acute ischemic stroke because there was an imbalance in the treatment arms for death. See www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136211.htm. (Accessed July 19, 2010.)

R. On April 30, and May 1, 2009, the FDA convened a meeting of the Risk Communication Advisory Committee to discuss methods and procedures to effectively convey and reduce risk to patients. The briefing and transcript information is available at www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/RiskCommunicationAdvisoryCommittee/ucm158758.htm. (Accessed July 19, 2010.)

S. On April 30, 2009, the FDA revised the March 2007 boxed warning to address issues regarding ESA use by both patients with cancer and patients with chronic kidney failure.

- The warning noted that ESA dosing in oncology studies with hemoglobin targets of 12 g/dL or greater, whether the target was achieved or not, has resulted in more rapid cancer progression or shortened overall survival in cancer patients with advanced breast, head and neck, lymphoid and non-small cell lung malignancies and that these risks have not been excluded in cancer patients with hemoglobin targets of less than 12 g/dL
- The warning noted that ESAs should only be used to treat chemotherapy-induced anemia while patients are undergoing chemotherapy and not other types of anemia. (The indications section indicated that the chemotherapy should be myelosuppressive.)
- The warning noted that ESA dosing in renal disease studies with higher hemoglobin targets (e.g., 13.5 g/dL versus 11.3 g/dL and 14 g/dL and 10 g/dL), whether the target was achieved or not, has resulted in greater risks of death and serious cardiovascular events including heart attack, stroke and heart failure in pre-dialysis and dialysis patients. (In the non-boxed warning section, the warning noted an increased risk of mortality and cardiovascular complications in renal patients poorly responsive to ESA doses and given high ESA doses [CHOIR and NHCT trials cited.]

T. In December 2009, the FDA issued the final version of the guidance for patient-report outcome measures. See www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. (Accessed July 19, 2010.)

U. In February 2010, the FDA required all ESAs to be prescribed and used under a risk evaluation and mitigation strategy (REMS) to ensure the safe use of these drugs. As part of the REMS, a Medication Guide explaining the risks and benefits of ESAs must be provided to all patients receiving ESAs. Information is available at www.fda.gov/AboutFDA/CentersOffices/CDER/ucm200847.htm, www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm109375.htm, www.fda.gov/AboutFDA/CentersOffices/CDER/ucm200847.htm, www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/103951s5197ltr.pdf, www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/103234s5199ltr.pdf. (Accessed July 19, 2010)

V. On October 18, 2010, the FDA convened a meeting of the Cardio-Renal Drugs Advisory Committee (CRDAC) to discuss safety issues for ESAs in TREAT trial. The briefing information is available at <http://www.fda.gov/downloads/AdvisoryCommittees/.../Drugs/.../UCM236323.pdf>. The transcript for the meeting is available at <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM233461.pdf>. (Accessed July 19, 2010.)

Prior to the CRDAC meeting, Amgen submitted proposed labeling changes to the FDA regarding the use of ESAs in chronic renal failure patients not on dialysis that would limit treatment to patients who are most likely to benefit, specifically those with significant anemia (< 10 grams per deciliter ["g/dL"]), and who are at high risk for transfusion and for whom transfusion avoidance is considered clinically important, including those in whom it is important to preserve kidney transplant eligibility. A more conservative dosing algorithm in these patients was also proposed. The sponsor also recommended against increased dosing in hyporesponsive patients. (See pages 88 and 89 www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM229328.pdf.) (Edgar 10-Q 08/09/10); accessed November 3, 2010)

VI. General Methodological Principles

When making national coverage determinations under section 1862(a)(1)(A) of the Act, CMS generally evaluates relevant clinical evidence to determine whether or not the evidence is of sufficient quality to support a finding that an item or service falling within a benefit category is reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. The critical appraisal of the evidence enables us to determine to what degree we are confident that: 1) the specific assessment question(s) can be answered conclusively; and 2) the intervention will improve health outcomes for beneficiaries. An improved health outcome is one of several considerations in determining whether an item or service is reasonable and necessary.

A detailed account of the methodological principles of study design that the Agency utilizes to assess the relevant literature on a therapeutic or diagnostic item or service for specific conditions can be found in Appendix A. In general, features of clinical studies that improve studies and decrease bias include the selection of a clinically relevant cohort, the consistent use of a single good reference standard, and the blinding of readers to both the index test and the reference test results.

Public commenters sometimes cite the published clinical evidence and provide CMS with useful information. Public comments that provide information based on unpublished evidence, such as the results of individual practitioners or patients, are less rigorous and, therefore, less useful for making a coverage determination. CMS uses the initial comment period to inform the public of its proposed decision. CMS responds in detail to the public comments that were received in response to the proposed decision when it issues the final decision memorandum.

VII. Evidence

A. Introduction

We are providing a summary of the evidence that we considered during our review.

Emerging data have better delineated the physiologic criteria for intervention in the setting of anemia. Emerging data also suggest that ESAs are associated with increased mortality and morbidity despite the alleviation of anemia. The evidence reviewed in a prior NCD focused on ESA use in the cancer setting and related safety considerations. ([www.cms.gov/medicare-coverage-database/details/nca-details.aspx?NCAId=203&ver=12&NcaName=Erythropoiesis+Stimulating+Agents+\(ESAs\)+for+non-renal+disease+indications&bc=BEAAAAAAAAAAAA&](http://www.cms.gov/medicare-coverage-database/details/nca-details.aspx?NCAId=203&ver=12&NcaName=Erythropoiesis+Stimulating+Agents+(ESAs)+for+non-renal+disease+indications&bc=BEAAAAAAAAAAAA&); accessed February 14, 2011.) The evidence reviewed in this NCA includes the literature on ESA therapy in populations with renal dysfunction, putative clinical benefits, and related safety issues. Studies were evaluated for information regarding dosage level, dose response, hemoglobin level, hemoglobin response, and correlation with clinical outcome(s). Studies comparing different ESA compounds or different routes of administration were included. The evidence reviewed encompassed studies germane to both dialysis and pre-dialysis patient populations. Materials found in published medical journal article were supplemented by data from additional technical sources as necessary.

B. Discussion of Evidence Reviewed

1. Question(s)

A. Is the evidence sufficient to conclude that the underlying cause for anemia in Medicare beneficiaries who have renal disease and are not on dialysis is absolute and irreversible erythropoietin deficiency?

B. If the answer to question A is affirmative, is the evidence sufficient to conclude that erythropoiesis (erythrocyte) stimulating agent (ESA) therapy affects health outcomes (including survival, cardiovascular event rates, exercise capacity, progression of renal disease, quality-of-life, transfusion rates, and ability to receive a transplant) when used by Medicare beneficiaries who have renal disease and are not on dialysis?

C. If the answer to Question B is affirmative, is there sufficient evidence to determine which characteristics of the patient, the disease, or the treatment regimen reliably predict a favorable or unfavorable health outcome when used by Medicare beneficiaries who have renal disease and are not on dialysis?

D. Is the evidence sufficient to conclude that the underlying cause for anemia in Medicare beneficiaries who have renal disease and are on dialysis is absolute and irreversible erythropoietin deficiency?

E. If the answer to question D is affirmative, is the evidence sufficient to conclude that erythropoiesis (erythrocyte) stimulating agent (ESA) therapy affects health outcomes (including survival, cardiovascular event rates, exercise capacity, quality of life, transfusion rates, and ability to receive a transplant) when used by Medicare beneficiaries who have renal disease and are on dialysis?

F. If the answer to Question E is affirmative, is there sufficient evidence to determine which characteristics of the patient, the disease, or the treatment regimen reliably predict a favorable or unfavorable health outcome when used by Medicare beneficiaries who have renal disease and are on dialysis?

2. External Technology Assessments

CMS requested two external technology assessments (TAs) on issues related to this technology.

The first technology assessment addressed changes in ESA utilization in the renal population. It was presented at the March 24, 2010 MEDCAC. (See Acumen slide set; www.cms.gov/determinationprocess/downloads/id78TA.pdf; accessed July 19, 2010.)

The second technology assessment addressed the impact of transfusions on renal transplant outcomes. The data were presented at the January 19, 2011 MEDCAC. (www.cms.gov/determinationprocess/downloads/id78TA.pdf; accessed February 2, 2011).

3. Internal Technology Assessment

a. Literature Search Methods

The reviewed evidence was gathered from articles submitted by the requestor and a search of the published literature, government databases, and other online references. CMS staff extensively searched Medline (1988 to present) for primary studies evaluating ESA therapy in renal disease. The emphasis was on studies structured to assess long-term health outcomes with hard clinical endpoints. CMS staff likewise searched for systematic reviews and technology assessments from other sources such as the Cochrane collection and the Agency for Healthcare Research and Quality (AHRQ) library. Systematic reviews were used to help locate some of the more obscure publications and abstracts. For material outside the domain of the published medical literature, additional sources were used.

CMS reviewed FDA reviews of the registration trials for erythropoietin alpha, darbepoetin alpha, and methoxy polyethylene glycol epoetin beta, as well as the FDA safety data for the two marked compounds, erythropoietin alpha and darbepoetin alpha. CMS also reviewed published data on other erythropoiesis stimulating agents not marketed in the U.S. CMS reviewed the transcripts and briefing documents (FDA and pharmaceutical sponsor) from the 2004 FDA Oncologic Drug Advisory Committee meeting, the 2007 FDA Cardio-Renal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting, and the 2010 FDA Cardio-Renal Drugs Advisory Committee meeting on ESA safety. CMS reviewed the FDA ESA drug safety alerts and label changes. CMS reviewed the development of the risk evaluation and mitigation strategy (REMS) program for ESAs. CMS searched the National Institutes of Health Clinical Trials.gov database for ongoing/completed trials of ESAs. CMS used internet searches to identify websites with clinical trial results, press releases for clinical trial termination, and U.S. government regulatory action. Preference was given to English publications, phase III and IV randomized, controlled studies with hard clinical endpoints (vs pilot studies or dose ranging studies), studies involving adults, and ESAs approved for use in the U.S.

Keywords used in the searches included: anemia and physiology, renal, kidney, dialysis, or pre-dialysis, chronic kidney disease (CKD), or end stage renal disease (ESRD); ESAs (erythropoietic stimulating agents, erythropoiesis stimulating agents, erythropoietin, epoetin, darbepoetin, pegylated erythropoietin, erythropoietin receptor activator, CERA, continuous erythropoietin receptor activator, peginesatide, hematide, or mimetibody) and anemia, dosing, pharmacokinetic-pharmacodynamic (PK-PD), transfusion, renal disease progression, exercise, (health-related) quality-of-life, pure red cell aplasia (PRCA), thrombosis, cardiovascular, tumor progression, morbidity, survival, mortality, renal transplantation, or resistance; transfusion and anemia, physiology, risk, renal transplantation, sensitization, panel reactive antibodies (PRA), or HLA-specific antibodies; renal transplantation and demographics, surgical criteria, UNOS data collection, immune suppression, protocols for sensitized patients, panel reactive antibodies (PRA), or HLA-specific antibodies; panel reactive antibodies (PRA) and HLA specific antibodies, assay type, or risk factors.

b. Evidence Review Findings

Summary

Despite an exhaustive search, we identified no high quality, randomized clinical trials that were of sufficient design, duration, and power to confidently conclude that ESAs provide clinical benefits other than increasing hemoglobin, a putative intermediate clinical surrogate. Despite an exhaustive search we identified no high quality, randomized clinical trials that were of sufficient design, duration, and power to definitely determine the absolute risk of adverse events including death, tumor progression, and cardiovascular-thromboembolic events in patients with renal insufficiency and/or renal failure, in geriatric patients (the largest growing renal population segment), using ESAs. No trials were structured to assess these hard endpoints stratifying by renal disease severity (and stage ascertained by studies other than estimated GFR), by entry hemoglobin in ESA-naïve patients, by prior ESA response, by ESA response after a limited number of doses, by *a priori* bone marrow reserve documented by biopsy studies, by concomitant drugs such as angiotensin converting enzyme inhibitors, by age, and by various co-morbidities. No trials eliminated a) the confounding associated with hemoglobin levels and targets and b) effects that might be non-linear by randomizing blinded cohorts with fixed dosing. No trials were structured to assess transfusion endpoints (number units, number persons, frequency, transfusion reason, antecedent hemoglobin) with *a priori* transfusion criteria based on accepted data-based criteria for transfusion. No trials used appropriately validated health-related quality-of-life (hrQOL) instruments and established clinically significant differences related to hemoglobin levels and change in hemoglobin levels. No trials limited dosing to physiologic replacement. No trials were structured to assess hard clinical outcomes in settings in which the ESA level is supra-physiologic because of dose itself, drug plasma-clearance/tissue residence times, the route of administration, or the dosing interval. No studies were adequately structured assess within class safety differences for ESAs. We did identify 4 large, randomized studies that were structured to assess survival or cardiovascular endpoints (Besarab 1998, Drueke 2006, Singh 2006, Pfeffer 2009). All used hemoglobin targets and none used fixed ESA dosing. Only one was placebo controlled. None included many of the types of patients that have become more common in the CKD population. Two were terminated early. High withdrawal rates complicated many of the studies. We did identify unpublished studies submitted to the FDA for registration and multiple studies which compared routes of administration, different treatment regimens, or different ESA agents. We detail our findings below.

i. Hypothesis Generating Studies

Although physiologic dysfunction with renal disease is multi-factorial, it was postulated that anemia might play an important role in exercise capacity, rate of renal function decline, cardiac morphology, and survival.

A cross-sectional study of 13 dialysis patients (Hb range 5.1-12.2 g/dl) by Mayer et al (1989) demonstrated that the impairment in oxygen (O₂) uptake at the anaerobic threshold was inversely related to the hemoglobin level. Maximum peripheral O₂ uptake was similarly correlated with hemoglobin levels.

Three randomized studies estimated the rate of decline in kidney function using surrogate measures. Kuriyama et al. reported that serum creatinine doubled in 26/31 (84%) anemic pre-dialysis patients not treated with erythropoietin versus 21/35 (60%) of non-anemic pre-dialysis patients not treated with erythropoietin versus 22/42 (52%) anemic pre-dialysis patients treated with erythropoietin for 36 weeks and followed for a median duration of 28 months. (Kuriyama 1997) (The differences between groups 2 and 3 were not statistically significant.) Limited data suggested that the presence of diabetes might reduce the effect of erythropoietin on progression. A study by Teplan et al. (n = 186) using inulin clearance changes suggested that supplementary dietary ketoacids and erythropoietin might independently contribute to decreased progression in patients on a low protein diet. (Teplan 2001a, b, Teplan 2003) Gouva et al. reported that the composite endpoint of serum creatinine doubling, initiation of dialysis, or death was met in 23/43 (54%) of those in whom erythropoietin treatment was delayed until hemoglobin levels decreased to less than 9 g/dl as compared 13/45 (29%) of those in whom treatment was initiated for milder anemia (hemoglobin 9 to 11.6 g/dl). (Gouva 2004)

A cross-sectional study of 78 dialysis patients by Silverberg et al. demonstrated that left ventricular mass was inversely related to hemoglobin levels (slope = [-1.2 g/m²]/g/l hb): quartile 1 (hb < 7.7 g/dl) 158 ±6 g/m², quartile 2 (hb 7.7-8.8 g/dl) 140±10 g/m², quartile 3 (8.8 -9.7 g/dl) 132 + 7 g/m², and quartile 4 (hb > 9.7 g/dl) 120+8 g/m² (and positively correlated to even modest systolic blood pressure elevation [slope = [0.57 mg/m²]/mm Hg]). (Silverberg 1989)

An observational study data conducted by Ma et al. (1999) using USRDS data reported that all- cause and cardiac death rates were highest in patients with the lowest hematocrit levels (Table 2). (Collins 1997, 2000, 2001, 2002, Ma 1999) Patients with diabetes had higher rates of both all-cause and cardiac than did non-diabetic patients. (No distinctions were made for type 1 vs type 2 diabetes.) (See Analysis.)

Table 2: Mortality and Anemia: Observational Data from USRDS

Mortality Rates (Deaths/1000 tx-yrs)	Hematocrit (Vol%)			
	< 27	27 to < 30	30 to < 33	33 to < 36
Groups & Causes of Death				
Non-diabetic—All Cause	214.7	192.0	170.6	161.4
Cardiac	80.1	77.8	71.8	69.0
Diabetic—All Cause	342.7	298.2	258.3	234.6
Cardiac	147.9	135.9	119.7	112.7

It was not known whether anemia management and therapeutic intervention with ESAs (and other agents) would improve the physiologic dysfunction associated with renal disease. At the time that ESAs were being developed, there were concerns about the use of transfusions and the safety of the blood supply (HIV and non-A/B hepatitis).

ii. Initial Pivotal Registration Studies

Erythropoietin-alpha (Trade names: Epogen and Procrit) was approved as an orphan drug (< 200,000 patients) for use in renal patients in 1989 (Asbury 1991, Coster 1992, FDA Summary Basis of Approval for BLA # 103234, NKF Position Paper 1989, Phase IV commitment study Nissenson 1991). Only three of the major registration studies have been published in full: 1) a blinded study of hemodialysis patients (Canadian Study Group) (86-004), 2) an uncontrolled study in hemodialysis patients (Eschbach) (8601), and 3) a blinded study of pre-dialysis patients (Teehan)(G88-011) (Table 3, Panels A, B, and C). Some of these studies were also presented as sub-studies or ancillary studies. Other registration studies were not published or were only sub-studies published by individual investigators. Multiple citations delineated in early product labels could not be located. The FDA reviews of the registration studies are not available.

Table 3A: FDA Registration studies-Erythropoietin alpha*

Study	Population	Blind	Size	Duration	Entry Criteria	Exclusion Criteria
8601 Eschbach 1989 x2, 1991	Hemo Adults	No control Open-label	426 or 412 or 333 or	Not stated 12+ mos	Hct < 30% Adequate Fe	Dx impairing EPO result Uncontrolled HTN

Study	Population	Blind	Size	Duration	Entry Criteria	Exclusion Criteria
Adamson 1989 Lundin 1991 FDA 1989 USA 9 sites			309			
86-004 Canadian Group 1990 Keown 1991 Laupacis 1991 FDA 1989 Canada 13 sites	Hemo Adults	Double	118	26 wks	Hb < 9	Non-epo deficiency anemia Unable to do walk test bc of disorders such as type 1 diabetes (Keown 1991)
8701 FDA 1989 <i>Unpublished</i> USA 3 sites	Hemo Adults	Double to Open-label	101 or 62 82 or 106	12 wk control to 12 wk extension	-	-
8904 FDA 1989 <i>Unpublished</i>	Peritoneal Adults	Double to Open-label	152	12 wk control to 12 wk extension	-	-
FDA 1989 <i>Unpublished</i> Canada 1 site	Hemo	Double	18	9 wks	-	-
US-Teehan 1991 Abels 1990 G88-011 Lim 1989 n=10 ?Stone 1988 FDA 1989 USA 15 sites	Pre-dialysis	Double to Open-label	117	8 wks to 6 mos extension	Hct ≤ 38 ♂ ≤ 32 ♀ Serum Cr used No GFR stated Good nutrition	Recent infection Major clinical dx Uncontrolled HTN Recent androgen use Recent transfusions
FDA 1989 Kleinman 1989 n=14 ?Watson 1990 <i>Complete trial unpublished</i> USA ? sites	Pre-dialysis	Double to ?Open & > dose	93	12 wks ?12 wk extension	Anemia undefined Serum Cr 3 to 11 mg/dl	Dx impairing EPO result Recent infection Major clinical dx, seizure Uncontrolled HTN Fe or vitamin deficiency GI/urinary blood loss Recent androgen use Obesity
FDA 1989 <i>Unpublished</i> Europe ? sites	Pre-dialysis	Open-label	24	8 wks	-	-

? = possibly or unknown

Cr = creatinine

Dx = diagnosis

EPO = erythropoietin

FDA = Food and Drug Administration

Fe = iron

GFR = glomerular filtration rate

Hb = hemoglobin

Hct = hematocrit

Hemo = hemodialysis

HTN = hypertension

Table 3B: FDA Registration studies-Erythropoietin alpha (continued)*

Study	Dose	Target Hb(Hct)	Transfusion Criteria	Stratification by		
				Hb (Hct)	Dose	Dialysis Adequacy or Renal Clearance
8601 Eschbach 1989 x2, 1991 Adamson 1989 FDA 1989 USA 9 sites	IV 300 to 150 to 75 U/kg	32 to 38%	None	No	No	No
86-004 Canadian Group 1990 Keown 1991 Laupacis 1991 FDA 1989	IV 100 U/kg to variable	9.5 to 11 vs 11.5 to 13 vs No EPO	None	Not entry QOL by target	No	No
8701 FDA 1989 Unpublished USA 3 sites	? Route 0 or 150 U/kg	35%	-	-	-	-
8904 FDA 1989 Unpublished	-	-	-	-	-	-
FDA 1989 Unpublished Canada 1 site	IV 0, 50, 100, or 200 U/kg	-	-	-	-	-
US-Teehan 1991 Abels 1990 G88-011 Lim 1989 ?Stone 1988 FDA 1989 USA 15 sites	IV 0, 50, 100, or 150 U/kg To IV or SQ & variable dose	-	None	No	No	No
FDA 1989 Kleinman 1989 ? Watson 1990 Complete study unpublished USA ? sites	SQ 0 or 100 U/kg (?150 U/kg extension)	-	None	-	-	-
FDA 1989 Unpublished Europe ? sites	IV 50, 100, or 150 U/kg	-	-	-	-	-

IV = intravenous
 QOL = quality-of-life
 SQ = subcutaneous

Table 3C: FDA Registration studies-Erythropoietin alpha (continued)*

Study	Results
8601 Eschbach 1989 x2, 1991 Adamson 1989 FDA 1989 USA 9 sites	T=0 hct data available for 304. Mean t=0 hct 22%. T=6 mos & 10 mos hct data available for n= 33 & 104. QOL testing limited to n=130 assessed at variable times. Reportedly transfusion need ↓, but no accounting for drop-out. Some kinds of transfusions, e.g., for dialysis blood loss not included in analysis. Non-responsive patients identified. Bone marrow bx not in protocol. HTN ↑ & perhaps associated with seizures. Vascular access clotting reported.
Canadian Group 1990 Keown 1991 Laupacis 1991 FDA 1989 Canada 13 sites	Mean t=0 hb 7 g/dl. Hb increased; mean dosing higher for higher targets. 41.5% had > 6U packed red blood cells in prior yr. ↓ transfusions in Epo groups. QOL reportedly better with Epo for Sickness Impact Profile, but > rigorous Time Trade-off ,score. Also not better. with higher vs lower Hb Epo tx levels. Kidney disease questionnaire Exercise stress test better, walking tolerance not better Diastolic HTN & vascular access clotting ↑. Bone marrow bx not in protocol.
8701 FDA 1989 Unpublished USA 3 sites	62/101 evaluable for efficacy Patients also evaluated after X-over in extension study Hct%: NA Transfusion: NA QOL: Karnofsky by patient; Nottingham Health Profile; National Kidney Dialysis & Kidney Transplantation Study; Single item patient-reported outcome: Per FDA meeting
8904 FDA 1989 Unpublished	Patients also evaluated after X-over in extension study Hct%: NA Transfusion: NA QOL : Karnofsky by patient; Nottingham Health Profile; National Kidney Dialysis & Kidney Transplantation Study; Single-item patient-reported outcome: Per FDA meeting
FDA 1989 Unpublished Canada 1 site	Hct increased per dose response: NA
US-Teehan 1991 Abels 1990 G88-011 Lim 1989 ?Stone 1988 FDA 1989 USA 15 sites	Mean t=0 hct 28.8%. Hct increased per dose response. Doses 75-150 U/kg TIW corrected hct. 106/117 completed 8 wks; 11 DC for AEs No transfusion data in FDA summary. No information on QOL instrument in methods. HTN adverse event data limited by lack of definition. Bone marrow bx done in 6 of Stone subset n=12 @8 wks. Concerns about doses ≥ 100 U/kg. (Stone) Pharmacokinetic data from 8 (Lim) Exercise data from 8 (1 placebo) (Lim)
FDA 1989 Kleinman 1989 ? Watson 1990	Hct corrected in 58% of Epo treated vs 4% of placebo No transfusion data in FDA summary. Bone marrow bx not in protocol. No complete publication. Kleinman subset n = 14. ?Watson subset n = 11.

Study	Results
Complete trial unpublished USA ? sites	
FDA 1989 Unpublished Europe ? sites	Hct increased per dose response: NA No transfusion data in FDA summary. Bone marrow bx not in protocol.

*Non-randomized studies not used for FDA approval such as Bommer 1987, Casati 1987, Eschbach 1987, Graf 1987, Moia 1987, Schaefer 1988, Strutz 1987, Winearls 1986 were not included.

? = unknown

↑ = increased

↓ = decreased

> = more (than)

Bx = biopsy

NA = not available for review

T = 0 = value at baseline or time zero

TIW = three time weekly

The registration clinical trials for erythropoietin-alpha assessed patient populations that differ from current renal populations. Many of the subjects were substantially more anemic than subjects in later trials. The mean hemoglobin in the Canadian study of hemodialysis patients was < 7 g/dl. Many of the subjects were substantially younger. The age in the Canadian study of hemodialysis patients is approximately 15 years younger than current hemodialysis patients. (Canadian Group, USRDS 2008, 2009) The Canadian study excluded patients with many co-morbidities including type 1 diabetes and patients who would not be likely to complete the exercise testing. Incident rates for diabetes in the dialysis population have doubled since 1990 (although the USRD data do not distinguish between type 1 and type 2 diabetes). (USRDS 2008, 2009) More than 36% of current dialysis patients have walking disabilities and more than 26% use assistive devices. (USRDS 2008) Co-morbidities markedly increase the likelihood of wheelchair use. (USRDS 2008)

The registration trials for erythropoietin-alpha did not distinguish between the various stages of pre-dialysis renal disease and used an insensitive measure of glomerular filtration function, (serum creatinine 3-10 g/dL). Causes of anemia other than iron, folate, and B-12 were not excluded. Bone marrow biopsies were not obtained. Multiple myeloma was indentified incidentally in one patient.

The registration trials did not always account for all patients or conduct intent-to-treat analyses. Amgen briefing materials indicate that 426 patients entered the single-arm phase III 12+ week trial (www.amgen.com/pdfs/misc/2007-AMGEN-FDA-CADRC.pdf; accessed July 19, 2010). Published materials suggest that only 333 patients entered the study (Eschbach 1989) and that only 309 had evaluable data (Adamson 1989). Reportedly only 266 remained on therapy 13 months after study initiation. The drop-out rate in the 6-month Canadian study was 16%. Subjects were not assessed unless they completed outcome assessments at four time points. There were no intent-to-treat analyses. The drop-out rate in the 8-week Teehan study was 10% and was due to adverse events. Curiously most of the drop-outs in the placebo cohort occurred early (10.5 days) versus late in the treatment cohorts (36.0 days). The presence of cancer in three participants raises questions about the screening procedures. The statistical plan did not delineate whether per-protocol or intent-to-treat analyses were conducted.

The registration trials were relatively small, short in duration, and focused on surrogate endpoints (hemoglobin [hematocrit] levels and changes in hemoglobin [hematocrit] levels), transfusion reduction, and quality-of-life including self reports of physical function (Tables 4 and 5). Hemoglobin levels did increase for many patients, but the studies provided no information on the characteristics of patients who required more than physiologic replacement to obtain a response or who did not respond. Nor did the studies provide information on the likelihood of response based on the pre-treatment hemoglobin (hematocrit) level. No patients were transfused in the pre-dialysis study (Table 5). Twenty five patients were transfused in the hemodialysis study and most of these were in the placebo arm (Table 4). There was an imbalance at baseline for transfusion dependence in favor of the high target erythropoietin arm. There were, however, no validated hemoglobin (hematocrit) thresholds for initiating transfusion. Nor were there pre-specified transfusion protocols. Information on the number of units transfused, the number of units per transfused person, the reason for transfusion, and the characteristics of the patients who received transfusion was lacking.

Quality-of-life data were submitted for the published Canadian hemodialysis (86-004) and the uncontrolled open-label 8601 studies. Reportedly data were also submitted for two unpublished studies in hemo- and peritoneal dialysis patients (8701 and 8904). None of the instruments used were validated to assess health-related quality-of-life in the populations studies. Some studies employed modified instruments and post-hoc analyses. There were no pre-specified power calculations based on values and changes in values established to be clinically meaningful. There were no pre-specified plans for addressing missing data. Changes in anemia symptoms and health-related quality-of-life parameters did not correlate with hemoglobin levels and changes in hemoglobin levels (\pm stratification based on baseline hemoglobin levels). The open-label design limited any interpretation of the self-report data. The short study lengths did not permit assessment of durability of any health-related quality-of-life improvements potentially attributable to a drug intended to be given on a chronic basis. The exclusion criteria for co-morbid conditions did not permit assessment of any health-related quality-of-life improvements in sicker populations. Although such claims were initially present in the label (*...Once the target hematocrit (32% to 38%) was achieved, statistically significant improvements were demonstrated for most quality of life parameters measured, including energy and activity level, functional ability, sleep and eating behavior, health status, satisfaction with health, sex life, well-being, psychological effect, life satisfaction, and happiness. Patients also reported improvement in their disease symptoms. They showed a statistically significant increase in exercise capacity (VO² max), energy, and strength with a significant reduction in aching, dizziness, anxiety, shortness of breath, muscle weakness, and leg cramps...*), after re-analysis by the FDA, the claims were removed the label and the FDA issued a guidance document for patient-reported outcome (PRO) claims. (2009 FDA Guidance Document for Patient-Reported Outcomes, Trentacosti 2007 Slide Set)

Table 4: Anemia and Transfusion in the Canadian Group Study: Hemodialysis 6 Month Study (Mean Age Mid 40s)

Blood Parameter	Placebo	Hct target 9.5-11% vol Variable IV dose 3x/wk	Hct target 11.5-13% vol Variable IV dose 3x/wk
Baseline Hct	7.1 \pm 0.9 n=40	6.9 \pm 1.0 n=40	7.1 \pm 1.2 n=38
Hct at 6 mo (completers)	7.4 \pm 1.2 n=32	10.2 \pm 1.0 n=34	11.7 \pm 1.4 n=33
Hct at end (ITT)		-	
Transfusion—patient number	23	1	1
Transfusion—number of blood units		-	
Transfusion—number of units/person transfused		-	
Transfusion—number of transfusions by <i>a priori</i> protocol established criteria		-	
Transfusions—number of transfusions for hct < 10		-(GI bleed)	(During surgery)
Transfusions—number of transfusions for hct < 7		-	
Transfused in prior year	7.3 \pm 8.3	6.6 \pm 6.8	5.6 \pm 6.4

Blood Parameter	Placebo	Hct target 9.5-11% vol Variable IV dose 3x/wk	Hct target 11.5-13% vol Variable IV dose 3x/wk
Transfusion dependent (≥ 6 transfusions/year; > 2 transfusions in 3 months if dialysis just started)	19	19	11
Anemia evaluation	Fe tests at t=0 & during study; Fe given prn	Fe tests at t=0 & during study; Fe given prn	Fe tests at t=0 & during study; Fe given prn

Fe+ = iron

Hct = hematocrit

ITT = intent-to-treat analysis

IV = intravenous

PRN = as needed

T = 0 = value at baseline or time zero

Table 5: Anemia and Transfusion in US Human Recombinant Erythropoietin Pre-dialysis Study Group (Teehan 1991) 8 Week Study (Mean Age 57.1 yrs)

Blood Parameter	Placebo	50 u/kg 3x/wk IV	100 u/kg 3x/wk IV	150 u/kg 3x/wk IV
Baseline Hct	M 29.9 ± 4.1 n=17 F 28.4 ± 3.1 n=12	M 29.7 ± 3.8 n=18 F=28.4 ± 2.6 n=10	M 29.4 ± 4.7 n=17 F 27.0 ± 2.1 n=11	M 28.2 ± 5.6 n=17 F 29.7 ± 3.3 n=13
Hct at 6 mo (completers)				
Hct at end (ITT)				
Hct ↑ of 6% vol during 8 wks	N=3	N=16	N=22	N=27
Discontinuation	N=4	N=1	N=3	N=3
Transfusion—patient number	N=0	N=0	N=0	N=0
Transfusion—number of blood units				
Transfusion—number of units/person transfused				
Transfusion—number of transfusions by <i>a priori</i> protocol established criteria				
Transfusions—number of transfusions for hct < 10				
Transfusions—number of transfusions for hct < 7				
Transfused in prior year				
Transfusion dependent (≥ 6 transfusions/year; > 2 transfusions in 3 months if dialysis just started)				
Anemia evaluation	Fe, B-12, Folate tests at t = 0. Folate given.	Fe, B-12, Folate at t = 0. Folate given.	Fe, B-12, Folate at t = 0. Folate given.	Fe, B-12, Folate at t = 0. Folate given. Multiple Myeloma incidentally found later

F = female
Fe + = iron
Hct = hematocrit
ITT = intent-to-treat analysis
IV = intravenous
M = male
"T = 0" = value at baseline or time zero

Although hypertension and thrombosis were observed, the registration studies were not structured to assess mortality, chronic morbidity, and less frequent adverse events. Although reversible bone marrow fibrosis, which would be distinct from that associated with profound hyperparathyroidism in some dialysis patients, was observed in the longer rodent and canine studies, no large and long-term studies with randomization (or stratification) by ESA dose assessed bone marrow changes. (Akada 2010, Bader 1992, Barosi 2005, Dokal 1989, Epogen label, Gallieni 2000, Kakumitsu 2005, Lacout 2006, Levine 2005, Reilly 1997, Tulliez 1989, Wernig 2006) Although animal carcinogenicity studies are frequently required for drugs, including hormones which can act as growth factors, e.g., insulin products, there were no such studies in the registration package. None of the registration clinical trials were long or large enough and included the appropriate patient populations to exclude oncogenic or promoter activities—especially with supraphysiologic doses (either via compressed dosing regimens, intravenous route of administration, or dose levels). Drug exposure in the registration trials was insufficient to reveal the subsequently identified antibody-mediated red cell aplasia associated with either long-term exposure to the active agent or package leachates. (Boven 2005, Howman 2007, Jacob 2006, Ryan 2006, Schellekens 2006) The registration studies for erythropoietin did not include analysis of safety and efficacy in geriatric patients (≥ 65 years) and racial-ethnic groups. Nor did they include drug interaction studies—although medications frequently used in the renal population, e.g., the anti-hypertensive, anti-proteinuric angiotensin-converting enzyme (ACE) inhibitors are thought to impair erythropoietin (endogenous and exogenous) efficacy. (Cruz 1996, Hayashi 2001, Quereshi 2007, Ripamonti 2006)

ii. Pivotal Registration Studies for Analogues

aa. Darbepoetin (Trade name: Aranesp)

The pivotal registration trials for darbepoetin were non-inferiority studies (Table 6). (Nissenson 2002, Varenterghem 2002) They included only patients who had previously been on ESAs. The populations were different than the original erythropoietin populations. In double-blind Study (970)117 based in North America, the 522 hemodialysis patients were more than a decade older (mean 57.9 years, range 20-90 years), they were less anemic albeit not ESA-naive, (mean hemoglobin 11.2 g/dl; range 9.6-12.6 g/dl), and hypertension and diabetes were found in 26% and 35%. The mean erythropoietin dose at entry was 13,776 U/week (range 1200-120,000). (Weekly dose for a 70 kg person dosed at 50 U/kg is 10,500 units.)

In open-label study (970)200 based in Europe and Australia, the 522 dialysis patients were more than a decade older (mean 60.4 years, range 18-88 years), they were less anemic, (mean hemoglobin 11.0 g/dl; range 9.5-12.5 g/dl), and hypertension and diabetes were found in 8% and 15%. The median erythropoietin dose at entry was 6,000 U/week (quartiles 4,000-9,000) (half of the 117 entry dosing).

The randomization for darbepoetin:erythropoietin was 1:2 for study 117 (reportedly an error, but one which limited darbepoetin exposure) and 2:1 for study 200. Neither study used fixed doses. Study 117 used only IV administration whereas Study 200 used both SQ and IV administration. Although the studies excluded patients with more established risk factors for ESA resistance such as inflammation, neither study assessed the potential impact of ACE inhibitors or ARBs on efficacy. Neither study had an algorithm for transfusion use and neither reported transfusion results (Table 9). Non-compliance and drop-out was high, limiting per-protocol analysis to approximately 70% of the initial population. For study 117, the death rates during the study or the 30 day follow-up period after last dose were 5% (9/169) for the darbepoetin arm and 7% (23/338) for the erythropoietin arm. For study 200, the death rates during the study, by the last contact date, and/or the 28 day follow-up period after the last dose were 12% (41/346) for darbepoetin and 6% (11/173) for erythropoietin (p = 0.06). Reportedly, the death rates converged at two year follow-up (19% vs 17%). Although these data suggest different time-to-death profiles for the two ESAs, survival curves were not provided. There was no analysis and discussion of the role that the different study doses might have played in the different mortality outcomes.

Two other major clinical studies were included in the registration package (Unpublished Study 211, Locatelli 2001 Study 980202. See ESA Type). Study 202 was open-label and enrolled 166 ESA-naïve, pre-dialysis patients for 3:1 darbepoetin:erythropoietin randomization with doses to be titrated over 24 weeks. Study 211 open-label and enrolled 122 ESA-naïve dialysis patients for 3:1 darbepoetin:erythropoietin randomization with doses to be titrated over 20 weeks. In both studies the major contributing causes to renal disease were diabetes and/or hypertension. The pre-dialysis patients were almost 8 years older than the dialysis patients. Both populations were less anemic than the original erythropoietin populations: Study 211 basal hemoglobin 8.6 g/dl; Study 202 basal hemoglobin 9.4 g/dl. Neither study was designed for rigorous statistical evaluation as either superiority or non-inferiority trials. The results are most notable for high frequency of transfusion in the darbepoetin arm, 27% of patients, versus the erythropoietin arm, 16% of patients in Study 211. This study remains unpublished.

The registration package did not include drug interaction studies, animal/human marrow studies for fibrosis (and resistance), and animal carcinogenicity studies.

The FDA review concluded that darbepoetin and erythropoietin are equivalent ESAs. Darbepoetin, however, does not carry the indication for transfusion reduction (only anemia management) because non-inferiority designs were used in the pivotal registration studies. In addition, the FDA reviewers noted that the pharmacokinetic relationship between the compounds is not linear and that IV administration may require higher dosing than with SQ administration (Table 9). Their composite analysis of the registration studies reportedly demonstrated equivalent safety and efficacy in geriatric patients (486 patients aged 65 to 74 years and 306 patients aged 75 years and older). There were 360 non-Caucasian patients (Black n = 234, Asian n = 54, Hispanic n = 36, Other = 36) in the study populations; limiting conclusions about safety and efficacy in racial-ethnic groups. The absence of placebo control and fixed doses in the clinical studies limited the conclusions that could be drawn about compound specific effects versus ESA class effects and the role of hemoglobin level versus dose on safety endpoints.

Table 6A: FDA Registration studies-darbepoetin alpha

Study	Population	Blind	Size	Duration	Entry Criteria	Exclusion Criteria
Study 117 Nissenson 2002 (IND) US sites 35 Canadian sites 5	HD Adult (57.9 yrs; range 20-90)	Double Blind Active Control	507(504) (1D:2 E) 361 PP	28 wk randomized tx 4 wk screening	Hb 9.5-12.5 g/dl (Actual hb 11.2 g/dl; range 9.6-12.6 g/dl) Stable IV Epo dose	Infection, inflammation Congestive heart failure Seizures Uncontrolled HTN Fe deficiency Recent transfusion

Study	Population	Blind	Size	Duration	Entry Criteria	Exclusion Criteria
(Amgen)						
Study 970200 or 200 Varenterghem 2002 (Non-IND) European sites 27 Australian sites 4 (Amgen)	HD, PD Adult (60.4 yrs; range 18-88)	Open-label Active Control	522(519) (2D:1E) 366 PP	32 wk randomized tx 4 wk screening +20 wk maintenance	Hb 9.5-12.5 g/dl Stable Epo dose	Infection, inflammation CHF, Seizures Uncontrolled HTN Fe deficiency Recent transfusion

CHF = congestive heart failure

D = darbe = darbepoetin

E = Epo = erythropoietin

Fe = iron

Hb = hemoglobin

HD = hemodialysis

HTN = hypertension

IND = study performed as an investigational new drug under the purview of the FDA

IV = intravenous

PD = peritoneal dialysis

PP = per protocol

Table 6B: FDA Registration studies-darbepoetin alpha (continued)

Study	Dose	Target Hb(Hct)	Transfusion Criteria	Stratification by		
				Hb (Hct)	Dose	Dialysis Adequacy or Renal Clearance
Study 117 Nissenson 2002 (IND) US sites 35 Canadian sites 5 (Amgen)	IV Initial dose based on prior Epo dose Epo 3x/wk vs Darbe 1x/wk + 2x/wk placebo Doses titrated	Hb within -1 & 1.5 g/dl of t=0 Hb 9-13 g/dl	-	- (Actual hb 11.2 g/dl; range 9.6-12.6 g/dl)	- (Actual t=Epo dose 13,776;1.2- 120 x10 ³ U/wk)	-
Study 970200 or 200 Varenterghem 2002 (Non-IND) European sites 27 Australian sites 4 (Amgen)	IV or SQ Initial dose based on prior Epo dose Epo same route & regimen vs Darbe q2 wk (if prior Epo 1x/wk) or 1x/wk (if prior Epo 2-3x/wk) by prior route Doses titrated	Hb within -1 & 1.5 g/dl of t=0 Hb 9-13 g/dl	-	- (Actual hb 11.2 g/dl; range 9.5-12.5 g/dl)	- (Actual t=median Epo dose 6000; quartiles 4-9 x10 ³ U/wk)	-

Hct = hematocrit

SQ = subcutaneous

Table 6C: FDA Registration studies-Darbepoetin alpha (continued)

Study	Endpoint/Results
Study 117 Nissenson 2002 (IND) US sites 35 Canadian sites 5 (Amgen)	Non-inferiority (Per-protocol)(~71-2% patients n=361)(drop-outs: 85; other non-per-protocol 68[71]) Endpoint Hb change t=0 to t=wk 21-28; also by regimen & route % hb values within target range (-1 & 1.5 g/dl of t=0; hb 9-13 g/dl) % dose change for out of range hb values Intra-patient hb variability Drug dose
Study 970200 or 200 Varenterghem 2002 (Non-IND) European sites 27 Australian sites 4 (Amgen)	Non-inferiority (Per-protocol)(~64% patients n=336)(drop-outs: ~76; other non-per-protocol ~110) Endpoint Hb change t=0 to wk 25-32 % hb values within target range (-1 & 1.5 g/dl of t=0; hb 9-13 g/dl) Intra-patient hb variability Transfusion level (not reported in paper; indicated in FDA review)

bb. Pegzerepoetin (Trade name: Mircera)

The six pivotal registration trials for methoxy polyethylene glycol-epoetin beta (pegylated erythropoietin) were non-inferiority studies (Table 7). (Canaud 2008, Klingler 2007, Levin 2007, Macdougall 2008, Spinowitz 2008, Sulowicz 2007) None of the studies were open-label. None had algorithms for transfusion use (Table 9). All excluded patients with inflammatory conditions that might induce ESA resistance.

Although the FDA medical officer review reported the inclusion of 559 patients 65 to 74 years of age (22%) and 508 patients 75 years of age or older (20%) in the pivotal trials, the label stated that there were insufficient numbers of patients for analysis of efficacy and safety in the geriatric population. The review also reported the inclusion of 476 patients of African descent (19%) and 127 patients of Asian descent (5%) in the pivotal trials. The FDA reviewer did note a higher incidence of death in Asian patients exposed to pegzerepoetin (5%) than Asians in the reference arms (2%), but cautioned about over-interpretation.

The registration package did not include animal carcinogenicity studies, animal/human marrow studies for fibrosis (and resistance), or drug interaction studies. The FDA review did note that more patients in the pegylated erythropoietin treatment arms (7.5%) than patients in active control ESA arms (4.4%) were likely to have decreased platelet counts (< 100x10⁹/L) and that there were more patients with serious bleeding episodes (and gastrointestinal hemorrhage in particular) in the pegylated arms (5.2% [1.2 %]) versus the ESA reference arms (4% [0.2 %]). The report did not provide any correlative information about these adverse events: whether the thrombocytopenia was related to the serious bleeding or whether the thrombocytopenia was related to marrow fibrosis or poor marrow reserve in the setting of chronic supraphysiologic ESA stimulation.

The FDA review concluded that pegylated erythropoietin-beta is equivalent to the other approved ESA, darbepoetin and erythropoietin-alpha. Pegylated erythropoietin, however, does not carry the indication for transfusion reduction (only anemia management) in renal disease because non-inferiority designs were used in the pivotal registration studies (Table 9). (Pegylated erythropoietin-beta is not indicated for anemia in the oncologic setting; drug development for this indication was terminated because of increased mortality in an early comparative dose ranging study.) The absence of placebos control and fixed doses in the clinical studies limited the conclusions that could be drawn about compound specific effects versus ESA class effects and the role of hemoglobin level versus dose on safety endpoints.

Table 7A: FDA Registration studies-Pegylated erythropoietin-beta

Study	Population	Blind	Size	Duration	Entry Criteria	Exclusion Criteria
Canaud (STRIATA) 2008 (Hoffmann La Roche)	HD, PD On IV darbe Adult	Open Active Control	313	36 wk randomized tx +16 wk safety period	Hb 10.5-13 g/dl HD Kt/V \geq 1.2; URR \geq 65% PD Kt/V >1.8 Adequate Fe	“Non-renal” anemia CRP $\uparrow\uparrow$ Life expectancy <12 mo
Klinger (AMICUS) 2007 (Hoffmann-LaRoche)	HD, PD Adult	Open Active Control	181 (C3:E1)	24 wk randomized tx (Part 1 ESA type)	Hb 8-11 g/dl HD Kt/V \geq 1.2;URR > 65% PD Kt/V \geq 1.8 Adequate Fe	Recent ESA use “Non-renal” anemia CRP $\uparrow\uparrow$ Uncontrolled HTN No severe disease No recent transfusion
Levin (MAXIMA) 2007 (Hoffmann La Roche)	HD, PD On IV epo 1- 3x/wk Adult	Open Active Control	673	36 wk randomized tx +16 wk safety period	Hb 10.5-13 g/dl Adequate Fe	“Non-renal” anemia CRP $\uparrow\uparrow$ No recent transfusion Life expectancy <12 mo
Macdougall (ARCTOS) 2008 (See Kessler 2010 extension with regimen change) (Hoffmann-LaRoche)	CRI Stage 3-4 Adult	Open Active Control	324	28 wk randomized tx + 24 wk re-randomi- zation in CERA	Hb 8-11 g/dl Adequate Fe	Stated ESA naïve, but really no recent ESA “Non-renal” anemia CRP \uparrow PLTs $\uparrow\uparrow$ Uncontrolled HTN Immuno-suppression Expected need for dialysis <6 mo No severe disease Life expectancy <12 mo No recent transfusion
Spinowitz (RUBRA) 2008 (Hoffmann La Roche) (See regimen)	HD, PD On Epo IV SQ Adult	Open Active Control	336(333)	36 wk randomized tx 4 wk baseline	Hb 10.5-13 g/dl HD (Kt/V \geq 1.2; URR \geq 65%) PD (Kt/V \geq 1.8) Adequate Fe	“Non-renal” anemia CRP $\uparrow\uparrow$ Life expectancy < 12 mo No recent transfusion
Sulowicz (PROTOS) 2007	HD, PD On SQ Epo Adult	Open Active Control	572	36 wk randomized tx +16 wk safety period	Hb 10.5-13 g/dl HD Kt/V \geq 1.2;URR > 65%	“Non-renal” anemia CRP $\uparrow\uparrow$

Study	Population	Blind	Size	Duration	Entry Criteria	Exclusion Criteria
(Hoffman-LaRoche)					PD Kt/V ≥ 1.2 Adequate Fe	PLTs ↑↑ Uncontrolled HTN No severe disease No recent transfusion

↑↑ = markedly increased

C = CERA= continuous erythropoiesis receptor activator=methoxy polyethylene glycol epoetin beta=pegylated erythropoietin-beta

CRI = chronic renal insufficiency; stage 3 & 4 are pre-dialysis

CRP = C-reactive protein

Darbe = darbepoietin

E = Epo = erythropoietin

Fe = iron

Hb = hemoglobin

HD = hemodialysis

HTN = hypertension

IV = intravenous

Kt/V = dialyzer clearance of urea x dialysis time/ volume of urea distribution in the body (measure of dialysis adequacy)

PD = peritoneal dialysis

PLTs = platelets

SQ = subcutaneous

URR = urea reduction ratio (measure of dialysis adequacy)

Table 7B: FDA Registration studies-Pegylated erythropoietin-beta (continued)

Study	Dose	Target Hb(Hct)	Transfusion Criteria	Stratification by		
				Hb (Hct)	Dose	Dialysis Adequacy or Renal Clearance
Canaud (STRIATA) 2008 (Hoffmann La Roche)	CERA IV q2 wks based on prior Darbe doses. Could be as high as Darbe >80 ug/wk, CERA 180 ug q 2wks.	Hb 10-13.5 g/dl Hb ±1 g/dl of baseline Doses titrated	-	-	-	-
Klinger (AMICUS) 2007 (Hoffmann-LaRoche)	CERA IV q2 wks. Start 0.40 ug/kg/2 wks Epo [alpha, beta] IV 3x/wk at approved tx doses	Hb ≥11 g/dl Hb ↑ of ≥1 g/dl Doses titrated	-	-	-	-
Levin (MAXIMA) 2007 (Hoffmann La Roche)		Hb 10-13.5 g/dl Hb ±1 g/dl of baseline Doses titrated	-	-	-	-

Study	Dose	Target Hb(Hct)	Transfusion Criteria	Stratification by		
				Hb (Hct)	Dose	Dialysis Adequacy or Renal Clearance
	CERA SQ q2 wks & q 4 wks based on prior Epo [alpha, beta] doses. Could be as high as Epo > 16,000 U/wk, CERA 180 ug q 2 wks & 360 ug q4 wks.					
Macdougall (ARCTOS) 2008 (See Kessler 2010 extension with regimen change) (Hoffmann-LaRoche)	CERA SQ started at 0.6 ug/kg/2 wks. Darbe SQ started at 0.45 ug/kg/wk	Hb ≥11 g/dl Hb ↑ of ≥1 g/dl Doses titrated	-	-	-	-
Spinowitz (RUBRA) 2008 (Hoffmann La Roche) (See regimen)	CERA SQ, IV q2 wks & q 4 wks based on prior Epo [alpha, beta] doses & prior route. Could be as high as Epo > 16,000 U/wk, CERA 180 ug q 2 wks.	Hb 10-13.5 g/dl Hb ±1 g/dl of baseline Doses titrated	-	-	-	-
Sulowicz (PROTOS) 2007 (Hoffman-LaRoche)	CERA SQ q2 wks & q 4 wks based on prior Epo [alpha, beta] doses. Could be as high as Epo > 16,000 U/wk, CERA 180 ug q 2 wks & 360 ug q4 wks.	Hb 10-13.5 g/dl Hb ±1 g/dl of baseline Doses titrated	-	-	-	-

D = Darbe = darbepoetin

Table 7C: FDA Registration studies-Pegylated erythropoietin-beta (continued)

Study	Results
Canaud (STRIATA)	Efficacy response rate=Change in Hb level t=0 & wks 29-36. Non-inferiority in the per-protocol population. (D -0.12 g/dl vs C 0.06 g/dl)

Study	Results
2008 (Hoffmann La Roche)	Hb level (D 11.8 g/dl vs C 12.1g/dl) Hb + 1 g/dl of baseline (ITT population) (D 65.5% vs C q2wk 71.8%) Hb variability (mean within pt SD) (D 0.5 g/dl vs C 0.6 g/dl) Transfusions (D 10.3% vs C q2wk 12.4%)(Hb prior to transfusion recorded) Death rate (D 7.7%, C q2wk 8.5%)
Klinger (AMICUS) 2007 (Hoffmann-LaRoche)	Efficacy response rate = Hb >11 g/dl & Hb ↑ of ≥ 1 g/dl during 24 wks; Per-protocol (C 98.3% vs E 97.2%) ITT (C 93.3% vs E 91.3%); Post hoc non-inferiority. Doses to achieve response rate QOL-short SF 36 Transfusions Fe supplementation requirements Cardiovascular disease imbalance at baseline E > C
Levin (MAXIMA) 2007 (Hoffmann La Roche)	Efficacy response rate=Change in Hb level t = 0 & wks 29-36. Non-inferiority in the per-protocol population. (E - 0.75 g/dl vs C q2wk -0.71 g/dl, C qmo -0.25 g/dl) Hb + 1 g/dl of baseline (during wks 29-36) (E 67% vs C q2 wks 68%, C q1 mo 68%) Hb variability (mean within pt SD)(post hoc) (E 0.6 vs C q2wk 0.6, C qmo 0.6 during wks 29-36) Transfusion incidence (E 8%, C q2wk 10% C qmo 7%) Death rate (E 8%, C q2wk 9% , C qmo 7%)
Macdougall (ARCTOS) 2008 (See Kessler 2010 extension with regimen change) (Hoffmann-LaRoche)	Efficacy response rate = Hb >11 g/dl & Hb ↑ of ≥1 g/dl during 28 wks. Per-protocol (D 99.3% vs C 99.3%) Hb level over time (D 12.0 g/dl vs 12.2 g/dl at 28 wks) Time to hb target (Median D 29 days vs C 43 days) Transfusion incidence (6.8% vs C 2.5%) QOL Short SF-36 (not clear if any differences were significant [biologically, statistically]; only reported improved from baseline) Deaths (D 6% vs C 5%)
Spinowitz (RUBRA) 2008 (Hoffmann La Roche)	Change in Hb level t = 0 & wks 29-36. Non-inferiority in the per-protocol population. (E -0.01 g/dl vs C 0.14 g/dl) Effect of route on primary endpoint No difference Hb + 1 g/dl of baseline (ITT population) Transfusions (ITT population) (E 11.3% vs C 9.7%) Doses (Median E 7,310 IU/wk [IQR: 4,000–13,800] vs C 60 ug/2 wks [IQR: 36–94]) Death rate (E = 10 vs C = 7)
Sulowicz (PROTOS) 2007 (Hoffman-LaRoche)	Efficacy response rate = Change in Hb level t = 0 & wks 29-36. Non-inferiority in the per-protocol population. (E - 0.11 g/dl vs C q2 wks 0.03 g/dl, C q1 mo -0.13 g/dl) Hb level (E 11.5 g/dl vs C q2wk 11.7 g/dl, C qmo 11.5 g/dl) (PP) Hb + 1 g/dl of baseline (ITT population) (E 72.2% vs C q2wk 75.6%, C qmo 66.1%) Hb variability (mean within pt SD)(post hoc) E 0.6 g/dl vs C q2 wks 0.5 g/dl, C q mo 6 g/dl) Transfusion incidence (E 9.9% vs C q2wk 6.3%, C qmo 10.5%) Death rate (E 1-3x/wk 6.3%, C q2wk 6.8%, C qmo 9.5%)

Study	Results
-------	---------

Fe = iron
 ITT = intent-to-treat
 Q = each
 QOL = quality-of-life
 SD = standard deviation
 SF-36 = Short Form Health Survey
 cc. Peginisatide

There were four pivotal trials intended for registration of the long-acting erythropoietin receptor stimulator, peginisatide (formerly known as hematide). All utilized an open-label, non-inferiority design (Table 8). (Analyst Day handout) Two were conducted in pre-dialysis patients (PEARL 1 and 2); two in dialysis patients (EMERALD 1 and 2). Hemoglobin changes from week 29 to 36 weeks (primary endpoint), the percentage of patients with hemoglobin increases > 1 g/dl and hemoglobin > 11 g/dl from week 29 to 36 weeks (secondary endpoint), and the percentage of patients who transfused during the 36 week study (secondary endpoint) were equivalent to predicate ESAs in dialysis populations. (These endpoints, however differed from those delineated in ClinicalTrials.gov and listed in Table 8C) (www.finance.yahoo.com/news/Affymax-to-Webcast-Analyst-bw-910437963.html?x=0&.v=1&vm=r; accessed November 10, 2010; www.shareholder.com/visitors/event/build2/mediapresentation.cfm?companyid=AFFY&mediaid=45251&mediauserid=4919438&TID=1078036874:aa4491b89ab2533a970727d26a7a8006&popupcheck=0&shexp=201102071258&shkey=71daf8baad92c9d1eb8eab268072410d&player=; accessed November 29, 2010; Piper Jaffray Healthcare Conference webcastingplayer.corporate-ir.net/player/PlayerHost.aspx?EventId=3497574&StreamId=1599057&TIK={B08FA7B7-20ED-4444-83F5-92B77BAF8ACB}&RGS=1; accessed December 1, 2010; www.talkpoint.com/content/17720C7F-49B7-4601-9993-DF7181F618CB/EE00B7DE-7621-4FBC-BC79-37F2B1B47529/35B0C560-15DB-48DB-B55F-AD3F0786CC5B/3/AffymaxAnalystDay122.pdf; accessed December 2, 2010.)

In the PEARL 2 study, more patients on low and high dose peginesitide, 11.4% and 10.4%, versus 4.9% on darbepoetin received transfusions. There were similar trends, although less robust, in PEARL 1. There were more patients with cardiovascular events (death, stroke, myocardial infarction, congestive heart failure, unstable angina, and arrhythmia) in the pooled PEARL studies: 21.6 % in the peginesatide arm versus 17.1% in the erythropoietin arm. The largest differences were seen in death (8.8% versus 6.7%, arrhythmia 2.4% versus 4.0%, and unstable angina 2.4% versus 0.9%). Most of the differences were found in PEARL 2; some, but not all were attributed to baseline imbalance.

Table 8A: FDA Registration studies-Peginesatide

Study	Population	Blind	Size	Duration	Entry Criteria	Exclusion Criteria
Study AFX-01-012 Emerald 1 (unpublished) (Affymax/Takeda)	HD Adult (median ~54; 49-67)	Open-label Active Control	803 (2:1 P:E)	36 wk randomized tx 4 wk screening	Hb 10-12 g/dl	Bleeding disorders Non-renal anemia Cancer Uncontrolled HTN
Study AFX-01-014 Emerald 2 (unpublished) (Affymax/Takeda)	HD Adult (median 59; 50-69)	Open-label Active Control	823 (2:1 P:E)	36 wk randomized tx 4 wk screening	Hb 10-12 g/dl	Bleeding disorders Non-renal anemia Cancer Uncontrolled HTN

www.clinicaltrials.gov/ct2/show/NCT00597753?term=affymax&rank=10

E = erythropoietin
Hb = hemoglobin
HD = hemodialysis
HTN = hypertension
P = peginesatide

Table 8B: FDA Registration studies-Peginesatide (continued)

Study	Dose	Target Hb(Hct)	Transfusion Criteria	Stratification by		
				Hb (Hct)	Dose	Dialysis Adequacy or Renal Clearance
Study AFX-01-012 Emerald 1 (Affymax/Takeda)	IV Doses titrated	Hb 10-12 g/dl	-	-	-	-
Study AFX-01-014 Emerald 2 (Affymax/Takeda)	IV Doses titrated	Hb 10-12 g/dl	-	-	-	-

Table 8C: FDA Registration studies-Peginesatide (continued)

Study	Endpoint/Results
Study AFX-01-012 Emerald 1 (Affymax/Takeda)	Non-inferiority Hb change t = 0 to wk 36 % patients with mean hb values between 10-12 g/dl t = 0 and 8 wks % patients transfused t=0 to 36 wks
Study AFX-01-014 Emerald 2 (Affymax/Takeda)	Non-inferiority Hb change t = 0 to wk 36 % patients with mean hb values between 10-12 g/dl t = 0 and 8 wks % patients transfused t=0 to 36 wks

Table 9: Anemia and Transfusion in ESA Analogue/Receptor Activator Pivotal Trials

Study	Randomized	Completed	Per-protocol	Hb (g/dl)	Dose (weekly) By wt*	Transfusion	Deaths
Nissenson 2002 Study 117	507 (D1:E2)	423	361	PP Wk 28 Mean from graph E 3x/wk ~ 11.2 D 1x/wk ~ 11.2	PP Wks 21-28 IV Mean(SD) E 3x/wk 13639 (12805) D 1x/wk 54.2 (47.6) Median (range) E 3x/wk 9900 (0-78,750)	? E 3x/wk 11% D 1x/wk 10% Transfusion > 1 unit	Safety T+ 28 d f/u E 3x/wk 23(6.9%) D 1x/wk 9(5.3%)

Study	Randomized	Completed	Per-protocol	Hb (g/dl)	Dose (weekly) By wt*	Transfusion	Deaths
					D 1x/wk 38.0 (0-309.0)	PP Wks 11-28 (endpoint) E 3x/wk 21(8.8%) D 1x/wk 7(5.8%)	
Varenterghem 2002 Study 970200 or 200	522	389	336	?Wk 24-32 Mean from graph E 1-3x/wk ~10.8 D q1or2/wks ~10.8	IV SQ Mean from graph for 4 wk period immediately after wk 24-32 evaluation period E 1-3x/wk IV ~ 7000 SQ 5000 D q1 or 2/wks IV ~ 27 SQ ~ 28	E 1-3x/wk D q1 or 2/wks	E 1-3x/wk 11/173(6%) D q1 or 2/wks 41/346(12%)
Canaud 2008 (STRIATA)	313	249	249	PP Mean(SD) Wks 29-36 D q1-2 wks 11.8 + 1.0 C q2 wks 12.1 + 1.0	?PP Median(range)* Wks 29-36 D q1-2 wks 28.1(17.6-52.0) C q2 wks 24.1(13.1-37.2)	? over 16 wks D q1-2 wks 10.3% C q2 wks 12.4%	ITT (unclear if 36 or 52 wks) Patient#(%) D q1-2 wks 10 (6.4%) C q2 wks 12(7.6%)
Klinger 2007 (AMICUS)	181 (C3:E1)	164	155(148)	PP Mean(SD) Wk 24 IV E 3x/wk 12.0 + 1.1 C q2 wks 12.1 + 1.4 No recent ESA	ITT Median(range)* Wk 24 IV E 3x/wk 5484 (2939-10186) C q2 wks 20.4 (8.1-31.2)	ITT Patient#(%) E 3x/wk 2(4.3%) or 3(6.5%) conflict C q2 wks 7(5.2%)	ITT Patient#(%) E 3x/wk 0(0%) C q2 wks 2(1.5%) (1 requested dialysis DC)
Levin 2007 (MAXIMA)	673	566	540	PP Mean(SD) Wks 29-36 E 1-3x/wk 11.9 + 0.8 C q2 wks 11.9 + 1.1 C q4 wks 11.9 + 1.0	Safety Median(range)* Wks 29-36 IV E 1-3x/wk 10800(6-18000) C q2 wks 28.5(14-50) C q4 wks 43.8(28.8-73)	Unclear if data collection limited to wks 28-36 or entire 36 wks E 1-3x/wk 17(8%) C q2 wks 21(10%) C q4 wks 16	ITT Patient#(%) [+ 16 wk f/u] [bf study end + after study completion or withdrawal] E 1-3x/wk 15(6.6%) 21(9.3%) 17(8%) C q2 wks 11(4.9%) 17(7.6%) 19(9%) C q4 wks 12(5.4%) 13(5.8%) 15(7%)
Macdougall 2008	324	297	283		?Median (no range)	Patient#(%) D 1x/wk 11(6.8%)	Safety Patient#(%) D 1x/wk 4(2.5)

Study	Randomized	Completed	Per-protocol	Hb (g/dl)	Dose (weekly) By wt*	Transfusion	Deaths
(ARCTOS)				?ITT Mean(noSD) Wk 28 D 1x/wk 12.0+?? C q2 wks 12. 2+ ?? No recent ESA	Wk 28 SQ D 1x/wk 15.3 +?? C q2 wks 13.1 +??	C q2 wks 4(2.5%)	C q2 wks 4(2.5%)
Spinowitz 2008 (RUBRA)	336(333)	282	256	PP Mean(SD) Wk 29-36 E 1-3x/wk 11.9 + 1.0 C q2 wks 11.9 + 1.0	Safety Median(range)* Wks 29-36 IV SQ E 1-3x/wk 7310 (4-13800) C q2 wks 30 (18-47)	Safety Transfusion#(Event#) E 1-3x/wk 59(23) C q2 wks 34(21)	Safety+F/U period Patient#(%) E 1-3x/wk 9+1(6.0%) C q2 wks 7 (4.2%)
Sulowicz 2007 (PROTOS)	572	499	474	PP Mean(SD) Wks 29-36 E 1-3x/wk 11.5 + 1.1 C q2 wks 11.7 + 1.0 C q4 wks 11.5 + 1.0	Safety Median(range)* Wks 29-36 SQ E 1-3x/wk 5500 (3-9000) C q2 wks 28 (13.5-42) C q4 wks 37.5(22.8-62.5)	Safety Patient#(%) E 1-3x/wk 19(9.9%) C q2 wks 12(6.3%) C q4 wks 20(10.5%)	Safety + F/U period Patient#(%) E 1-3x/wk 11 + 1(6.3%) C q2 wks 12 + 2(6.8%) C q4 wks 18(9.5%)

? = unknown if

C = CERA= continuous erythropoiesis receptor activator= methoxy polyethylene glycol epoetin beta=pegylated erythropoietin-beta

d = day

D = darbepoetin

DC = discontinued

E = erythropoietin

F/U = follow-up

ITT = intent-to-treat

IV = intravenous

PP = per protocol

SD = standard deviation

SQ = subcutaneous

T = study duration

iii. Other Potential Benefits from ESAs

We looked for other potential benefits from erythropoiesis stimulating agents including exercise capacity for activities of daily living, intermediate surrogates for cardiac function, progression to dialysis, and health-related quality-of-life measures.

aa. Exercise Capacity (Endurance; Strength)

We identified eight randomized studies with ESA as a treatment arm and objective measures of exercise capacity as endpoints (Table 10). Studies with patient-reported (n = 22) or physician-reported assessment (n = 2) of physical function were not included.

One of these studies (Furuland 2003), however, changed its focus from exercise to safety when many of the recruited subjects were unable to complete exercise testing. Another one of studies (Palazzuoli 2006) was conducted in congestive heart failure patients with some renal insufficiency and anemia. The congestive heart failure inclusion criteria were well defined and characterized: New York Heart Association Class 3 or 4 whereas the renal criteria were less well defined: serum creatinine less than 5 mg/dl (actual: 2.4 ± 0.5 g/dl).

Of the seven studies with exercise results, six were conducted in adults. One was conducted in children. Six were nominally double-blind. The largest study by Parfrey et al. blinded the patients and those conducting the assessment, but not the treating physicians. Of the remaining two studies, one was single-blind and the other open-label. Six studies were conducted in patients on dialysis; two were conducted in the pre-dialysis patient population. Four of the studies compared ESA treatment to no ESA treatment; one of these also employed hemoglobin target level cohorts. One of the studies included an exercise training variable in addition to ESA treatment at two hemoglobin target levels. Two studies had more than 100 participants. The first with n = 596 had a 54% completion rate; the other with n = 118 had an 84% completion rate. (Canadian 1990, Laupacis 1990, 1991, Parfrey 2005) Only one study, by Parfrey et al., had treatment arms longer than 12 months in duration. Many of the studies assessed peak oxygen consumption (VO_{2max}). Others assessed time or distance walked/biked-often, but not always, with formal stress testing. The baseline imbalance for exercise capacity in two studies was not addressed. (Canadian 1990, Clyne 1992, Laupacis 1990, 1991)

The studies reveal no consistent improvement in exercise capacity. In the largest study by Parfrey et al., there was intra-group improvement in the six-minute walk test for both of the treatment arms among patients who completed the study although there was no inter-group difference. There was no intra-group improvement for either treatment group when intent-to-treat analyses with last observation carried forward were conducted. In other words, there were no improvements when available results from the drop-out population (46%) were included-suggesting differences between the completer and drop-out patient populations regardless of treatment cohort. Even in the studies with reported improvement, performance results were noted to be sub-optimal. (McMahon 1999, 2000, Painter 2002) Analyses evaluating any potential correlation between hemoglobin and exercise capacity or between the change in hemoglobin and the change exercise capacity were not performed except in the Palazzuoli et al. study in congestive heart failure patients with mild renal insufficiency (N = 38). (Palazzuoli 2006) Indeed in the Painter et al. study with its four treatment arms, VO₂ improved in both of the treatment arms with exercise training regardless of hemoglobin target. A higher hemoglobin target did not confer any benefit for functional capacity.

Table 10: Exercise Studies

Study	Size	Duration	Blind	Hb(Hct)	Dose	Results
Canadian Group 1990 Laupacis 1990, 1991 Orthobiotech/ J&J	118 99 completers HD	6 mos	DB	11.5-13 vs 9.5 to 11 vs No EPO	Variable	Mean hb Δ 7.1 → 11.7 g/dl (↑ hgb) arm vs 6.9 → 10.2 g/dl (usual hb) vs 7.1 → 7.4 g/dl (placebo) (at 6 mo) Exercise stress test (time walked) better: 16.1 → 19.7 min (↑ hgb) vs 11.2 → 14.8 min (usual hb) vs 11.4 → 13.2 min (placebo)(at 6 mo) but imbalance at baseline Exercise tolerance (distance walked) not different: 470 → 521 m (↑ hgb) vs 418 → 451 m (usual hb) vs 421 → 440 m (placebo) (at 6 mo)

Study	Size	Duration	Blind	Hb(Hct)	Dose	Results
Clyne 1992 Swedish National Federation of Kidney Patients, Swedish Society of Nephrology, Karolinska Inst.	12 tx; 8 control CRI	3 mos	Open	30 vs No EPO	Variable	Mean hb Δ 8.6 \rightarrow 11.7 g/dl (Epo arm) vs 9.3 \rightarrow 9.4 g/dl (placebo) T=0 imbalance favored tx arm/determinationprocess/downloads/ Δ in maximal exercise capacity (bike) better 128 \rightarrow 145 W (Epo arm) vs 98 \rightarrow 101 W (placebo) Perceived exertion & leg fatigue did not differ by group
Furuland 2003 Janssen-Cilag	Adult 416 210 completers (33 withdrawn bc of Besarab study) CRI, HD, PD	48-76 wks Length \uparrow because of slow hb Δ	Open	13.5 -15 F & 14.5 -16 M vs 9-12	Variable	Mean hb Δ (48 wks) Pre-dialysis 10.6 \rightarrow 14.3 g/dl (\uparrow hgb) vs 10.9 \rightarrow 11.7 g/dl (usual hb) vs PD 11.2 \rightarrow 13.4 g/dl (\uparrow hb) vs 11.2 \rightarrow 11.5 g/dl (usual hb) vs HD 11 \rightarrow 13.5 g/dl (\uparrow hb) vs 11 \rightarrow 11.3 g/dl (usual hb) Powered for exercise tests. Exercise component not completed bc many patients could not perform test.
McMahon 1999, 2000 Janssen-Cilag, Australian Kidney Fdn, Thailand	Adult 30 sedentary 14 completers HD (X-over)	4-8 mo titration; 4 wk maintenance	DB	14 vs 10	Variable	Mean hb Δ ~8.6 \rightarrow ~14 g/dl (\uparrow hb) vs ~8.4 \rightarrow ~10.3 g/dl (usual hb) (in completers) Leg fatigue was the reason for exercise stoppage Peak work rate better (bike) at study end 145 (\uparrow hgb) vs 134 (usual hb) W (in completers); no t=0 Peak VO ₂ better (bike) at study end 19.9 (\uparrow hgb) vs 19.1 (usual hb) L/min (in completers); no t=0
Morris 1993 BM	Children 14 7 completers HD, PD (X-over)	2-24 wk tx arms	SB	10.5-12 g/dl vs placebo	Variable	Mean hb Δ 7.3 \rightarrow 11.2 gdl 2 minute walk test (only 7 old enough to do) approached, but did not reach statistical significance with n=7 in each arm Treadmill test (only 6 old enough to do; Bruce n=3; modified Bruce n=3) approached, but did not reach statistical significance with n=5 in each arm No means presented; individual patient results presented graphically
Painter 2002 Amgen	Adult 65 HD 55 completers	5 mos	DB	40-42 vs 30- 33 \pm exercise training	Variable	Mean hb Δ 10.5 \rightarrow 13.1 g/dl (\uparrow hb) vs 10.5 \rightarrow 13.7 g/dl (\uparrow hb+exercise) vs 10.6 \rightarrow 10.7 g/dl (usual hb) vs 10.4 \rightarrow 10.4 (usual+exercise) Peak VO ₂ minimally better (& not normal) with exercise training, but not \uparrow Hct (Hb) Mean peak VO ₂ 18.8 \rightarrow 18.7 ml/kg/min (\uparrow hb) vs 18.5 \rightarrow 20.8 ml/kg/min (\uparrow hb+exercise) vs 19.8 \rightarrow 19.9 ml/kg/min (usual hb) vs 19.5 \rightarrow 22.1 ml/kg/min (usual hb+exercise) Analysis on completers
Parfrey 2005 J&J	Adult 596 Incident HD 324 completers No cardiac sx	24 wk titration; 72 wk maintenance	DB treating MDs not blinded	13.5-14.5 vs 9.5-11.5		Mean hb Δ 11 \rightarrow 13.1 g/dl (\uparrow hb) vs 11 \rightarrow 10.8 g/dl (usual hb)

Study	Size	Duration	Blind	Hb(Hct)	Dose	Results
						6 minute walk test not different 277→ 143 m (completers) or 242 m (ITT) (↑ hb) vs 284→ 142 m (completers) or 254 m (ITT) (usual hb) Left ventricular volume not different (1° endpoint). (See cardiac section.)
Palazzuoli 2006 Roche, NDRC & CKF salary support	Adult 40 CHF w CRI 38 completers (2 placebo pts received transfusions for hb < 8 g/dl despite GI work-up) Hb < 11 g/dl	3 mos 1 year follow-up (open-label)	DB	11.5-12 (Epo+Fe) vs Only Fe	6000 U 2x/wk	Mean hb Δ 10.4→ 12.4 g/dl (Epo+Fe) vs 10.6→ 10.5 g/dl (Fe) 3 non-responders to Epo (2 polycystic kidney disease; 1 monoclonal gammopathy) Exercise tolerance (modified Naughton) better. Mean distance walked: 278→ 356 M (Epo+Fe) vs 285→ 266 m (Fe). Mean time: 5.8→ 7.8 min (Epo+Fe) vs 5.8→ 6.0 min (Fe) (completers) Peak VO ₂ better. VO ₂ 12.8 to 115.1 ml/kg/min (Epo+Fe) vs 12.5 to 12.0 ml/kg/min (Fe)(completers) Correlation Δ peak VO ₂ & Δ Hb: r ² =0.036 (Epo+Fe only); Hb & NYHA class: r ² = -0.41 (Epo+Fe only n=?16)

1 Non-randomized studies were not included. (Akiba 1995, Baraldi 1990, Barany 1991, 1993, Bocker 1988, Braumann 1991, Bonzel 1991, Davenport 1992, Delano 1989, , Grunze 1990, Guthrie 1993, Harris 1991, Hase 1993, Juric 1995, Leikis 2006, Lewis 1993, Lim 1989, Lundin 1991. Macdougall 1990a,b, Marrades 1996, Martin 1993, Mayer 1988, Metra 1991, Montini 1990, Robertson 1990, Rosenlof 1989, Suzuki 1995, Topuzovic 1999, Tsutsui 1989, Warandy 1991, Wizemann 1992)

2—Abstracts were not included (Stray-Gunderson 1997)

3—Studies with patient-reported physical function were not included. (Abu-Alfa 2008, Alexander 2007, Benz 2007, Beusterian 1996, Druke 2006, Foley 2000, Fukuhara 2008, Gandra 2010, Islam 2005, Johansen 2010, Levin 1993 MacDougall 2008, McMahon 1992 a,b, Moreno 1996, 2000, Muirhead 1992, Provenzano 2004, Provenzano 2005, Revicki 1995, Roger 2004, Rossert 2006, Singh 2006.)

4 Studies with physician-reported physical function were not included. Both were open-label. (Delano 1989, Evans 1990)

Δ = delta = change

1° = primary

BM = Boehringer Mannheim

Bruce & McNaughton = cardiac/exercise test protocols

CHF = congestive heart failure

CRI = chronic renal insufficiency, but not on dialysis

DB = double blind

Epo = erythropoietin

F = female

Fe = iron

Fdn = foundation

GI = gastrointestinal

Hb = hemoglobin

HD = hemodialysis

ITT =intent-to-treat

J&J = Johnson and Johnson

M = male

MD = physician

NYHA = New York Heart Association
PD = peritoneal dialysis
SB = single blind
Sx = symptoms
T = 0 = value at baseline or time zero
VO₂ = oxygen consumption
X-over = cross-over

Of note, Leikis et al. followed a small cohort of 12 patients with stage 3-4 chronic renal insufficiency with exercise performance testing (fatigue with isokinetic dynamometry, leg extension strength, peak VO₂) and observed deterioration in exercise function in concert with renal decline function despite maintenance of hemoglobin levels. (Leikis 2006) These data suggested the importance of factors other than hemoglobin in exercise capacity.

Three related studies also suggested benefit from exercise training itself. Kouidi et al. studied seven hemodialysis patients before and after a 6-month thrice weekly exercise program including stretching, resistance, and aerobic activities. (Kouidi 1998) The mean hematocrit did not change during the study 30.9 to 30.4 volume %. Exercise duration (29%) and peak VO₂ (48%) improved. Lactate levels (16%) decreased. Although morphologic evidence of atrophy persisted, concomitant muscle biopsies showed an increase in muscle volume: type 1 fibers (slow twitch) (26%) and type 2 fibers (fast twitch) (24%).

De Paul et al. randomized 38 hemodialysis patients into two open-label exercise programs: resistive isotonic quadriceps/hamstring strengthening and endurance training on a cycle ergometer or a range-of-motion exercises for 12 weeks. (DePaul 2002) Erythropoietin use, hemoglobin levels (11.6 vs 11.1 g/dl), and dialysis adequacy were similar for the two groups. Exercise sessions were conducted at the time of dialysis. Maximal ergonomic workload changed from 21 to 44 watts in the strengthening/endurance training group and from 22 to 30 watts in the range-of-motion exercise group. Thigh strength changed from 166 to 228 lb in the strengthening/endurance training group and from 171 to 173 in the range-of-motion exercise group. A distance walked in a six minute interval changed only 460 to 464 meters in the strengthening/endurance training group and from 426 to 430 meters in the range-of-motion exercise group. Curiously, the mean SF-36 and Kidney Disease Questionnaire scores did not change by treatment group. The nine patients who did not complete the exercise assessments reportedly had worse baseline physical functioning at baseline and more co-morbidity. Although the exercise programs may have contributed to improvements in strength, they did not normalize function.

In a similar study, Ouzouni et al. randomized 35 patients to an exercise program or a no-exercise treatment arm. Exercise sessions were conducted at the time of dialysis. The exercise program consisted initially of 30 minutes each of cycling and strengthening/flexibility exercises. (Ouzouni 2009) Duration and workload were increased over time. Among the 33 subjects who completed the trial, the duration of exercise during a modified Bruce protocol treadmill test changed from 16.9 to 20.9 minutes in the exercise arm and 15.9 to 15.1 minutes in the placebo arm. Exercise capacity changed from 9.1 to 11.2 metabolic equivalents of task (METs) and 8.7 to 8.9 METs in the placebo group. Peak VO₂ changed from 20.9 to 25.3 ml/kg/min in the exercise arm and from 20.3 to 20.1 ml/kg/min in the control arm. Exercise, but not hemoglobin level, was identified as the contributory factor to improved quality-of-life scores in regression analyses.

A survey study by Kontos et al. identified barriers to exercise participation by older hemodialysis patients. (Kontos 2007)

bb. Intermediate Surrogates for Cardiac Outcomes

Left ventricular hypertrophy and poor cardiac output in renal patients have been linked with anemia and poor clinical outcomes. (London 1989, Okada 1989, Silberberg 1989) We identified nine randomized studies with ESA as a treatment arm and objective measures of cardiac function as endpoints.

Table 11: Intermediate Cardiac Surrogate Studies

Study	Size	Duration	Blind	Hb(Hct)	Dose	Results
Conlon (part of NHCT) 2000	31 HD w CHF, ischemia	28 wks	Open	42 vs 30	Variable	Silent ischemia (Holter) not different
Cianciaruso 2008	95 CRI	24 mos (Δ 12 mos)	Open	12-14 vs No EPO unless < 9	Variable	LV mass index not different
Levin 2005	172 (152) CRI	24 mos	Open	12-14 vs No EPO unless < 9	Variable	LV mass index not different
McMahon 1999 & 2000	30 enrolled 14 completed Dialysis	18 mos	DB X-over	14 vs 10	Variable	LV-end diastolic volume decreased and correlated with plasma and blood volumes, but not hemoglobin mass
Palazzuoli 2007	51 CRI w CHF	4 mos	DB	12-12.5 vs No EPO	6000 U 2x/wk	LV function & geometry better
Pappas 2007	31 CRI	1 yr	Not stated	> 13 vs No EPO	Variable	LV function & geometry better
Parfrey 2005 Foley 2008,9	596 HD	96 wks	DB	13-14.5 vs 9.5-11.5	Variable	LV cavity volume not different
Roger 2004	155 CRI	2 yrs or dialysis	Open	12-13 vs 9-10	Variable	LV mass index not different
Sikole 1993	40 (38) HD	12 mo for controlled segment	Not stated	30-35 vs No EPO	Variable	LV mass & morphology better LV function not different

1—Non-randomized studies were not included. (Abdulhadi 1990, Ayus 2005, Bedani 2001, Chen 2008, Furuland 2005a,b [subset of 2003], Frank 2004, Grutzmacher 1988, MacDougall 1990, Pascual 1991, 1992, Schwartz 1991, Silberberg 1990, Tagawa 1991, Thanakitcharu 2007)

Δ = delta = change

CHF = congestive heart failure

CRI = chronic renal insufficiency, but not on dialysis

DB = double blind

EPO = erythropoietin

HD = hemodialysis

LV = left ventricular

Rx = medication

X-over = cross-over

cc. Progression to Dialysis

As noted in the Hypothesis Generating section, we identified three pilot studies which reported improvements in the rate of renal function decline using surrogate measures. (Gouva 2004, Kuriyama 1997, Teplan 2001 a,b, Teplan 2003)

We also note four additional studies of renal decline using surrogate endpoints. Roth et al. studied changes in renal function over 48 weeks in 83 pre-dialysis patients treated with erythropoietin or placebo. (Roth 1994) The open-label study, which was performed to exclude a negative consequence of erythropoietin exposure, did not reveal any treatment related differences in GFR change (¹²⁵I-iothalamate clearance).

Similarly, Kleinman et al., in what appears to be a subset of an unpublished, randomized registration study, followed reciprocal serum creatinine changes in eight of 14 patients over 12 weeks in an attempt to to exclude secondary accelerated renal decline. (Kleinman 1989)

In a two year open-label study, Roger et al. assessed changes in left ventricular hypertrophy (LVH) by echocardiography (primary endpoint) and renal function by calculated creatinine clearance, ⁵¹Cr-EDTA or ^{99m}Tc-diethylenetriamine penta-acetic acid clearance, or progression to dialysis (secondary endpoint) in 155 pre-dialysis patients randomized to hemoglobin targets of 12 to 13 g/dl versus 9 to 10 g/dl. (Roger 2004) Renal function testing reportedly did not differ by treatment group, but there was a trend (p = 0.08) to increased initiation of dialysis: 24 (32%) in the high target arm versus 15 (19%) in the lower target arm.

The ECAP (Effect of Early Correction of Anemia on the Progression of CKD) open-label study by Rossert et al., but written by Dr. Amy Ferry (Medica Excerpta) with Ortho Biotech funding, had a primary endpoint of rate of GFR decline using plasma iohexol clearance, a planned enrollment of 630 subjects, and a scheduled duration of 40 months (four months of titration and stabilization and 36 months of maintenance). (Rossert 2006, 2007) The study, however, was terminated early reportedly because of emerging safety concerns about pure red cell aplasia (PRCA) with subcutaneous administration. (Boven 2005, Jacob 2006, Howman 2007, Ryan 2006, Schellekens 2006) (Indeed, two cases of occurred in the high target arm.) Enrollment in the two treatment arms (hemoglobin targets 14.0-15.0 g/dl for men and 13.0-14.0 g/dl for women versus 11.0-12.0) was limited to n = 391. Two-hundred forty-one subjects completed the stabilization phases and entered the maintenance phase for a mean follow-up of approximately eight months. Two or more GFR measurements were available for n = 163. Changes in GFR did not differ by treatment group and were substantially less than expected. The blunted progression was attributed to ACE inhibitors, blood pressure targets, and lipid control.

We identified three randomized studies which reported data on renal disease progression to end-stage renal disease, a more definitive endpoint (Tables 12 and 23). This endpoint was not the primary outcome parameter for any of the studies. All were multi-year studies and all had more than 500 patients. Two were open-label (CHOIR and CREATE); one was blinded (TREAT). Each study employed a different ESA. Baseline renal function data in all studies was limited by the use of serum creatinine and formulas to estimate glomerular filtration (GFR). No study conducted analyses correlating changes in hemoglobin (with or without stratification by baseline renal function and/or baseline [ESA naïve] hemoglobin) with changes in GFR. None of the studies showed that use of ESAs to achieve a higher hemoglobin target resulted in a decreased likelihood of progressing to end-stage renal disease and the need for dialysis. Indeed in the CREATE study, the difference between the treatment cohorts reached statistical significance. Comparative ESA dose information on those who progressed to end-stage renal disease and those who did not was not available.

Table 12: Studies of Progression to Dialysis

	Hgb (g/dl) Target	Tx	N=	Entry GFR Criteria (ml/min/1.73 m2)	Baseline GFR (ml/min/1.73 m2) High vs Low Target	Progression to RRT High vs Low Target
CHOIR Singh 2006	13.0-13.5 (Δ to 13.5) vs 10.5-11.0 (Δ to 11.3)	Epo α	1432	15-50 (MDRD)	27.0 vs 27.3	155 (21.7%) 134 18.7
CREATE Drueke 2006	13.0-15.0 vs 10.5-11.5	Epo β	605 (603)	15-50 (CG)	24.9 vs 24.2	127 vs 111 p=0.03
TREAT Pfeffer 2009	~13 vs ESA rescue if < 9 g/dl	Darbe α	4047 (4038) DM	20-60 (MDRD)	34 vs 33	338 16.8 330 16.3

Δ = delta = change

CG = Cockcroft-Gault formula for estimating GFR using serum creatinine

Darbe = darbepoetin

DM = patients with Type 2 diabetes

Epo = erythropoietin

GFR = glomerular filtration rate

MDRD = Modification of Diet in Renal Disease formula for estimating GFR using serum creatinine

RRT = Renal Replacement Therapy (need for dialysis or renal transplant)

Tx = treatment

Of note, dialysis adequacy as measured by Kt/V ([Dialyzer Clearance of Urea x Dialysis Time]/Volume Urea Distribution) was not better after treatment in the higher hemoglobin target arm (1.35; change -0.03)(n = 618) versus in the lower hemoglobin target arm (1.44; change + 0.06) (n = 612) in the Normalization of Hematocrit Trial.(Besarab 1998, KDOQI Hemodialysis Adequacy Guidelines 2006) A higher proportion of patients in the higher target arm (32%) had endpoint Kt/V values below 1.20, the minimal level for dialysis adequacy, compared to patients in the lower target arm (22%).

dd. Health-related Quality-of-Life

We identified 11 blinded, randomized studies which reported use of quality-of-life measures (Table 13). Studies which compared different treatment regimens, other than hemoglobin targets, were excluded. Two studies (8701 and 8904) submitted for the initial erythropoietin NDA submission and resubmitted for the 2007 FDA advisory committee meeting on ESAs and quality-of life-measures have never been published and were not available for review despite requests to the FDA and the sponsor (Amgen). (See FDA section.)

Most of the identified studies were small and of limited duration. None of the studies described employed instruments of health-related quality-of-life that were validated in the population to be studied. (2009 FDA Guidance to Industry on PRO Claims) None of the studies were powered *a priori* for health-related quality-of-life testing based on biologically significant changes. (In addition, because the sponsor declined to provide information about SF-36 survey, which is proprietary, it was not possible to determine the clinical relevance of specific score levels and changes in scores.) Some studies selected subsets of test instruments. Some studies tested at multiple time-points or used multiple instruments, but did not apply Bonferroni corrections for multiple measures. In studies in which several instruments were used, results were not internally consistent. Frequently testing and analysis occurred only in completer populations. Because many of these studies had high drop-out rates, results cannot be applied to the enrolled patient populations or extrapolated to the general renal population. Putative improvements in these more subjective measures did not clearly correlate to changes in hemoglobin (hematocrit) levels or absolute hemoglobin (hematocrit) values. Nor did they correlate with objective measurements of physical function or intermediate cardiac endpoints such a left ventricular function or anatomy. Finally none of the studies demonstrated durability of effect. For example, although the open-label CREATE study reported statistically significant higher scores in the higher target (and not necessarily achieved) hemoglobin group at one year, the difference disappeared by the following year.

Table 13: Quality of Life (QoL) Studies

	Population	Duration	Treatment	Instruments/Results	Correlation with Patient Level		
					Hb(hct) Level/ Change	Exercise Tests	Cardiac Tests
Canadian Group EP-86-004 1990 Laupacis 1991 Keown 2010 (Muirhead 1992 for uncontrolled 12 mo extension)	Adult 118 HD	26 wks	Hb target x2 +placebo	KDQ SIP TTO QOL reportedly did not differ between 2 hb targets (Keown 2010 is a post hoc analysis of ITT population using imputation [vs completer population in initial publications])	NR	NR	NA
McMahon 1992	Adult 12 HD	4 month arms X-over	Hb target x2	SIP-reported improvement in both treatment arms compared to baseline, but the results did not differ by hemoglobin target. Most improvement was reported in the physical dimension (<i>ambulation and mobility</i> , but not <i>body care and movement</i>) and the total composite score. Improved <i>work</i> status did not result in increased employment.	NR	NA	NA
McMahon 2000	Adult 30(14) HD	2-6 wk arms X-over	Hb target x2	SIP-reported improvement in total, psychosocial, and work categories, but not physical dimension categories.	NR	NA	NR
Morris 1993 SB	Children 11 1-CRI, 1 HD, 9 PD	2-24 wks arms X-over Single-blind	ESA vs placebo	25 element questionnaire for parents modified from instrument used Bacon 1981 for barbiturate study. Post hoc clustering of elements. Global score not different. Reportedly better “general health” and “physical function”.	NR	NR	NA
Parfrey 2005 Foley 2009	Adult 596 Incident HD	96 wks	Hb target x2	FACIT-limited to fatigue question-not improved KDQoL-a-Improvement in Δ energy/ fatigue question score at interval time-points, but not at endpoint. Final absolute score not > for \uparrow hb target bc of > t = 0 score for \downarrow hb target arm. Estimated mean difference over study period not > 10% of baseline score. KDQoL-b-Social interaction question score not improved.	NR	NR	NR

	Population	Duration	Treatment	Instruments/Results	Correlation with Patient Level		
					Hb(hct) Level/ Change	Exercise Tests	Cardiac Tests
				KDQoL-c- Reportedly ↑ baseline ESA predicted deterioration in scores; ↑ age predicted deterioration in KDQoL physical function scores. SF-36 Vitality question score improved at some interval timepoints and endpoint, but interpolated data were used. Mean difference at endpoint: 3.5 not > 7% of baseline score.			
Pfeffer 2009	Adult 4038 CRI	Max 4 yrs Mean 29 mos	Hb target x2	FACT-fatigue: 1.4 (of 50) change; SF-36: No difference	NR	NA	NA
US Recombinant Human Erythropoietin Predialysis Study Group Teehan 1991	Adult 117 CRI	8 wks	ESA vs placebo	Weekly questionnaire to rate energy level & ability to do work on 5 point scale. “More energy” reported in 60% (ESA) vs 42% (placebo) 0.97 point more “work capacity” reported in ESA vs placebo treated patients	NR	NA	NA
Kleinman 1989 Possible subset	Adult 14 CRI	12 wks	ESA vs placebo	Weekly questionnaire of 3 questions for energy, work capacity, and general QoL expressed using unlabeled 10 cm VAS. Instrument reference Gough 1983 for QoL in cancer. Results converted to a 100 point scale. Reportedly general QoL improved.	NR	NA	NA
Lillevang 1990 Subset of a larger study (Danish)	Adult 19 HD	8 wks	ESA vs placebo	Structured interview	NR	NA	NA
8701 Not published*	Adult 82 HD	12 wks (partial X-over to 12 wk open-label extension)	ESA vs placebo	_____	NR	NA	NA
8904 Not published*	Adult 68 PD	12 wks (partial X-over to 12 wk open-label extension)	ESA vs placebo	_____	NR	NA	NA

1—Non-randomized studies were not included. (Abu-Alfa 2008, Alexander 2007, Benz 2007, Beusterian 1996, Delano 1989, Eschbach 1989 (Study 8601), Evans 1990, Fukuhara 2008, Harris 1991, Islam 2005, Levin 1993, Matuszkiewicz 1996, Provenzano 2004, 2005)

2—Open-label studies were not included. (Drueke 2006, Foley 2000, Furuland 2003, Klinger 2007, MacDougall 2008, Muirhead 1992a [uncontrolled extension segment of the Canadian study], Painter 2002, Revicki 1995, Roger 2004, Rossert 2006, Singh 2006, Trembecki [Polish])

* Information from FDA 2007 CRAC briefing documents www.fda.gov/ohrms/dockets/ac/cder07.htm#CardiovascularRenal.
<http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-04-AMGEN.pdf> and slide set www.fda.gov/ohrms/dockets/ac/07/slides/2007-4315s1-09-FDA-Trentacosti_files/slide0086.htm. (Accessed July 19, 2010.)

CRI = chronic renal insufficiency, but not on dialysis
FACT = Functional Assessment of Cancer Therapy
FACIT = Functional Assessment of Chronic Illness Therapy
Hb = hemoglobin
HD = hemodialysis
KDQ = Kidney Disease Questionnaire (Laupacis 1992)
KDQoL = Kidney Disease Quality of Life
NA = not applicable
NR = not-reported
PD = peritoneal dialysis
QOL = quality of life
SF-36 = Short Form 36 Health Survey
SIP = Sickness Impact Profile
TTO = Time Trade Off
X-over = cross-over
VAS = Visual Analogue Scale

iv. Emerging Signals of Harm

Several studies suggested that there might be unappreciated harm associated with ESAs.

Data from early surveys of the United States Renal Data System (USRDS)(1993-1999) were interpreted to mean that a higher hemoglobin level contributed to decreased mortality in dialysis patients.(Table 2) (Collins 1997, 2000, 2001, 2002, Ma 1999) Several societies, e.g., Canadian Society of Nephrology 1999, European Best Practice 2004, KDOQI 2007, UK Renal Association 2006, adopted treatment goals to achieve hemoglobin goals of 10 to 12 g/dl or greater. These USRDS data, however, did not reflect the natural history of the disease. Hematocrit (hemoglobin) data are typically entered into the system only in conjunction with Medicare claims for ESAs. (Koller direct review of USRDS files, Messina 2009) Many of the patients had been exposed to variable doses of erythropoietin, but the impact of this intervention was not addressed. In addition, the relatively small size of the cohorts with higher hematocrit levels and the limitations in extrapolating such data were not addressed.

Madore et al. conducted an analysis using census data from 21,899 patients at National Medical Care dialysis centers on January 1, 1993 and laboratory data for the antecedent three months. (Madore 1997) Complete laboratory data were available for 14,896. Descriptive statistics for parameters of interest were performed. The odds ratio for death increased progressively for hemoglobin levels below 10 g/dl. The odds risk associated with a hemoglobin of ≤ 8 g/dl was twice that associated with a hemoglobin between 10 and 11 g/dl. There was no survival benefit from achieved hemoglobin levels greater than 11 g/dl. Hemoglobin levels were inversely related to erythropoietin doses.

The Cotter group retrospectively analyzed the United States Renal Data System (USRDS) administrative claims data from 2000-2001 for 94,569 prevalent hemodialysis patients. (Cotter 2004, Zhang 2004) Patients were divided into cohorts on the basis of reported ESA dose and hematocrit(hemoglobin) at t = 0. Mortality over the next 12 months was assessed for each patient. Mortality was highest in those with the highest erythropoietin dose and the most severe anemia at baseline (Table 14).

Table 14: One Year Unadjusted Mortality (per 1,000 USRDS patients) by Hematocrit and Erythropoietin Dose Cohort (Zhang 2004)

Epo Dose Quartile	Hematocrit (Vol%)				
	< 30	30-32.9	33-35.9	36-38.9	≥ 39
Q1-lowest dose	215	198	172	176	181
Q2	302	242	221	195	193
Q3	348	303	246	231	230
Q4-highest dose	486	395	327	295	279

Regidor et al assessed data from July 2001 to June 2003 for 58,058 patients dialyzed at the DaVita chain. (Regidor 2006) Information on co-morbid conditions was limited to that which could be extracted from the CMS Medical Evidence Form 2728. The results revealed increased mortality for patients with both higher and especially lower hemoglobin levels (Table 13). Trends were similar for unadjusted hazard ratios and ratios adjusted for case-mix differences and for incident and prevalent patients. Decline in hemoglobin levels over time was associated with increased mortality. The results also revealed disproportionately more mortality, both all cause and cardiovascular, for patients using higher doses of erythropoietin (Table 15). Baseline hemoglobin doses were higher in patients receiving the highest erythropoietin doses (Table 16).

Table 15: Case-Mix Adjusted Mortality Hazard Ratio by Hemoglobin Level (Regidor 2006)

Death	Hemoglobin Level (g/dl)											
	< 9	9 to < 9.5	9.5 to < 10	10 to < 10.5	10.5 to < 11	11 to < 11.5	11.5 to < 12	12 to < 12.5	12.5 to < 13	13 to < 13.5	13.5 to < 14	≥ 14
All Cause	3.1	2.5	2.2	2.0	1.7	1.2	1.0	0.9	0.9	1.0	1.2	1.2
Cardiovascular	2.5	2.4	1.9	2.0	1.6	1.3	1.0	0.9	1.0	1.1	1.2	1.2

Table 16: Mortality and Erythropoietin Dose (Regidor 2006)

Epo Dose (U/wk)	Baseline Hb (g/dl)	All Cause Death N (%)	Cardiovascular Death N (%)	Cohort Size N (%)
None	12.3	833 (22%)	315 (8%)	4,087 (7%)

Epo Dose (U/wk)	Baseline Hb (g/dl)	All Cause Death N (%)	Cardiovascular Death N (%)	Cohort Size N (%)
1 to < 6,000	12.4	1,335 (20%)	640 (10%)	6,539 (11%)
6,000 to < 12,000	12.2	2,523 (21%)	1,097 (9%)	12,033 (21%)
12,000 to < 18,000	12.1	2,533 (24%)	1,122 (11%)	10,751 (19%)
≥ 18,000	11.6	7,258 (29%)	3,069 (13%)	24,671 (43%)

Epo = erythropoietin (or erythropoietin equivalent)

Hb = hemoglobin

Building on the Regidor and Cotter-Zhang analyses, Messina et al. retrospectively analyzed CMS Medical Evidence Form 2728 and Medicare claims data from 2002 to 2004 for 393,967 hemodialysis patients in a cross-sectional study. (Messina 2009) Mean quarterly hematocrit (hemoglobin) levels and erythropoietin/darbepoetin doses were determined (N = 2,712,197 patient-facility quarters). Case-mix adjustment was performed. 100,086 deaths were identified. Although they identified increased mortality at both high and low hematocrit levels, they observed a J-shape curve for mortality risk when dose was incorporated (Table 17). For any given hematocrit (hemoglobin) level, greater mortality was found with higher erythropoietin dosing. Co-morbidities were found to be an important factor in morbidity at low achieved hematocrit (hemoglobin) levels.

Table 17: Mortality Hazard Ratio (based on quarterly USRDS data) (Messina 2009)

Epo Dose (U/wk)	Mean Hematocrit (Vol%)					
	< 30	30-32.9	33-35.9	36-38.9	39-41.9	> 42
0	2.84	1.68	1.12	1.32	1.67	1.96
1-5999	2.52	1.56	0.92	0.87	1.23	1.70
6000-11,999	2.82	1.63	1.00 reference	0.91	1.12	1.55
12,000-17,999	3.32	1.85	1.24	1.13	1.32	1.77

Epo Dose (U/wk)	Mean Hematocrit (Vol%)					
	< 30	30-32.9	33-35.9	36-38.9	39-41.9	> 42
> 18,000	3.83	2.41	1.71	1.71	1.92	2.52

Selinger et al. used the Veterans Affairs system data base to retrospectively assess the role of ESAs in acute stroke (CVA) in patients with estimated GFRs < 60 cm³/min per 1.73 m² and hemoglobin levels < 12 g/dl using a case control design. (Selinger 2011) After adjustment for confounding variables, the likelihood of stroke was found to be greater in CKD patients using ESAs (odds ratio: 1.3) and even greater in CKD patients with cancer who used ESAs (odds ratio: 1.85). The median ESA dose was four time higher in CKD with cancer patients versus CKD patients without cancer whereas pre-treatment hemoglobin level did not differ.

v. Studies with Limitations

a—Scandinavian study by Furuland is sometimes cited as proof that the normalization of hemoglobin is safe. (Furland 2003, 2005a,b). This open-label study recruited a variety of renal patients (pre-dialytic, on peritoneal dialysis, and on hemodialysis) with mild anemia (hemoglobin levels between 9 and 12 g/dl without an exogenous ESA). It initially excluded patients with uncontrolled hypertension, diabetes, renal management problems, infection, inflammation, and cancer. Mid-study, after the results of the NHCT Besarab study were released, additional cardiac restrictions were added. 416 subjects were randomized into a 48 week (Finland, Iceland, Norway n = 163) or 76 (Sweden n = 253) week study in which entrants were dosed with erythropoietin to achieve a normal hemoglobin (13.5 -15 g/dl for women, 14.5-16 g/dl for men) or a subnormal level (9-12 g/dl). The death rate was reported to be equivalent for the normal hemoglobin and subnormal hemoglobin level treatment arms (Table 18). The study, however, was powered for exercise and not mortality.

Further evaluation of the cumulative mortality curves suggests that the mortality within each treatment arm was greater and occurred earlier for those who achieved lower hemoglobin levels. (Figure 9, Panels A and B) In addition, the drop-out rate was greater in the normal hemoglobin arm 56% versus the subnormal hemoglobin arms (43%) and greater at all time points resulting in a five week difference in study participation. The reasons for withdrawal differed for transplantation, 14.8% versus 12%, and adverse event/investigator decision, 15.7% versus 7.5%, in the normal and subnormal hemoglobin treatment arms respectively. Although there were significant differences in erythropoietin doses by renal disease category and treatment arm cohort, there were no analyses assessing the role of erythropoietin dose in mortality and other causes for study withdrawal.

Table 18: Scandinavian Study

	Total		Pre-dialysis		Hemodialysis		Peritoneal Dialysis	
	N-Hb	S-Hb	N-Hb	S-Hb	N-Hb	S-Hb	N-Hb	S-Hb
	N = 216	N = 200	N = 36	N = 36	N = 157	N = 136	N = 23	N = 28
Death due to All Causes	29	27	4	1	21	20	3	6
Cardiovascular Death	24	16	3	1	18	10	3	5
Non-Cardiovascular Death	5	11	1	0	3	10	0	1
Mean Achieved Hb (g/dl) Wk 48	-	-	14.3 ± 1.1	11.7 ± 1.3	13.5 ± 1.4	11.3 ± 1.3	13.4 ± 1.5	11.5±1.2
Mean Epo Dose (U/kg/wk) Wk 48	-	-	107 ± 117	39 ± 53	236 ± 148	140 ± 182	168 ± 118	58 ± 86

Epo = erythropoietin

N-Hb = Normal Hb target 13.5 -15 g/dl for women, 14.5-16 g/dl for men

S-Hb = Subnormal Hb target 9-12 g/dl

Figure 9: Scandinavian Study: Mortality Curves by Achieved Hemoglobin by Treatment Cohort

Panel A Normalized Hemoglobin

Panel B Subnormal Hemoglobin

b—Other Studies Not Structured to Assess Long-term Safety

Many studies subsequent to the initial pivotal studies for approval of erythropoietin were not designed to assess long-term-safety and mortality. Many of these utilized active controls when comparing different routes of administration (subcutaneous or intravenous injection. Many compared different ESAs (different active ingredient, different excipient, or different production-packaging technique) in either head-to-head or in switch studies (Table 20). Many utilized active controls when comparing different treatment regimens, e.g., hemoglobin targets or dosing frequency. Still others assessed the role of other concomitant treatments, e.g., EMLA cream, on the impact of ESA tolerability (Table 22). Many of the studies were relatively short in duration, six months or less. (Bahlmann 1991; n =129) Many of the studies were open-label. Many of the studies included less anemic populations. Few of the studies employed fixed dosing. None stratified by entry hemoglobin. Hemoglobin change, dose requirement, pain level, and patient satisfaction were frequent endpoints. Many of the studies, including several studies performed for regulatory approval, were equivalency or non-inferiority studies and presumed that studies of and (surrogate) endpoints for the predicate were adequate, that risk was equivalent for different patient populations, and that any safety issues were class-related (Tables 6, 7, and 8). Furthermore, the selection bias introduced by long screening periods and the inclusion of patients who were “washed-out” of from use another ESA (and not truly ESA-naïve) does not permit true assessment of drug response and adverse event incidence. Several of these studies remain unpublished (Table 3, Pivotal-Registration Studies section).

Table 19: Randomized Active Control Studies: Route of Administration

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Aarup 2006 (Amgen)	HD on ESA Adult No sig dx	Open	71	20 wk each arm 3 wk run-in on titrated darbe SQ	Cross-over Darbe SQ vs IV 1x/wk Doses titrated	Dose requirement (mean) Hb AUC
Bommer 2008	HD On SQ darbe Adult No sig dx	Open	126	48 randomized tx 4 wk screening+baseline	Darbe IV vs SQ on prior schedule Doses titrated (Transfusions per MD)	Dose requirement Hb level Relationship between t = 0 dose & hb level Epo resistance index = darbe dose x200/weight x hb
Boran 1993	HD Hb < 9g/dl	Not stated	36	Presumably 12 wks	Epo 25-40 U/kg SQ vs 50- 90 U/kg IV; both 3x/wk	Hb response (≥ in SQ arm)

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
	No ↑↑ HTN					AEs (4/18 with accelerated HTN in IV arm)
Cervelli 2005 (Amgen)	HD on ESA Fe replete Adult No sig dx	Not stated	53	6 mo arms 4 mo dose titration→ 2 mo dose observation	Cross-over Darbe SQ vs IV 1x/wk Doses titrated	Dose requirement mos 5-6 Hb level mos 5-6 (24 in analysis)
Chazot 2009 (Amgen) (See route)	HD on Epo SQ Adult	Open	154	6 mo randomized tx 3 mo screening	Equivalence Non-randomized: Epo IV→ Darbe IV Randomized: Darbe SQ x2 mo→ Darbe IV vs Darbe IV converted directly	% w stable Hb at 6 mo Dose requirement Hb stability at 3 mo
De Schoenmakere 1998 (Janssen-Cilag author)	HD on SQ epo Adult Hct 28-36% Inflammation PKD	Not stated	30	12 mos 6 mo SQ→ 6 mo IV vs 12 mo SQ	Epo SQ vs IV 6 mo SQ→ 6 mo IV vs 12 mo SQ Doses titrated	Dose requirement by route Hct level Fe studies
Jensen 1996 (Danish Medical Research Council)	D Adult Transfusion need &/or hb < 5.8 mmol/l No sig dx	Open	50	>10 mos 1 mo fixed dose → Time to titrated to target→ 4 mo maintenance→ cross-over	Cross-over Epo-beta SQ vs IV	Dose requirement by route Hb level Dialysis adequacy Fe studies BP & HTN rx
Kaufman (Veterans' Adm) 1998 (Amgen, Schwartz Pharma, Schein)	HD Fe replete	Open	208	Period for dose ↓ Hct < 30% Dose ↑ to hct 30-33% for 26 wks	SQ vs IV Doses titrated for both phases	Dose requirement Pain
Kim	HD	Open	65	24 wk randomized tx	Equivalence	Dose requirement wks 20-24

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
2009 (Korea Health, Ministry of Commerce, Industry, Energy)	On SQ Epo Adult Hb 8-11 g/dl No sig dx			8 wk baseline 4 wk screening	Darbe IV 1x/wk or SQ 1x/wk Dose titrated	Hb level wks 20-24
Lai 1991 (Liu Re-search Fund)	PD Hb < 9g/dl No ↑↑ HTN	Not stated	20	16 wks	Epo α SQ vs IP Doses titrated	Hb level (less response with IP- dose info not provided) BP (6/10 in IP arm vs 2/10 in SQ arm required anti-HTN rx change; dose relationship not provided) Labs: ANP, endothelin, plasma renin activity
Lee 2009	HD On SQ Epo Adult No sig dx	Open	78	4-77 mo	Epo SQ 2-3x/wk vs Epo IV 2-3 x/wk Doses titrated hb 9-12 g/dl Stratified by access type & diabetes status	Time to vascular access failure (shorter w SQ) CV events Dose requirement Hb level
Leikis 2004 (Janssen-Cilag)	HD URR ≥65% On Epo SQ Hb 10.5-30 g/dl Fe replete No ↑ CRP, AI toxicity, thrombosis	Not stated	88(81)	6 mo randomized tx Fe adequacy maintained	Superiority Cross-over Eprex SQ vs IV (with re- randomization to subgroups 1x, 2x, or 3x/wk Constant dose	Hb level Change in hb Effect of dose frequency
Lui 1990 (L.C. Research Fund & Cilag)	CAPD No other anemia cause (Hb < 9 g/dl) No ↑↑ HTN	Not stated	20	16 wks	SQ vs IP Doses titrated	% in target 10-12 g/dl Dose requirement by route PK parameters AEs

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Muirhead 1992 (R W Johnson Pharmaceutical Research Institute)	HD w co-morbid disease Adult Hb < 9.5 g/dl	Not stated	128	4 wk randomized tx with dose titrations 4 wk single-blind placebo run-in ?24 wk follow-up period	Epo SQ vs IV Doses titrated	Dose requirement by route Hb level Dialysis need by route QoL KDQ Thrombosis by route Dose requirement by co-morbid disease (? post hoc) (Large drop-out)
Ostrvica 2010 (See ESA type) (See regimen)	HD on Epo β Adult Hb 9-11 g/dl No cancer	Not stated	60	6 mo randomized tx	Epo α IV vs Epo β IV vs Epo β SQ 3x/wk	Hb level Dose requirement
Paganini 1995 (Amgen) (See ESA type) (See regimen)	HD on IV Epo in prior studies	Open	108	12 wk randomized tx 12-24 wk run-in Epo SQ 3x/wk Extension study	Diluted Epo α 3x/wk vs undiluted Epo 3x wk vs Epo 1x wk Doses titrated	Dose requirement by route Change in Hb level t = 0 to either wks 13-16 or 12-24 Pain
Ruedin 1992 (French)	HD	-	50	8 mo 2 mo IV administration 3 mo SQ administration in some & 6 mo in others	Cross-over Epo SQ vs IV	Dose requirement Hb level Pain level
Schaller 1994 (Boehringer Mannheim) (See ESA type)	D Fe replete No sig dx	DB	90	8 wk randomized tx Unspecified length open extension	Production site (1 in U.S; 1 in Germany) Epo β SQ vs IV Doses titrated	Dose requirement by route Change in Hct level (packed cell volume) Antibodies AEs
Sohmiya 1998	CRI Type 2 diabetes & malnutrition	Not stated	5	8 wk randomized tx arms Intervening 4 wk washout	Cross-over	Plasma epo level Retic count Hb change

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Ministries of Education-Culture & Health-Welfare-Japan, Fdn for Renal Disorders					Epo β SQ injection (6000 U) 1x wk vs continuous SQ infusion (36 U/0.24 ml/hr) Fixed doses	
Spinowitz (RUBRA) 2008 (Hoffmann La Roche) (See ESA type)	HD (Kt/V \geq 1.2; URR \geq 65%) PD (Kt/V \geq 1.8) On Epo IV SQ Fe replete Adult Hb 10.5-13 g/dl No sig dx	Open	366	36 wk randomized tx 4 wk run-in on prior dose & route	Non-inferiority Epo SQ or IV 1-3x/wk vs SQ or IV CERA q2wks (using prior route) Doses titrated	Hb change t = 0 & wks 29-36 Effect of route on Hb change # pts with stable hb # transfusions (but no tx algorithm)
Stockenhuber 1991	HD, PD	Not stated	42	3 mo	Epo SQ vs IV HD-7 SQ dose; 7 IV dose PD-7 SQ dose Fixed dose	Change on hb
Taylor 1994	HD No sig dx	Not stated	16	14 wk randomized tx 4 wk no rx 6 wk dose adjustment 8 wk maintenance	Cross-over w washout Epo SQ vs IV Doses titrated	Dose requirement by route Change in Hb level Retic count
Viot 1996	HD on IV epo No sig dx	Not stated	49	4 mo randomized tx	Epo SQ vs IV Stratified by prior epo needs	Dose requirement by route & epo need strata at 120 d Hb level

1—Serial switch studies were not included. (Salmonson 2000, Zehnder 1989, 1990)

↑ = increased

ANP = Atrial natriuretic peptide, endothelin, plasma renin activity

AUC = area-under-the-curve

CERA = C = continuous erythropoiesis receptor activator=methoxy polyethylene glycol epoetin beta=pegylated erythropoietin-beta

CRI = chronic renal insufficiency, but not on dialysis

CRP = C-reactive protein

CV = cardiovascular

Dx = diagnosis
 Epo = erythropoietin
 Fe = iron
 Hb = hemoglobin
 Hct = hematocrit
 HD = hemodialysis
 IP = intraperitoneal
 IV = intravenous

Kt/V = dialyzer clearance of urea x dialysis time/ volume of urea distribution in the body (measure of dialysis adequacy)

MD = physician
 PD = peritoneal dialysis
 SQ = subcutaneous
 Tx = treatment

URR = urea reduction ratio (measure of dialysis adequacy)

Table 20: Randomized Active Control Studies: ESA Type

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Berthoux 2008 (Hoffmann La Roche)	Normals Adult No sig dx	SB	40	Single injections w 1 wk washout	Superiority design Placebo then randomization to Epo β SQ vs Darbe SQ	Pain level Pain duration
Canaud (STRIATA) 2008 (Hoffmann La Roche)	HD (Kt/V ≥ 1.2; URR ≥ 65%) PD (Kt/V ≥ 1.8) On IV darbe Adult Hb 10.5-13 g/dl Fe replete, no other anemia No ↑ CRP	Open	313	36 wk randomized tx 4 wk run-in 28 wk dose adjustment 8 wk evaluation + 16 wk randomized safety observation after endpoint using new target range	Non-inferiority CERA IV q2wks vs Darbe IV q 1 or 2 wks Doses titrated	Hb change t = 0 & wks 29-36 % pts maintaining stable hb Hb variability # needing dose adjustments Transfusions (no algorithm) AEs (Consideration of #s on ACE inhibitors & angiotensin II receptor antagonists)
Chazot 2009 (Amgen) (See route)	HD on Epo SQ Adult	Open	154	6 mo randomized tx 3 mo screening	Equivalence Non-randomized: Epo IV → Darbe IV	% w stable Hb at 6 mo Dose requirement Hb stability at 3 mo

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
					Randomized: Darbe SQ x2 mo → Darbe IV vs Darbe IV converted directly	
Frenken 1991	HD On SQ Epo Adult	DB	32	1 day; injections separated by 1 hour	Cross-over Epo α albumin citrate vs Epo β lyophilisate (freeze dried under vacuum)	Pain level Pain duration
Goh (Biogeneric Study Group) 2007 (NCPC GeneTech Biotechnology)	HD On IV Eprex Adult Hb ≥ 9 g/dl Fe replete No sig dx	Open	186(188)	12 wk randomized tx	Non-inferiority Eprex IV vs generic Epo IV Dose changes not recom-mended	Change in Hb t = 0 to wk 12
Granolleras 1991	HD On SQ Epo Adult No ↑↑ HTN	DB	18	2 wks 2 of 3 tx given during each period	3 period cross-over Epo α albumin citrate vs Epo β lyophilisate vs placebo	Pain level
Haag-Weber (INJ-9) 2009 (Sandoz/Hexal)	HD on IV Epo Adult Hb 10-13 g/dl No ↑CRP	DB	479 2:1 Rand	28 wk randomized tx 28 wk open extension	Equivalence Eprex/Erypo IV vs Epo α HX575-Sandoz/Hexal Doses titrated	Hb change t=0 & wks 25-28 Dose requirement Antibodies AEs
Jensen 1994 (Danish)	HD	DB	22	Two 4 wk arms	Cross-over Epo albumin Epo lyophilisate	Pain level & duration Local reaction
Klinger (AMICUS) 2007	HD (Kt/V ≥ 1.2; URR ≥ 65%) PD (Kt/V ≥ 1.8) No recent ESA	Open	181 3:1 rand Then 1:1	24 wks-part 1 ESA type	Post hoc non-inferiority	Change in Hb ≥1 g/dl Hb ≥ 11 g/dl anytime during study

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
(Hoffmann-LaRoche) (See regimen)	Adult No other anemia No sig dx (but baseline CVD imbalance)			28 wks-part 2 Regimen	Epo (α, β) IV 3x/wk vs CERA IV q2 wks Then if CERA response→ CERA IV q2 wks vs 4wks (Epo control retained) Doses titrated	Antibodies QoL short SF-36
Krivoshiev (Epoetin Zeta Study Group) 2008 (STADA)	HD ±ESA Adult Hb < 9 g/dl No sig dx	DB	609	24 wk randomized tx 6 wk run-in for anemia dx & Fe correction 28 wk open extension	Equivalence Epo α IV 1-3x/wk vs Epo-zeta IV 1-3x/wk Doses titrated	Mean dose during last 4 wks Mean Hb during last 4 wks Antibodies
Krivoshiev (Epoetin Zeta Study Group) 2010 (STADA)	HD on Epo (see run-in) Adult No sig dx	Dose adjuster blind	462	28 wk randomized tx 12-16 wks pre-randomization dose titration Epo-zeta (N = 679) 54 wk open extension	Equivalence Epo α SQ vs Epo-zeta SQ Doses titrated	Mean Hb during last 4 wks (Equivalence ±0.5 g/dl) Mean dose during last 4 wks (Equivalence ±45 U/kg/wk) Antibodies AEs (11 deaths on Epo-zeta during run-in & 16 deaths/ 37 SAEs on Epo-zeta vs 7 deaths/9 SAEs on Epo α
Levin (MAXIMA) 2007 (Hoffmann La Roche)	HD, PD On IV Epo 1-3x/wk Adult Hb 10.5-13 g/dl Fe replete No ↑↑ CRP	Open	673	36 wk randomized tx 4 wk run-in 28 wk titration 8 wk assessment +16 wk randomized extension	Non-inferiority Epo IV 1-3x/wk vs CERA q2 wks vs CERA q4 wks Doses titrated	Change in Hb t = 0 & wks 28-36 Patient number with hb within 1 g/dl of t = 0 Transfusions

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Li 2008 (Kirin Pharmaceu- tical)	PD On SQ Epo Adult Hb 8-12 g/dl No sig dx	Open	46(45)	24 wks randomized tx	Epo (~3x/wk) vs Darbe (1x/mo) Doses titrated	Hb change t = 0 & wks 17-22 or wks 23-24 Dose requirement Dosing frequency AEs
Locatelli (NESP 980202 Study Group) 2001 (Non-IND) (Amgen) Long-term extension not complete at time of FDA review	CRI No recent ESA Hb < 11 g/dl No sig dx	Open	166 D3:E1 rand	24 wk randomized tx	Darbe 1x wk vs Epo 2x/wk Doses titrated	Hb change ≥ 1 & level ≥ 11 g/dl Antibodies AEs
Locatelli 2008 (Hoffmann La Roche) (See regimen)	HD	Open	289	28 wks	Equivalence Epo α IV qwk vs Darbe qwk vs Epo 2- 3x/wk	Hb change t = 0 & wks 16-28 Dose requirement
Locatelli 2010 8 pooled studies (Hoffmann La Roche)	CRI & dialysis	Not stated	2737	Variable duration	Variable design CERA vs other ESAs (Epo α , Epo β , Darbe)	Adverse events
Macdougall (ARCTOS) 2008 (See Kessler 2010 extension with regimen change) (Hoffmann-LaRoche)	CRI Stage 3-4 Stated ESA naïve, but really no recent ESA Adult Hb 8-11 g/dl Fe replete, no other anemia No sig dx	Open	324	28 wk randomized tx 18 wk dose adjustment 10 wk evaluation + 24 wk randomized extension (See Kessler 2010)	Non-inferiority CERA IV q 2wk vs darbe q1wk Extension with in- group randomization if on CERA to q2wk or q1mo; if on Darb given choice of q1 or 2 wks Doses titrated	Change in Hb ≥ 1 g/dl & Hb ≥ 11 g/dl t = 0 & wks 19-28 (% response) Change in Hb Transfusions Antibodies QoL Short SF-36

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Martin (Delta 3001 Study Group) 2007 (Shire/Hoechst Marion Roussel) (See below)	HD On Epo α Adult Hb 9.6-12.4 g/dl Fe replete No $\uparrow\uparrow$ HTN	DB	752 D3:A1 rand	24 wk randomized tx (28 wk extension)	Equivalent hb level IV Epo α vs Epo-delta Doses titrated	Hb level during wks 12-24 Antibodies
Martin (Delta 3001 Study Group) 2007 (Shire/Hoechst Marion Roussel) (See above)	HD On Epo α Adult Hb 9.6-12.4 g/dl Fe replete No $\uparrow\uparrow$ HTN	Open	583	28 wk extension study	All patients on Epo-delta Doses titrated	Hb level during wks 25-52 Antibodies
Milutinovic 2006 (See below)	HD Adult Hb <9.5 g/dl Fe replete No sig dx	SB	77	12 wk randomized tx 4 wk safety follow-up	Epo α SQ vs Epo-omega SQ 2x/wk Doses titrated	Dose requirement Change in Hb level (Consideration of #s on ACE inhibitors)
Milutinovic 2006 (See above)	HD Adult Hb <9.5 g/dl Fe replete No sig dx Completed above study	SB	54	12 wk cross-over with completers from above 4 wk safety follow-up Duration between studies 5-16 mos	Cross-over from above Epo α SQ vs Epo-omega SQ 2x/wk Doses titrated	Dose requirement Change in Hb level (Consideration of #s on ACE inhibitors)
Nissenson 2002 ?FDA approval	HD	DB	507 504 D1:E2 rand	20 wk titration 8 wk evaluation	Non-inferiority Darbe 1x wk vs Epo 3x/wk Doses titrated	Hb change t = 0 to wks 21-28
Ostrvica	HD on epo β		60			Hb level

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
2010 (See route) (See regimen)	Adult Hb 9-11 g/dl No cancer	Not stated		6 mo randomized tx	Epo α IV vs Epo β IV vs Epo β SQ 3x/wk	Dose requirement
Paganini 1995 (Amgen) (See regimen) (See route)	HD on IV Epo in prior studies	Open	108	12 wk randomized tx 12-24 wk run-in Epo SQ 3x/wk Extension study	Diluted Epo α 3x wk vs undiluted Epo 3x wk vs Epo 1x wk Doses titrated	Dose requirement by route Change in Hb level t=0 to either wks 13-16 or 12-24 Pain
Roger (COMFORT) 2008 (Hoffmann La Roche)	CRI Stage 3-4, PD, Transplant Adult Hb 10-13 g/dl	SB	48	2 wk arms 2 injections/arm	Cross-over Epo β SQ 1x/wk vs Darbe SQ 1x/wk Fixed doses	Pain Patient preference
St Peter 1998 (Amgen)	HD	TB	28	2- arms; 1 day for each formulation Separated by 1 wk	Cross-over SQ Epo α single dose formulation vs Epo α multi-dose formulation-benzyl alcohol SQ placebo in opposite arm	Pain level & duration
Schaller 1994 (Boehringer Mannheim) (See regimen)	D Fe replete No sig dx	DB	90	8 wk randomized tx Unspecified length open extension	Production site (1 in U.S.; 1 in Germany) Epo β SQ vs IV Doses titrated	Dose requirement by route Change in Hct level (packed cell volume) Antibodies AEs
Schmitt 2006 (Hoffmann- LaRoche)	HD, PD On ESA Pediatric	DB	13	12 wks Initial injection Epo β	Darb SQ vs Epo β SQ q 4 weeks x2	Pain Pain duration

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
				Then randomization		
Spinowitz (RUBRA) 2008 (Hoffmann La Roche) (See regimen)	HD (Kt/V \geq 1.2; URR \geq 65%) PD (Kt/V \geq 1.8) On Epo IV, SQ Fe replete; no other anemia Adult Hb 10.5-13 g/dl No sig dx	Open	366	36 wk randomized tx 4 wk run-in on prior dose & route 28 wk titration 8 wk evaluation	Non-inferiority Epo SQ or IV 1-3x/wk vs SQ or IV CERA q2wks (using prior route) Doses titrated	Hb change t = 0 & wks 29-36 Effect of route on Hb change # pts with stable hb # transfusions (but no tx algorithm) during titration & evaluation
Sulowicz (PROTOS) 2007 (Hoffman-LaRoche)	HD Kt/V \geq 1.2 &/or URR \geq 65% PD Kt/V \geq 1.2 On SQ Epo Adult Hb 10.5-13 g/dl Fe replete, no other anemia No sig dx	Open	572	36 wk randomized tx 4 wk baseline +16 wks randomized extension	Non-inferiority Epo SQ 1-3x/wk vs CERA SQ 1x/2 wks vs CERA SQ 1x/4 wks Doses titrated	Change in Hb level t = 0 & wks 29-36 Hb level Hb variability (post hoc) Death rate Epo 1-3x 6.3%, q2wk 6.8%, qmo 9.5%
Ter Wee 2009	CRI stage 4, PD On SQ ESA	DB	42	1 day-4 injections 4 sites	Placebo x2 (0.3 or 0.5 ml) vs Darbe SQ vs Epo β SQ	Pain
Tolman 2005 (Yorkshire Kidney Research Fund)	HD On 3x/wk SQ Epo Adult No $\uparrow\uparrow$ HTN	Open	217	9 mo randomized tx	Darbe SQ 1x/wk vs Epo β SQ 1x/wk Dosing via algorithm	Doses requirement Hb level Iron required Transfusions for hb \leq 8 g/dl & sx (only PP D 22 in 8, E 32 in 11)
Vanrenterghem NESP 970200 Study Group) 2002	HD/PD On SQ/IV epo Adult Hb 9.5-12.5 g/dl	Open	522 D2:E1 rand	Up to 52 weeks 4 wk baseline 32 wk randomized tx	Non-inferiority SQ vs IV dosing If Epo 1x/wk, then Darbe 1x/2wks	Hb change t = 0 to wks 25-32 Hb variability Pain Antibodies

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
For FDA approval (Amgen)	No inflammatory or hematologic conditions			20 wk extension	If Epo 2-3x/wk, then Darbe 1x/wk Doses titrated	AEs (death D 12% vs E 6%; p=0.06)
Veys 1992 (see below)	HD on SQ epo α	SB	10	4 wk trial ESA type randomized by individual dose	Sequential random administration SQ Epo α albumin citrate vs Epo β lyophilisate	Pain level
Veys 1992 (part of above)	HD on SQ/IV epo β	SB	40	1 day Simultaneous random administration of ESA types to different thighs	Simultaneous random administration SQ Epo α albumin citrate vs Epo β lyophilisate	Pain level Pain by prior route
Veys 1992 (part of above)	HD on SQ/IV Epo β	DB	6 Subset of above	1 day Simultaneous random administration of ESA types to different thighs	Simultaneous random administration SQ Epo α albumin citrate vs Epo β lyophilisate	Pain level
Wizeman (Epoetin Zeta Study Group) 2008 (STADA)	HD on Epo Adult No sig dx	DB	313	2-12 wk randomized tx arms 12-18 wk run-in w Epo α 28 wk open extension	Equivalence Cross-over Epo α IV 1-3x/wk vs Epo-zeta IV 1-3x/wk	Intra-patient Hb differences (Equivalence ± 0.6 g/dl) Intra-patient dose differences (Equivalence ± 45 U/kg/wk) # transfusions (but no tx algorithm) Antibodies AEs
Yu	HD, PD	SB	40			Pain level and duration

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
1998				2 injections for each formulation; 1 in each arm. Repeat dosing separated by 1 wk	Epo α citrate buffer vs Epo α phosphate buffer Fixed doses	
Unpublished 211 FDA-IND study (Amgen)	HD epo naïve (no epo in last 12 wks) Adult Hb < 10 g/dl Fe, B12, folate replete No sig dx	Open	160 D3:1E	20 wk randomized tx	Supportive equivalence Darbe 0.45 μ g/kg QW vs Epo 50 U/kg 3x/wk IV or SQ initially Doses titrated	% with Hb \uparrow \geq 1.0 g/dL & H b \geq 11.0 g/dL during study (Designating 50% response rate as clinically meaning-ful; Not accepted by FDA) Hb & change in Hb q4 wks Time to target Dose Antibodies
Unpublished EMERALD 1 AFX01-12 (Affymax-Takeda)	HD on epo IV Adult Hb 10-12 g/dl No other anemia No sig dx	Open	803 vs 793 P2:E1	36 wk randomized tx	Non-inferiority P QW vs Epo 1-3x/wk Doses titrated	Hb change t = 0 & wks 29-36 % target range t = 0 & wk 8 Transfusions t = 0 & 36 wks
Unpublished EMERALD 2 AFX-01-014 (Affymax-Takeda)	HD on epo IV Adult Hb 10-12 g/dl No other anemia No sig dx	Open	823 vs 815 P2:E1	36 wk randomized tx (?52 + wk tx)	Non-inferiority P QW vs Epo 1-3x/wk Doses titrated	Hb change t = 0 & wks 29-36 % target range t = 0 & wk 8 Transfusions t = 0 & 36 wks
Unpublished PEARL 1 AFX01-11 (Affymax-Takeda)	CRI GFR < 60 ml/min/1.73m ² Adult Hb 8-11 g/dl No other anemia	Open	490 P ₁ 1:P ₂ :1D ₁ :1	36 wk randomized tx (?52 + wk tx) 4 wk screening	Non-inferiority	Hb change t = 0 & wks 29-36 % target range over 36 wks

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
	No sig dx				P 0.025 mg/kg QW vs P 0.04 mg/kg QW vs Darbe 0.75 µg/kg Q2W Doses titrated	Transfusions over 36 wks
Unpublished PEARL 2 AFX01-013 (Affymax-Takeda)	CRI GFR <60 ml/ min/1.73m ² Adult Hb 8-11 g/dl No other anemia No sig dx	Open	493 P ₁ 1:P ₂ :1D ₁ :1	36 wk randomized tx (?52+ wk tx) 4 wk screening	Non-inferiority P 0.025 mg/kg QW vs P 0.04 mg/kg QW vs Darbe 0.75 µg/kg Q2W Doses titrated	Hb change t = 0 & wks 29-36 % target range over 36 wks Transfusions over 36 wks
Unpublished AFX-01-15 (Affymax-Takeda)	HD Not on epo Adult Hb 8-11 g/dl No other anemia No sig dx	Open	114 P ₁ 1:P ₂ :1D ₁ :1	7+ mo tx 4 wk screening (Russian sites)	2 Peginesatide doses Q4 wks vs 1 Epo 3x/wk Doses titrated	Hb change t = 0 & wk 8 Hb response over 28 wks Transfusions over 28 wks

1—Abstracts were not included (Choukroun G 2005 cited by Roger 2008)

2—Uncontrolled and switch studies were not included. (Akizawa 2007, Amar 1994, Thanakitcharu 2007, Thitiachkul 2007)

↑ = increased

? = possibly

AE = adverse event

C = CERA = continuous erythropoiesis receptor activator = methoxy polyethylene glycol epoetin beta = pegylated erythropoietin-beta

CRI = chronic renal insufficiency, but not on dialysis

CRP = C-reactive protein

CVD = cardiovascular disease

D = darbe = darbepoetin

DB = double blind

Dx = diagnosis

E = epo = erythropoietin

Fe = iron

GFR = glomerular filtration rate

Hb = hemoglobin

HD = hemodialysis

HTN = hypertension

Kt/V = dialyzer clearance of urea x dialysis time/ volume of urea distribution in the body (measure of dialysis adequacy)

Q = each

QoL = quality of life

P = peginesitide

PD = peritoneal dialysis

SF-36 = Short Form 36 Health Survey

Sig = significant

TB = triple blind

Tx = treatment

URR = urea reduction ratio (measure of dialysis adequacy)

Table 21: Randomized Active Control Studies: Different Treatment Regimens

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Buemi 1993	HD	Open	26	Not stated <i>a priori</i>	Daytime vs nighttime dialysis & Epo dosing Doses titrated	Dose & time required to reach hct 32%
Frifelt 1996 (Ercopharm)	PD Completed epo stabilization Adult No sig dx	Not stated	33	3 mo stabilization 3 mo randomized tx	Epo β SQ 3x/wks vs 1x/wk Doses titrated in a limited way	Hb change at 3 mo Dose requirement by route Fe need (7/73 died during 3 mo stabilization)
Kessler (ARCTOS-extension) 2010 (See Regimen Macdougall 2008) (Hoffman La Roche)	CRI (responder on CERA in 28 wk ACTOS) Adult No rapid renal decline No \uparrow CRP	Open	296	24 wk extension period (See Macdougall 2008)	If responded in earlier 28 wk study, randomized to remain on CERA SQ q2wks vs CERA SQ q4 wks. Darbe pts given option of qwk or q2wk dosing	Hb level Dose requirement Hb variability at wk 36 Death: Cq2wk 2/73, Cq4wk 1/72, D6/161
Klinger (AMICUS) 2007 (Hoffmann-LaRoche) (See ESA type)	HD (Kt/V \geq 1.2; URR \geq 65%) PD (Kt/V \geq 1.8) No recent ESA Adult No sig dx (but baseline CVD imbalance)	Open	181 3:1 rand Then 1:1	24 wks-part 1 ESA type 28 wks-part 2 Regimen	Post hoc non-inferiority Epo (α,β) IV 3x/wk vs CERA IV q2 wks Then if CERA response \rightarrow CERA IV q2 wks vs 4wks (Epo control retained) Doses titrated	Change in Hb \geq 1 g/dl Hb \geq 11 g/dl Antibodies QoL SF-36
Koch 1995	CRI Hct < 30%	Open	275 (266)	Variable	Epo β SQ 3x wk vs 1x wk	Dose requirement Hct change

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
(Boehringer Mannheim author)	No sig dx		(2 study combo)		Doses titrated	Serum creatinine change
Lee 2008	HD on Epo Hb 9-12 g/dl	Open	83	(Pre-study 4 wk dose adjustment period) 12 wks: 10 wk maintenance + 2 wk evaluation period	Espogen (epo- α) SQ 1x/wk vs 2-3x/wk Stratified by prior Epo dose	Dose requirement Hb level
Locatelli (Study Group) 2002 (Hoffmann La Roche)	HD (Kt/V \geq 1.2 On Epo β Adult Hct 28-38% Fe replete No sig dx	Open	173	24 wk randomized tx 4 wk pre—study period with Epo SQ 3x/wk	Equivalence Epo β SQ 3w/wk vs 1x/wk Doses titrated	Hct AUC wks 13-24 Dose requirement wks 13-24 Hb & hct change Transfusion (no algorithm)
Locatelli 2008 (Hoffmann La Roche) (See regimen)	HD	Open	289	28 wks	Equivalence Epo α IV qwk vs Darbe qwk vs Epo 2-3x/wk	Hb change t=0 & wks 16-28 Dose requirement
Lui 1991 (Cilag)	CAPD No other anemia cause (Hb <8 g/dl) No $\uparrow\uparrow$ HTN	Not stated	20	16 wks	Equivalence Epo 1x q wk vs 2x q wk Doses titrated	Hb change t=0 & wk 16 Dose requirement Fe metabolism AEs
Lui	HD	Not stated	20	12 wks	Equivalence	Hb change t=0 & wk 12

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
1992 (Cilag)	No ↑↑ HTN (Hb <6 g/dl)				Epo 1x q wk vs 2x q wk Doses titrated	Dose requirement Fe metabolism AEs
Macdougall (NESP 960245/46 Group) 2003 (Amgen) (See below)	HD No recent Epo Hb <10 g/dl Adult Fe replete No sig dx	Not stated	75	4 wks if no hb ↑ ≥ 1g/dl 52 wks if hb ↑ (non-responders could re-enroll at a higher dose)	Serial dose escalation with randomization by regimen Darbe IV 3x/wk vs 1x/wk Doses titrated after 16 wks	Hb change ≥ 1g/dl at 4 wks Hb at 16 wks Antibodies AEs
Macdougall (NESP 960245/46 Group) 2003 (Amgen) (See above)	PD No recent Epo Hb < 10 g/dl Adult Fe replete No sig dx	Not stated	47	4 wks if no hb ↑ ≥ 1g/dl 52 wks if hb ↑ (non-responders could re-enroll at a higher dose)	Serial dose escalation with randomization by regimen Darbe SQ 3x/wk vs 1x/wk Doses titrated after 16 wks	Hb change ≥ 1g/dl at 4 wks Hb at 16 wks Antibodies AEs
Mircescu 2006 (Hoffmann-LaRoche)	HD Hb > 10 g/dl (w baseline Epo tx) Replete Fe Adult No DM; sig dx	Open	207	24 wk randomized tx 8 wk baseline with Epo q 1x/wk	Epo β SQ 1x/wk vs q2 wks Doses titrated	Mean hb level wks 13-24 Dose requirement AEs (Systolic BP 8.7 mm Hb higher in q2/wk arm)
Nagaya 2010 (Japan Dialysis Outcome Group)	HD on IV darbe (see run-in) Adult No sig dx	Not stated	48(39)	8 wks pre- randomization for dose stabilization on darbe Presumably 24 wk randomized tx	Darbe IV q1wk vs q2wks Doses titrated	Mean dose requirement at wk 24 (dose requirement higher with longer interval) Hb level AEs (BP higher with longer interval & perhaps higher doses)

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Ostrvica 2010 (See ESA type) (See route)	HD on Epo β Adult Hb 9-11 g/dl No cancer	Not stated	60	6 mo randomized tx	Epo α IV vs Epo β IV vs Epo β SQ 3x/wk	Hb level Dose requirement
Paganini 1995 (Amgen) (See ESA type) (See route)	HD on IV Epo in prior studies	Open	108	12 wk randomized tx 12-24 wk run-in Epo SQ 3x/wk Extension study	Diluted Epo α 3x wk vs undiluted Epo 3x wk vs Epo 1x wk Doses titrated	Dose requirement by route Change in Hb level t = 0 to either wks 13-16 or 12-24 Pain
Pergola 2009 (Epo-AKD-3001) (J&J)	CRI (Stage 3-4) Adult No recent ESA Hb < 11 g/dl* No sig dx	Open	375	44 wks of tx, but at 22 wks 3x/wk cohort → 1x/wk 4 wk post tx period	Non-inferiority Epo α 3x/wk vs 1x/wk vs q2wks Doses titrated	Hb change t = 0 to mean wk 14-wk 22 Hb change ≥ 1g/dl AEs (although suggestion transfusion, progression, CHF may be worse)
Pergola 2010 (Epo-AKD-3002) (J&J)	CRI stage 3-4 On Epo 1x/wk Hb 10-11.9 g/dl No sig dx	Open	430 1:1:2 rand	36 wks	Non-inferiority Epo α 1x/wk vs q2wks vs q4 wks Doses titrated	Change in Hb level t=0 to last 12 wks AEs
Rocha 1998	HD on IV epo No sig dx	Not stated	20	12 week arms	Cross-over Continuous IV vs bolus IV Dose fixed	Hct level Urea kinetics PTH
Weiss (Swedish Study Group) 2000	HD (Kt/V > 1) No ↑↑ HTN Replete Fe Hb 10-12.5 g/dl (w 8 wk Epo tx) Adult	Open	158	24 wk randomized tx 8 wk baseline	Original SQ injection 2 or 3x/wk vs SQ 1x wk Doses titrated	Dose requirement Hb level AEs (Pain, BP) (High drop-out)

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
-------	------------	-------	------	----------	----------------	--------------------

1—Serial switch studies were not included. (Akizawa 2007, Grezsczak, 2005, Nomoto 1994)

2—Economic analyses were not included. (Piccoli 1995 was an economic analysis of Nomoto 1994)

↑ = increased

AE = adverse event

AUC = area-under-the-curve

BP = elevated blood pressure

C = CERA = continuous erythropoiesis receptor activator = methoxy polyethylene glycol epoetin beta = pegylated erythropoietin-beta

CHF = congestive heart failure

CRI = chronic renal insufficiency, but not on dialysis

CVD = cardiovascular disease

D = darbe = darbepoetin

DM = diabetes mellitus

Dx = diagnosis

E = epo = erythropoietin

Fe = iron

Hb = hemoglobin

Hct = hematocrit

HD = hemodialysis

HTN = hypertension

IV = intravenous

Kt/V = dialyzer clearance of urea x dialysis time/ volume of urea distribution in the body (measure of dialysis adequacy)

QoL = quality of life

PD = peritoneal dialysis

Sig = significant

SQ = subcutaneous

PTH = parathyroid hormone

Tx = treatment

URR = urea reduction ratio (measure of dialysis adequacy)

Table 22: Randomized Active Control Studies: Other Study Types

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
Brandt 1999	CRI, D Hb <-2 SD age < 21 yrs Fe replete No ↑↑ HTN, seizure	Not stated	44	~ 12 wks; until hb target	Fixed doses Epo 150 vs 450 U/kg/wk Doses titrated after 12 wks	Hb change t = 0 to 12 wks Time to target Dose requirement Changes in renal function/ dialysis adequacy Panel reactive antibodies Transfusion (no algorithm)
Morris	HD	DB	48			Pain

Study	Population	Blind	Size	Duration	Treatment Arms	Endpoints/Comments
1994				2 comparisons made on each of 2 days	SQ epo alpha vs SQ Epo beta +/- EMLA anaesthetic cream	

↑ = increased

CRI = chronic renal insufficiency, not requiring dialysis

DB = double-blind

Epo = erythropoietin

Fe = iron

Hb = hemoglobin

HD = hemodialysis

HTN = hypertension

SD = standard deviation

SQ = subcutaneous

Although these studies were not structured to assess long-term safety, safety signals emerged in at least two of the studies. In the open-label non-inferiority non-U.S.-based study comparing darbepoetin with the predicate in a 2:1 randomization over 32 weeks with a 20 week extension in 522 dialysis patients, a higher proportion of the 52 deaths that occurred (during the study or within the 28 day window of last drug dose or last assessment) were in the darbepoetin arm 41/346 (12%) versus the erythropoietin arm 11/173 (6%); $p = 0.06$ (Tables 6,18). (Vanrenterghem 2002) Safety parameters seldom reach that level of statistical significance because studies are powered for efficacy, not safety. In addition, the descriptive data suggest that deaths occurred earlier in the darbepoetin arm, but that there was a convergence in cumulative mortality after an extended observation period (mean: two years). No survival curve was presented. Although these results were not replicated in the other pivotal study based by Nissenson et al, that U.S.-based study did differ by dosing (Tables 6, 18). (Nissenson 2002) Darbepoietin and erythropoietin doses were twice that used in the Vanrenterghem study.

In open-label, non-inferiority studies comparing the new mimetibody, hematide, and the erythropoietin analogue, darbepoetin, in 983 pre-dialysis patients over 36 weeks with a 16-68 week extension period, there were differences in the cardiovascular composite safety endpoint that did not favor the study drug: 21.6% versus 17.1% (Table 8: PEARL study results). There were consistent difference in death (8.8% versus 6.7%), arrhythmia 5.6% versus 4%), and unstable angina (2.4% versus 0.9%). The cardiovascular adverse event disparity was greatest in the PEARL 2 study. Not all of the differences could be accounted for by imbalance at baseline. These safety risks were not balanced by reduction in transfusion risk. In the PEARL 2 study ($n = 493$), transfusions were required in more patients on hematide (11.4% in the initially low dose arm; 10.4% initially high dose) than on darbepoetin (4.8%). There were similar findings in the PEARL 1 study ($n = 490$) although they did not reach statistical significance.

Although it has been presumed that efficacy and adverse events associated with ESAs represent a class effect, we have been unable to find studies analyzing parameters that could assess and define risk differences between different ESAs.

vi. Studies to Assess Survival and/or Cardiovascular Endpoints

We have identified four studies that were structured to assess survival and/or cardiovascular endpoints: the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial, Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE), the Normalization of Hematocrit Trial (NHCT), and the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) (Table 23). All were designed to assess target hemoglobin levels—although the targets differed by study. None were designed to assess dose effect in any of the three ESAs evaluated (erythropoietin-alpha: CHOIR and NHCT; erythropoietin-beta: CREATE; darbepoetin: TREAT). All were designed to follow patients for at least one year. All recruited more than 500 patients. Three of the studies were open-label (CHOIR, CREATE, and NHCT). Three of these studies were conducted in pre-dialysis patients (CHOIR, CREATE, and TREAT). Renal status for inclusion in these three studies was determined using glomerular filtration rates (GFR), but these rates were not measured directly or with the use of concomitant serum and urinary creatinine values. They were estimated using serum creatinine values in formulas (Cockcroft– Gault for CREATE [inclusion range 15.0-35.0 ml/min/1.73 m²]; Modification of Diet in Renal Disease for CHOIR [inclusion range 15-50 ml/minute/1.73 m²] and TREAT [inclusion range 20-60 ml/minute/1.73 m²]. Patients with anemia not attributable to renal disease were included. (See Anemia Background section.) Two studies specifically recruited patients with either cardiac disease (NHCT) or type 2 diabetes with its known likelihood of macrovascular disease (TREAT).

No studies stratified patients on the basis of ESA-naïve hematocrit (hemoglobin) levels, ESA doses or dialysis adequacy/renal clearance. One study (TREAT) stratified patients using urinary protein:creatinine ratios because of its putative value for cardiovascular disease. (Hemmelgarn 2010, Keane 2003) No study included criteria for red blood cell transfusion. No study collected data on the reason for red blood cell transfusion (anemia management versus other indication e.g. surgical procedure or GI bleed), the pre-transfusion hematocrit (hemoglobin) level, or the number of units transfused. The reported data are limited to numbers of patients transfused. Drop-out rates were high (CREATE 21% overall, 25% high target, 17% low target; CHOIR 46% overall, high target: death 7%, other 21%, non-fatal primary event 10%, renal replacement therapy 18%, low target death 5%, other 22%, non-fatal primary event 8% renal replacement therapy 16%; TREAT high target: death 20%, death in 30 day window after closure 0.4%, non-fatal primary event 2%, other 11%, treatment stopped-continued in study 21%, low target: death 20%, death in 30 day window after closure 0.5%, non-fatal primary event 2%, other 11%, treatment stopped-continued in study 22%). Drop-out rates were not reported for the NHCT. Two of the studies were terminated early (NHCT and CHOIR). The NHCT was halted by the safety monitoring board because a divergence in survival, not in favor of the higher hemoglobin treatment arm. The trial was stopped before statistical significance could be reached. The CHOIR trial was halted by the monitoring board because it was thought to be unlikely that benefit for the high hemoglobin target would be demonstrated. The trial was stopped before statistical significance for futility could be reached.

The studies were able to achieve hemoglobin (hematocrit) separation between the high and low target arms in all studies. Not all patients within the target arms achieved the desired targets despite the individualized titration. Indeed, in CHOIR, the doses for those patients who achieved the target hemoglobin (whether high or low) were lower than those who failed to achieve the target hemoglobin: 10.5-11 g/dl target: total cohort mean 6276 U/wk, achieved 6057 U/wk, not achieved 11,098 versus 13-13.5 g/dl target: total cohort mean 11,215 U/wk, achieved 10694 U/wk, not achieved 12,884 U/wk. (See Table 23 for original and amended target values.) (This heterogeneity in response in non-fixed dose studies has confounded attempts to determine whether hemoglobin levels or drug exposure parameters, e.g., peak dosage, cumulative dose, or peak serum dose via various dose regimens and/or routes of administration, are contributing factors to adverse events and whether different mechanisms underlie different adverse events.)

None of the trials demonstrated any benefit for either survival or decreased morbidity from cardiovascular events (Tables 23 and 28). Indeed, review of the actual numbers of events suggests that there was a trend to more deaths and cardiovascular events in the higher target arms—although stroke (cardiovascular accident = CVA) accounted for most of these events in the TREAT trial. There was also a trend to more cancer deaths in the higher target treatment arm of TREAT. This occurrence in patients with a history of cancer, but no known active oncologic disease at the time of enrollment, suggests a tumor “promoter” role and is consistent with that which was seen in oncology patients using ESAs on a more intermittent basis. (See NCD CAG-0383N.) Although these results were unexpected, they are consistent and provide a strong safety signal. Statistical significance would not be expected because the studies were designed and powered for a different hypothesis and two were terminated early. The absence of definitive proof of harm cannot be used to establish absence of risk. (See NCD CAG-0383N for studies with nascent negative outcomes that were terminated or remained unpublished.)

Table 23A Studies Designed to Assess Survival and/or Cardiovascular Outcomes

Study	Population	Blind	Size	Duration	Entry Criteria	Exclusion Criteria
NHCT Besarab 1998 epo α USA 51 sites Amgen	Hemo	Open-label	1253	3+ yrs (planned)	CHF Ischemic HD Hct 27-33 on ESA	Recent cardiac events Diastolic HTN \downarrow life expectancy Fe deficiency Androgen use
CREATE Drueke 2006 epo β 22 nations 94 sites	Pre-dialysis	Open-label	603	> 2 yrs Max 4.25 yrs Mean 3 yrs	Hb 11-12.5 GFR calculated (CG)* 15-35	Non-renal anemia Prior ESA use Inflammation Serious CVD Transplant need
CHOIR Singh 2006 epo α USA 130 sites Ortho Biotech/J&J	Pre-dialysis	Open-label	1432	Max 3 yrs	Hb < 11 GFR calculated (MDRD)** 15-50	Prior ESA Uncontrolled HTN Angina CA GI bleed Frequent transfusion
TREAT Pfeffer 2009 darbe α 24 nations 623 sites Amgen	Pre-dialysis	Double	4038	Max 4 yrs Mean 29 mo	Hb \leq 11 Transferrin > 15% Type 2 DM Stratified by CVD & spot urine protein	Recent ESA Antibiotics Uncontrolled HTN Recent CV event HIV, CA, or CA tx Bleeding, Hematologic disease Recent seizure Fe insufficiency Transplant need

\downarrow = decreased

\uparrow = increased

CA = cancer

CG = Cockcroft-Gault formula for estimating GFR using serum creatinine

CHF = congestive heart failure

CV(D) = cardiovascular (disease)

DM = diabetes mellitus

Fe = iron

GFR = glomerular filtration

GI = gastrointestinal

Hb = hemoglobin

Hct = hematocrit

HD = Hemo = hemodialysis

HTN = hypertension

MDRD = Modification of Diet in Renal Disease formula for estimating GFR using serum creatinine

Tx = treatment

Table 23B: Studies Designed to Assess Survival and/or Cardiovascular Outcomes (continued)

Study	Dose	Target Hb (g/dl) or Hct (%)	Transfusion Criteria	Stratification by		
				Hb (Hct)	Dose	Dialysis Adequacy or Renal Clearance
NHCT Besarab 1998 epo α USA 51 sites Amgen	\uparrow by 1.5x, then 25% of t = 0 q 2 wks vs 10-25 U/kg q2 wks until target*. Actual use: Mean ~460 U/kg/wk vs ~120 U/kg/wk. IV or SQ	Hct 39-45 vs 27-33	No	No	No	No
CREATE Drueke 2006 epo β 22 nations 94 sites Hoffman-La Roche	Initial dose of 2000 U/wk with an increase of 25-50% q 4 wks Actual use: Median 5000 U/wk (range 3000-8000) vs 2000 U/wk (range 1000-3000)	Hb 13-15 vs 10.5-11.5 (ESA if < 10.5)	No	No	No	No
CHOIR Singh 2006 epo α USA 130 sites Ortho Biotech/J&J	10,000 U/wk 20,000 U/wk max (in appendix) SQ	Hb 13-13.5 vs 10.5-11 (13.5 vs 11.3)	No	No	No	No
TREAT Pfeffer 2009 darbe α 24 nations 623 sites Amgen	Initial dose 0.75 ug/kg with increases by algorithm to a maximum of 6000 ug/mo 104-305 ug/mo (in appendix) SQ	Hb ~13 (ESA if < 9)	No	No	No	Spot urinary protein-to-creatinine ratio < 1, \geq 1

IV = intravenous
SQ = subcutaneous

Table 23C: Studies Designed to Assess Survival and/or Cardiovascular Outcomes (continued)

Study	Results (high vs low target)
NHCT Besarab 1998 epo α USA 51 sites Amgen	1 ^o endpoint: time to death or 1 st non-fatal myocardial infarction Study stopped at 29 mo Withdrawal rates not indicated 183 deaths + 19 non-fatal myocardial infarctionss vs 150 deaths + 14 non-fatal myocardial infarctions Venous access thrombosis: 243 vs 176; p = 0.001 Transfusion: 129 vs 192 persons (many for surgical or GI bleeding) Kt/V: \downarrow in high target arm 1.38 vs \uparrow in low 1.44; p < 0.001 Hospitalization: 445 vs 425 Quality of life: Global SF-36: No difference. Reported improvement in physical function domain. Dose: Not reported in 1 ^o paper Post hoc analysis (Kilpatrick 2008): \uparrow mortality with \downarrow ESA responsiveness
CREATE Drueke 2006 epo β 22 nations 94 sites	1 ^o Endpoint : time to death & CV composite Cardiac event rate lower than expected based on prior calculations Withdrawal: 25% experimental group; 17% control group

Study	Results (high vs low target)
	<p>1st cardiovascular event 58 vs 47 (including stroke and transient ischemic attack 13 vs 7) Mortality: 31 vs 21 Left ventricular mass: no difference. Thrombosis of fistula: 12/127 vs 8/111 Transfusion: 26 vs 33 persons Progression to RRT: 127 vs 111; p = 0.03 Hospitalization: 61% vs 59% (unclear if limited to cardiac-related admissions) Quality of life (SF-36): Reported improvements at 1 year, but maximal differences in subunit scores apparently converted to 100 scale were ≤ 8 units. These differences were not sustained beyond the first year. Dose: Not reported</p>
<p>CHOIR Singh 2006 epo α USA 130 sites Ortho Biotech/J&J</p>	<p>1^o endpoint: (time to) mortality & CV composite Study stopped because ability to show efficacy unlikely Withdrawal 38% with imbalance in those not → transplant Composite events: 125 vs 97. (Death 52 vs 36, CHF 64 vs 47, MI 18 vs 20, CVA 12 vs 12) Progression to renal replacement: 155 vs 134 Thrombovascular: 126 vs 120 Transfusion: Not reported Progression to RRT: 155 vs 134 Hospitalization: 369 vs 334 Quality-of- life: (LASA, KDQ, SF-36): No difference Dose: 11,215 U/wk (10,694 if achieved; 12,884 if did not) vs 6276 U/wk (6057 if achieved; 11,098 if did not)</p>
<p>TREAT Pfeffer 2009 darbe α 24 nations 623 sites Amgen</p>	<p>1^o endpoint: time to death or cardiovascular composite endpoint & time to death or renal failure Imbalance at baseline for placebo and congestive heart failure Withdrawal: Treatment stopped, but followed 20% + Discontinued without follow-up except +/- death status 13% Mortality and/or cardiovascular endpoint (includes stroke): 632 vs 602. Stroke: 101 adjudicated (161, ischemic 150, hemorrhagic 89) vs 53 adjudicated (102, ischemic 96, hemorrhagic 49) Cancer death: 39 vs 25 Venous thromboembolic events: 41 vs 23; p = 0.02 Arterio thromboembolic events 178 vs 144; p = 0.04 Transfusion: 297 vs 496 persons Progression to RRT: 338 vs 330 (mean GFR information not reported) Hospitalization: Not reported Quality-of-life: FACT-fatigue: 1.4 (of 50) change; SF-36: No difference Dose: Not reported</p>

1^o = primary

CHF = congestive heart failure

CV = cardiovascular

CVA = stroke

FACT-fatigue = Functional Assessment of Cancer Therapy-Fatigue subscale

GI = gastrointestinal

KDQ = Kidney Disease Questionnaire

LASA = Linear Analogue Self Assessment

MI = myocardial infarction

RRT = renal replacement therapy (dialysis or transplantation)

SF-36 = Short Form 36 Health Survey

c. Systematic Reviews

We are aware of several published systematic reviews of erythropoiesis stimulating agents, anemia, and/or transfusions and describe them below briefly. Systematic reviews are based on a comprehensive search of published materials to answer a clearly defined and specific set of clinical questions. A well-defined strategy or protocol (established before the results of individual studies are known) is optimal.

i. Cochrane Collaboration

aa. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review)

Carless PA, Henry DA, Carson JL, Hebert PPC, McClelland B, Ker K

Publication status and date: Edited (no change to conclusions), published in Issue 10, 2010. Review content assessed as up-to-date: 31 July 2009.

“...Most clinical practice guidelines recommend restrictive red cell transfusion practices, with the goal of minimising exposure to allogeneic blood (from an unrelated donor). The purpose of this review is to compare clinical outcomes in patients randomised to restrictive versus liberal transfusion thresholds (triggers)...Restrictive transfusion strategies did not appear to impact on the rate of adverse events compared to liberal transfusion strategies (i.e. mortality, cardiac events, myocardial infarction, stroke, pneumonia and thromboembolism). Restrictive transfusion strategies were associated with a statistically significant reduction in the rates of infection (RR=0.76; 95% CI 0.60 to 0.97). The use of restrictive transfusion strategies did not reduce hospital or intensive care length of stay...The existing evidence supports the use of restrictive transfusion triggers in patients who are free of serious cardiac disease. The effects of conservative transfusion triggers on functional status, morbidity and mortality, particularly in patients with cardiac disease, need to be tested in further large clinical trials. For most patients, blood transfusion is probably not essential until haemoglobin levels drop below 7.0 grammes per decilitre...”

Comment: The review has not been updated to include major studies including TRACS (Hajjar 2010; n = 512) and the most recent FOCUS data (Carson 2009 -abstract; 2011).

bb. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease (Review)

Strippoli GFM, Navaneethan SD, Craig JC, Palmer SC

Publication status and date: Edited (no change to conclusions), published in Issue 2, 2010. Review content assessed as up-to-date: 14 August 2006.

“...Full-text assessment of 49 potentially eligible papers identified 22 eligible trials (3707 patients) (Abraham 1990; Bahlmann 1991; Berns 1999; Besarab 1998; Brandt 1999; Canadian 1991; Clyne 1992; Conlon 2000; Foley 2000; Gouva 2004; Kleinman 1989; Kuriyama 1997; Levin 2005; Lim 1989; Morris 1992; Parfrey 2005; Revicki 1995; Roger 2004a; Scandinavian 2003; Sikole 1993; Teehan 1991; Watson 1990)...Twenty two trials (3707 patients) were included. In general study quality was poor. There is a need for more adequately powered, well-designed and reported trials. Trials should be pragmatic, focusing on hard endpoints (mortality, ESKD, major side effects) or outcomes which were previously not studied adequately (e.g. seizures, quality of life). In general study quality was poor. There is a need for more adequately powered, well-designed and reported trials. Trials should be pragmatic, focusing on hard endpoints (mortality, ESKD, major side effects) or outcomes which were previously not studied adequately (e.g. seizures, quality of life).”

Comment: The review has not been updated to include major studies including CREATE (Drueke 2006; n = 603), CHOIR (Singh 2006; n = 1432), and TREAT (Pfeffer 2009; n = 4038)

cc. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients (Review)

Cody JD, Daly C, Campbell MK, Khan I, Rabindranath KS, Vale L, Wallace SA, MacLeod AM, Grant A, Pennington S

Publication status and date: Edited (no change to conclusions), published in Issue 1, 2009. Review content assessed as up-to-date: 24 May 2005.

“...The review now includes 15 trials (Abraham1990; Brown 1995; Clyne 1992; Eschbach 1989; Ganguli 2003; Kleinman 1989; Kuriyama 1997; Lim 1989; Roth 1994; Stone 1988; Teehan 1989; Teehan 1991; Teplan 2001; Teplan 2003; Watson 1989) with a total of 461 participants. Twelve trials were reported in full published papers, and three reported in abstract form only (Brown 1995; Ganguli 2003; Teplan 2001). The degree of renal function was broadly similar amongst the participants of the trials with the exception of Teplan 2003 where renal failure was less advanced. It was subsequently confirmed that four of these studies (Abraham 1990; Eschbach 1989; Lim 1989; Stone 1988) formed part of a larger multicentre trial (Teehan 1991)...Fifteen trials (461 participants) were included. Treatment with rHu EPO in pre-dialysis patients corrects anaemia, avoids the requirement for blood transfusions and also improves quality of life and exercise capacity. We were unable to assess the effects of rHu EPO on progression of renal disease, delay in the onset of dialysis or adverse events. Based on the current evidence, decisions on the putative benefits in terms of quality of life are worth the extra costs of pre-dialysis rHu EPO need careful evaluation...” The excluded studies are listed on page 38.

Comment: The review does not include major studies including CREATE (Drueke 2007; n = 603), CHOIR (Singh 200; n = 1432), and TREAT (Pfeffer 2009; n = 4038).

ii. **National Institute for Clinical Excellence (NICE)** NICE does not conduct assessments/reviews of transfusions because “this procedure does not fall within the Institute's definition of an interventional procedure. To fall within the Programme's remit, a notified procedure must involve an incision or a puncture or entry into a body cavity, or the use of ionising, electromagnetic or acoustic energy.”

iii. **Serious Hazards of Transfusions (SHOT)**

An independent haemovigilance group funded by the UK Blood Services (NHS Blood and Transfusion, Northern Ireland Blood Transfusion Service, Scottish National Blood Transfusion Service, Welsh Blood) and affiliated with the Royal College of Pathologists. *Annual Review 2009* (www.shotuk.org/wp-content/uploads/2010/06/SHOT-2009-Summary.pdf; www.shotuk.org/wp-content/uploads/2010/07/SHOT2009.pdf; accessed 11/28/2010.) Cohen H, Mold D, Jones H, Davies T, Mistry H, Ball J, Asher D, Cawley C, Chaffe B, Chapman C, Gray, Jones J, Milkins C, New H, Norfolk D, Regan F, Still E, Tinegate H, Taylor C.

Deaths from transfusion have declined over time to less than 10% of those in 1996-1997 (Table 25). Red blood cell transfusions decreased to 80% of those in 1999-2000 (Table 24).

Table 24: Secular Trends in Blood Usage in the United Kingdom

HSE	1999-2000	2000-2001	2001-2002	2002-2003	2003-2004	2004-2005	2005-2006	2006-2007	2007-2008	2008-2009
-----	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------	-----------

HSE	1999-2000	2000-2001	2001-2002	2002-2003	2003-2004	2004-2005	2005-2006	2006-2007	2007-2008	2008-2009
RBC	2,737,572	2,706,307	2,679,925	2,678,098	2,607,410	2,428,934	2,316,152	2,235,638	2,174,256	2,209,153
Cry, FFP, PLT, RBC	3,446,855	3,426,782	3,404,865	3,399,988	3,340,221	3,103,200	3,002,797	2,914,228	2,845,459	2,903,760

Cry = Cryoprecipitate

FFP = Fresh frozen plasma

PLT = Platelet

RBC = Red blood cell

Table 25: Adverse Events with Blood Usage in the United Kingdom

Adverse Event	IBCT	I&U	HSE	AntiD*	ATR	HTR	TRALI	TACO	TAD	PTP	TA-GvHD	TTI	Autologous	Total
Death: Transfusion reaction causal contributory	27	4	0	0	19	11	42	5	0	2	13	15	0	138
Major morbidity: Probably/definitely attributed to transfusion	116	3	0	25	58	48	165	18	1	13	0	48	0	495
Minor/no Morbidity: with transfusion reaction/error	3439	161	335	361	1154	383	50	29	4	34	0	6	42	5998
Unknown	11	0	0	0	3	1	0	0	0	0	0	0	0	15
Total	3593	168	335	386	1234	443	257	52	5	49	13	69	42	6646

AntiD = Anti-D antigen related events. There were also 127 cases of potential major morbidity where anti-D had been omitted or given more than 72 hours after the event.

ATR = Acute transfusion reaction

Autologous = Autologous transfusion

HSE = Handling & storage errors

HTR = Hemolytic transfusion reaction

IBCT = Incorrect blood component transfused

I&U = Inappropriate & unnecessary transfusion

PTP = Post transfusion purpura

TACO = Transfusion related circulatory overload

TAD = Transfusion associated dyspnea

TA-GvHD = Transfusion associated graft vs host disease

TRALI = Transfusion related acute lung injury

TTI = Transfusion transmitted infection

4. MEDCAC

A Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting was convened on this issue on March 24, 2010. Chronic renal disease and anemia management with erythropoietic stimulating agents were reviewed discussed. (www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=52&bc=BAAQAAAAAAAA&; accessed July 19, 2010.)

A second Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting was convened on this issue on January 19, 2011. At the request of the panelists on the March 2010 MEDCAC, renal transplantation and the impact of red blood cell transfusion were reviewed. (www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=57&bc=BAAQAAAAAAAA&; accessed January 21, 2011.)

5. Evidence-based guidelines

a. **American Medical Directors Association** in conjunction with representatives from the American Association of Homes and Services for the Aging, the American College of Health Care Administrators, the American Geriatrics Society, American Health Care Association, the American Society of Consultant Pharmacists, National Association of Directors of Nursing Administration in Long-Term Care, National Association of Geriatric Nursing Assistants, and the National Conference of Gerontological Nurse Practitioners
Anemia in the Long-term Care Setting 2007. NGC:005655 Guidelines not on website Hardcopy on file with CMS.

“...The World Health organization defines anemia as a hemoglobin of less than 12 g/dl in women and less than 13 g/dl in men...Anemia is a marker for increased morbidity, hospitalizations, mortality, and health care costs...Caregivers and health care professionals may not relate non-specific symptoms such as fatigue, weakness, and lack of stamina to anemia...Anemia associated with chronic kidney disease (CKD) was redefined in 2006 by the National Kidney Association (NKF) Kidney Disease Outcomes Quality Initiative (K/DOQI) as hemoglobin of less than 12 g/dl in women and less than 13.5 g/dl in men in the presence of renal dysfunction...Anemia associated with CKD can be severe and may lead to cardiovascular complications and death...Deficiency of the hormone erythropoietin is the primary but may not be the sole cause of anemia associated with CKD...Synthetic erythropoietin-stimulating agents (ESAs) are available to treat this type of anemia...The use of ESAs to treat anemia associated with CKD should be carefully evaluated in frail elderly patients in the longterm care setting...”

The authors state that they were an interdisciplinary group. The guideline provides an algorithm for assessment, treatment, and monitoring anemia although the authors did not do a comprehensive review of primary data, grade evidence, or provide a rating scheme for the strength of the recommendations. For example, the WHO criteria were developed for epidemiologic surveillance of nutrient, especially iron, deficiencies in third world settings. For example, anemia is not erythropoietin-mediated until after the initiation of dialysis (Radtke 1979). For example, the text implies that ESAs will improve hematocrit level, transfusion need, quality of life, exercise performance, and cognitive function based on only two cited studies with 11 and 23 patients respectively (Bedani 2001 and Moreno 1996) which were not critically assessed. The report of an 8 g/dl improvement in older patients does not appear to match the values in figure 1 (Moreno 1996 [reference 57]) and does not address the impact of drop-out (14% for total ESA treated population). The guideline can only be obtained at a cost of \$15. Funding for the guideline was supported by the following: Amgen, Merck & Co., Inc., Ross Products Division of Abbott Laboratories, and Sanofi-Aventis.

b. **British Committee for Standards in Haematology**

Guidelines for the Clinical Use of Red Cell Transfusions 2001 (British Journal of Haematology 113: 24-31) Currently under revision

“...Red cell transfusion when estimates of actual and anticipated haemoglobin concentrations are >10 g/dl. Red cell transfusion is indicated when the haemoglobin concentration is < 7 g/dl. Red cell transfusions should be given in relation to the rate of ongoing red cell loss...The correct strategy for transfusion of patients with haemoglobin concentrations between 7 and 10 g/dl is less clear. Clinicians often transfuse red cells, although available evidence suggests that this is often not justified. In patients who may tolerate anaemia poorly, e.g., patients over the age of 65 years and patients with cardiovascular or respiratory, consider adopting a higher concentration at which transfusions are indicated, e.g., when the haemoglobin concentration becomes < 8 g/dl. ... In principle, red cell transfusions for patients with chronic anaemia should be given at intervals to maintain the haemoglobin just above the lowest levels associated with symptoms of anaemia, but it may be difficult to determine what this is for individual patients...”

Guideline on the Administration of Blood Components 2009. (www.bcshguidelines.com; accessed 12/01/2010)

Harris A, Atterbury C, Chaffe B, Elliott C, Hawkins T, Hennem S, Howell C, Jones J, Murray S, New H, Norfolk D, Pirie L, Russell J, Taylor C.

The purpose of this guideline is to provide national guidance on pre-transfusion blood sampling and the prescription, requesting, collection and administration of blood components to adults, children and neonates in order to provide a basis for the development of standardised local guidelines and practice.

c. Canadian Society of Nephrology

Guidelines for the management of chronic kidney disease 2008. (Canadian Journal of Medicine)

Levin A, Hemmelgarn B, Cullerton B, Tobe S, McFarlane P, Ruzicka M, Burns K, Manns B, White C, Madore F, Moist L, Klarenbach S, Barrett B, Fole Ry, Jindal K, Senior P, Pannu N, Shurraw S, Akbari A, Cohn A, Reslerova M, Deved V, Mendelsohn D, Nesrallah G, Kappel J, Tonelli M.

“...Anemia is prevalent among patients with an estimated glomerular filtration rate less than 60 mL/min/1.73 m². Anemia is associated with adverse outcomes in patients with chronic kidney disease, including hospital admission, cardiovascular disease and mortality. Although erythropoietin deficiency is a well-known cause of anemia in this population, the guidelines recommend that other potential causes of anemia should be sought (e.g., iron deficiency) and treated accordingly. To date, therapies to normalize the hemoglobin level in these patients have not shown any health benefit. These therapies have been associated with an increased incidence of death or need for dialysis. Based on this evidence, a target hemoglobin level of 110 g/L is recommended for patients with chronic kidney disease (acceptable range 100 – 120 g/L). The use of erythropoiesis-stimulating agents for the treatment of anemia in patients with chronic kidney disease is associated with potential adverse outcomes, including increased blood pressure and thrombotic complications. They should be prescribed by a specialist with experience in prescribing these agents. Iron therapy is an important component of anemia management. We recommend that the oral form of iron be considered preferentially over the intravenous form...”

d. Caring for Australasians with Renal Impairment-Australian and New Zealand Society of Nephrology Erythropoietin 2004 (www.cari.org.au/CKD_Prevent_List_Published/Erythropoietin.pdf; accessed 12/01/2010) Johnson D.

The weight of clinical evidence indicates that erythropoietin exerts neither a beneficial nor deleterious effect on the progression of renal impairment in patients with chronic renal insufficiency. (Level II Evidence, 6 small randomised controlled trials; clinically relevant outcomes; inconsistent effects) Of the 6 RCTs published to date, 5 trials have found no significant effect of erythropoietin administration on the progression of CKD. One trial with significant flaws observed that erythropoietin significantly retarded renal failure progression, primarily in non-diabetics.

Biochemical and haematological targets. Haemoglobin. 2008 (Nephrology) McMahon L.

“The targeting of haemoglobin concentrations above 13 g/L has been associated with an increased mortality in chronic kidney disease (CKD) patients (dialysis and pre-dialysis) and is therefore currently considered inadvisable (Level I evidence)”.

“...Substantial evidence now indicates that targeting (without necessarily achieving) haemoglobin concentrations above 130 g/L with ESA in patients with CKD results in an increased mortality and morbidity with little benefit (compared to targeting concentrations below 120 g/L) and at a higher cost. Older patients and those with more advanced cardiovascular disease and/or diabetes are at highest risk, which appears to pertain to both dialysis and pre-dialysis patients. In addition, there appears to be an increased risk of hypertension and arteriovenous access thrombosis in patients targeted for higher haemoglobin concentrations without substantial evidence of benefit in quality of life or normalisation of exercise capacity. The ESA dosage and associated cost of achieving and maintaining higher haemoglobin concentrations is significantly greater...”

The other clinical recommendations were based primarily on Level 3 (case control or cohort) or level 4 (cases series) evidence.

e. College of American Pathologists (CAP)

This professional group no longer issues transfusion practice guidelines although they have done so in the past.

f. European Blood Alliance *Manual of Optimal Blood Use: Support for Safe, Clinically Effective Use of Blood in Europe 2010* (www.optimalblooduse.eu; accessed 12/15/2010) *McClelland DBL, Pirie E, Franklin IM for the EU Optimal Blood Use Project Partners; Co-funded by the European Commission and the Scottish National Blood Transfusion Service Published by the Scottish National Blood Transfusion Service*

“...Optimal use of blood is defined in this manual as “The safe, clinically effective and efficient use of donated human blood.” However, for many of the familiar and widely accepted indications it is a fact that there is surprisingly little high quality evidence to establish the effectiveness of transfusion therapy. As a result, clinical transfusion guidelines must often be based on inadequate information. Information in this chapter about the quality and grading of evidence for clinical practice guidelines has been drawn from the German Guidelines for Therapy with Blood Components and Plasma Derivatives (2009.) Another useful sources (sic) is the database of systemic reviews at the website www.transfusionguidelines.org.uk. Studies in several European countries show that although patients undergoing surgery and treatment for malignant disease are major users of transfusion, a substantial portion of all transfusions are used for patients who do not belong to any simple category, who are in older age groups and who have essentially “medical” conditions, often with multiple diagnoses, interventions, and episodes of hospital care. ...Decision-making can be relatively straightforward when a patient has a life-threatening major haemorrhage, bleeding associated with profound thrombocytopenia, or severe, disabling symptoms of anaemia associated with cancer chemotherapy. The decision is much less clear – for example in an elderly patient, who has a haemoglobin concentration of 80g/l, has no evident symptoms of anaemia, is haemodynamically stable and is not bleeding....”

The following information in the Alliance manual is based on the German Medical Association's cross sectional guidelines for therapy with blood components and plasma derivatives in *Bundesaerztekammer* 2009, 4th revised edition (Table 26).(Heim 2009) The information presumes that the patient is not hemoconcentrated and not hypovolemic.

Table 26: Transfusion Guidance and Evidence Rating

Hemoglobin (g/dl)	Compensatory Capacity Risk Factor(s)	RBC Transfusion	Evidence Rating
≤ 6 g/dl	-	Yes	1C+ No randomised, controlled studies, but unambiguous data available
>6-8 g/dl	Symptomatic Decompensation (ECG ischemia, hypotension, lactic acidosis, tachycardia)	Yes	1C+ No randomised, controlled studies, but unambiguous data available
	Limited Compensation Risk factors such as cardiovascular disease & cardiac insufficiency	Yes	1C+ No randomised, controlled studies, but unambiguous data available
	Adequate Compensation No risk factors	No	1C+ No randomised, controlled studies, but unambiguous data available
> 8-10 g/dl	Symptomatic Decompensation (ECG ischemia, hypotension, lactic acidosis, tachycardia)	Yes	2C Very Weak recommendation , depending on the individual case, a different course of action may be indicated
> 10 g/dl	-	No	1A Strong recommendation . Valid for most patients.

g. European Renal Association-European Dialysis and Renal Transplant Association.
European RenalBestPractice (European Best Practices Guidelines)

Locatelli F, Covic B, Eckardt K-U, Wiecek A, Vanholder R, ERA-EDTA ERBP Advisory Board: Abramovicz D, Cannata Andia J, Cochat P, Fouque D, Heimbürger O, Jenkins S, Lindley E, London G, MacLeod A, Marti A, Spasovski G, Tattersall J, Van Biesen W, Wanner C, Zoccali C.

“...A specially appointed ERA-EDTA Work Group met in Paris to discuss European guideline planning in early January 2008, and agreed that the Association should continue producing and updating guidelines in collaboration with KDIGO. It also agreed that ERA-EDTA should issue suggestions for clinical practice in areas in which evidence is lacking or weak, which will be presented as ‘position statements’ rather than clinical guidelines. It was also decided to issue position statements about guidelines (recommendations issued by other bodies, of which the current publication is the first result). Finally, the group opted to change the name EBPG to European Renal Best Practice (ERBP) as a means of acknowledging that, especially in nephrology, it is difficult to generate real ‘guidelines’ because of the lack of sufficient evidence. In this context, and while awaiting the publication of the KDIGO anaemia guidelines possibly in 2011, an *ad hoc* work group was commissioned by the ERBP Advisory Board to give its opinion on the ‘hot topic’ of Hb targets, including recently raised issues that were not covered by KDOQI in 2006...”

Regarding the definition of anemia, “...In 2006, KDOQI modified this definition by giving a single criterion for diagnosing anaemia in adult males (Hb < 13.5 g/dl, regardless of age) because the decrease in Hb among males aged > 60 years is often attributable to concurrent diseases. The ERBP Work Group agrees with this new definition...In the opinion of the ERBP Work Group, it appears reasonable to maintain the lower limit of the target, although the actual evidence for choosing this value is also very limited. On the basis of new evidence, Hb values of 11 – 12 g/dl should be generally sought in the CKD population without intentionally exceeding 13 g/dl...The ERBP Work Group believes that there is a need for better understanding as to whether any harm may be associated with attempts to reach higher Hb values in patients with comorbidities or those who are hyporesponsive to ESAs...The ERBP Work Group agrees with the recent position of KDIGO that the available quality of life data vary in quality and are often inconclusive. In the opinion of the ERBP Work Group, ESA therapy should be cautiously used in patients with CKD and malignancies as no information is available concerning the risk of mortality and tumour growth in this subset of patients...”

“...In the opinion of the group, epoetin delta should be administered similarly to epoetin alpha...The ERBP Work Group considers the safety and tolerability of CERA to be similar to that of other ESAs...The ERBP Work Group recommends stringent pharmacovigilance for biosimilars of epoetin alpha that can be administered only intravenously...”

The workgroup did not consider the TREAT study which they indicated was ongoing at the time of the guideline discussions.

h. Kidney Disease Improving Global Outcomes (KDIGO) (managed by the National Kidney Foundation)

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target
(www.kidney.org/professionals/kdoqi/guidelines_anemiaUP/index.htm accessed 11/28/2010)

VanWyck D, Eckardt K-U, Adamson J, Berns J, Eckardt K-U, Fishbane S, Foley R, Ghaddar S, Gill J, Jabs K, Bargo McCarley P, Nissenson A, Obrador G, Stivelman J, White C. Liaison Members Locatelli F, Macdougall IC. Evidence Review Team National Kidney Foundation Center for Clinical Practice Guideline Development and Implementation at Tufts-New England Medical Center

(KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease 2006)

www.kidney.org/professionals/kdoqi/guidelines_anemia/guide1.htm; accessed 11/28/2010)

(Adamson J, Bailie G, Berns J, Fishbane S, Foley R, Ghaddar S, Gill J, Jabs K, Bargo McCarley P, Messner H, Nissenson A, Obrador G, Stivelman J, White C.

“...In the opinion of the Work Group, in dialysis and nondialysis patients with CKD receiving ESA therapy, the selected Hb target should generally be in the range of 11.0 to 12.0 g/dL...In dialysis and nondialysis patients with CKD receiving ESA therapy, the Hb target should not be greater than 13.0 g/dL...”

Currently this clinical guideline is undergoing revision. “Anemia in CKD” is under the leadership of Drs. Patrick Parfrey and John McMurray (Anticipated Publication – 2012)

i. National Collaborating Centre for Chronic Conditions

Anaemia management in chronic kidney disease. National clinical guideline for management in adults and children.
London (UK): Royal College of Physicians; 2006. 172 p. [295 references]

“...Patients with CKD should be evaluated for risk stratification of cardiovascular disease. Patients with CKD should be assessed for cardiovascular risk including fasting lipid profile, blood pressure, tobacco use (smoking) history, family history of premature cardiovascular disease, obesity, and physical activity level. Strategies to reduce cardiovascular risk factors should be implemented. Consider treatment of anemia in patients with CKD with an erythropoietic stimulating agent if the hemoglobin is less than < 10 g/dL and after appropriate evaluation and ruling out other possible causes. Such treatment may require referral to nephrology or hematology and more frequent monitoring of hemoglobin values...” Adverse events were listed: “...Hypertension occurs in 20 to 30 percent of patients and is easily treatable. Vascular access thrombosis. Hyperkalemia. Myalgia and flu-like symptoms. Injection pain and skin irritation around the injection site. Pure red cell aplasia is very rare and is associated with anti-erythropoietin antibodies...” The following evidence table is based on the evidence table in the guidelines (Table 27).

Table 27: NCCCC Anemia Management Guidelines for Patients with Renal Disease

Conclusion	Source	Evidence Quality	Overall Quality
Iron should be given to anemic CKD patients with serum ferritin <100 ng/ml or TSAT <20 percent or CHr <29 pg/cell	National Kidney Foundation, 2007 Panesar & Agarwal, 2002; Silverberg et al., 1996; Stoves, Inglis, Newstead, 2001;	At least 1 properly randomized controlled trial	Good High grade evidence (I or II-1) directly linked to health outcome
Insufficient evidence regarding the lower threshold of ESA	Levin et al., 2005; Locatelli et al., 2004; National Kidney Foundation, 2007; Roger et al., 2004	At least 1 properly randomized controlled trial	Fair High grade evidence (I or II-1) linked to intermediate outcome or Moderate grade evidence (II-2 or II-3) directly linked to health outcome
Hemoglobin >13 g/dL are associated with increased mortality and frequency of cardiovascular events.	Drueke et al. 2006; Singh et al., 2006; National Kidney Foundation, 2007	At least 1 properly randomized controlled trial	Fair High grade evidence (I or II-1) linked to intermediate outcome or

Conclusion	Source	Evidence Quality	Overall Quality
			Moderate grade evidence (II-2 or II-3) directly linked to health outcome
Vitamin C, androgens, or carnitine should not be administered.	National Kidney Foundation, 2007	At least 1 properly randomized controlled trial	Fair High grade evidence (I or II-1) linked to intermediate outcome or Moderate grade evidence (II-2 or II-3) directly linked to health outcome

j. National Institute for Health and Clinical Excellence (NICE)

Anaemia Management in People with Chronic Kidney Disease: Clinical Guideline: Rapid Update of Guideline #39 (Accessed July 21, 2010 and March 1, 2011)

“Consider investigating and managing anaemia in people with CKD if: their Hb levels falls to 11 g/dl or less (or 10.5 g/dl if younger than 2 years) or they develop symptoms attributable to anaemia (such as tiredness, shortness of breath, lethargy, and palpitations.” (No grade assigned) (p 41)

“ESAs need not be administered where the presence of comorbidities, or the prognosis, is likely to negate the benefits of correcting the anaemia.” (Grade D) (p42)

“Treatment with ESAs should be offered to people with anaemia of CKD who are likely to benefit in terms of quality of life and physical function.” (Grade A) (p43)

“A trial of anaemia correction should be initiated when there is uncertainty over whether the presence of comorbidities, or the prognosis, would negate the benefit from correcting the anaemia with ESAs.” (Grade D) (p42)

“The correction to normal levels of Hb with ESAs is usually not recommended in people with anaemia of CKD. Typically maintain the aspirational Hb range between 10 and 12 g/dl for adults, young people and children aged 2 years and older, and between 9.5 and 11.5 g/dl for children younger than 2 years of age, reflecting the lower normal range in that age group. To keep the Hb level within the aspirational range, do not wait until Hb levels are outside the aspirational range before adjusting treatment (for example, take action when Hb levels are within 0.5 g/dl of the ranges’s limits).” (No grade assigned) (p44)

“Where a trial of ESA therapy has been performed, the effectiveness of the trial should be assessed after an agreed interval. Where appropriate, a mutual decision should be agreed between the clinician, the person with anaemia of CKD and their families and carers on whether or not to continue ESA.” (Grade D) (p42)

“All people started on ESA therapy should be reviewed after an agreed interval in order to decide whether or not to continue using ESAs” (Grade D) (p42)

“After other causes of anaemia, such as intercurrent illness or chronic blood loss have been excluded, people with anaemia of CKD should be considered resistant to ESAs when: an aspirational Hb range is not achieved despite treatment with ≥ 300 IU/kg/week of subcutaneous epoetin or ≥ 450 IU/kg/week of intravenous epoetin cleteti or 1.5 ug/kg/week of darbepoetin, or there is a continued need for the administration of high doses to maintain the aspirational Hb range.” (Grade D) (p44)

Comments: Recommendations without the usual accompanying evidence grade assessments or low grade assessments raise questions about the validity of the recommendation.

The basis for the 10-12 g/dl aspirational goal appears to be based on the Collins group retrospective assessments mortality and hemoglobin based on USRDS data (NICE reference 60). The USRDS data do not reflect the natural history of anemia because hematocrit (hemoglobin) levels infrequently enter the system unless they are on a billing claim for ESAs. The presence, magnitude, and impact of an intervention (ESA) on outcomes were not addressed in the papers.

k. World Health Organization (1994)

Indicators and Strategies for Iron Deficiency and Anemia Programmes. Report of the WHO/UNICEF/UNU Consultation. 1994

Achadi E, El Amin A, Florentino R, Galil A, Hallberg L, Suboticanes-Buzina K, Thwin A, Viteri F, Walter T, Wenzhen C, Harrison K, Kachondham Y, Zavaleta N, Clay W, Dirren H, Parr R, Robinett D, Seifman R, Simon S, Theuer R, Yip R, Alnwick D, Scrimshaw N, Antezana F, Bailey K, Benbouzid D, Buzina R, de Benoist, B, Herrman J, Johnson R, Savioli L, Underwood B, Van der Pols J, Verster, A. Conference in Geneva, Switzerland, 6–10 December, 1993.

The World Health Organization (WHO) definitions for anemia were developed for surveillance of anemia due to nutritional deficiency and parasitic infections. Anemia was defined to present at sea level with hemoglobin levels < 13 g/dl in adult men, < 12 g/dl in non-pregnant adult women, < 11 g/dl in pregnant adult women, < 12 g/dl in children aged 12-14 years < 11.5 g/dl in children 5-11 years, and < 11 g/dl in children 6 to 59 months. The report notes that “It is well known that normal haemoglobin distributions vary with age and gender, at different stages of pregnancy, and with altitude and smoking” (Chanarin 1971, Hurtado 1945). “There is also evidence of a genetic influence. In the United States, for example, individuals of African extraction have haemoglobin values 5 to 10 g/l lower than do those of European origin. This contrast is not related to iron deficiency” (Perry 1992)... “Annex 3 provides age-related criteria for normal haemoglobin and haematocrit levels developed by the Centers for Disease Control and Prevention in Atlanta, USA “(Expert Scientific Working Group. AJN 1985). “Criteria for stages of pregnancy, and adjustment factors for altitude and smoking are also provided. For populations of African extraction, recent analysis indicates that achieving a similar screening performance (sensitivity and specificity) requires a haemoglobin criterion that is 10 g/l (0.62 mmol/l) lower than those shown in Table 6” (Johnson-Spear 1994, Yip 1997)... “Severe anaemia in pregnancy is defined as haemoglobin < 70 g/l and requires medical treatment. Very severe anaemia is defined as haemoglobin < 40 g/l. Very severe anaemia in pregnant women is a medical emergency due to the risk of congestive heart failure; maternal death rates are greatly increased....”

6. Professional Society Position Statements

Various professional societies expressed positions via submitted public comment.

a. The American Society of Nephrology (ASN) believe that current ESAs may be dangerous if used for overly aggressive treatment targets compared with practices that are compatible with current treatment guidelines. They also believe that continued access to ESAs is required to give both dialysis and non-dialysis patients with CKD, a better chance at receiving and maintaining the function of a kidney transplant.

b. The National Kidney Foundation (NKF) believes that the anemia target should be generally consistent with the recommendation in the 2007 Kidney Disease Outcomes Quality Initiative (KDOQI) Update of Hemoglobin (HB) Target, and the FDA package inserts for the three approved ESAs, i.e. a range from 10 to 12 g/dL.

7. Expert Opinion

We may receive expert opinions on the proposed decision during the comment period.

8. Public Comments

Public comment sometimes cites the published clinical evidence and gives CMS useful information. The CMS uses the initial public comments to inform its proposed decision. The CMS responds in detail to the public comments on a proposed decision when issuing the final decision memorandum.

Initial Comment Period: 6/16/10 – 7/16/10

During this public comment period, the CMS received a total of nine timely comments. Of these public comments received, five were from professional organizations, two were from marketers of ESAs, one was from a professional society and one was from a patient advocacy group.

The majority of comments suggest that policies should align with FDA approved labeling and that policies should differentiate between dialysis patients and non-dialysis patients. Some commenters suggested that quality of life (QoL) should be considered an important patient outcome. Other commenters were concerned with the effect the new prospective payment system (PPS) may have on the treatment of anemia. However, the PPS is outside the scope of this NCD.

One commenter supported CMS' efforts to review the available clinical evidence due to recent evidence and Food and Drug Administration (FDA) action that highlight safety concerns and potential overuse of ESAs for this population. This commenter also supported CMS' commission of a TA from an outside entity and suggested we not move forward on a proposed decision until the conclusion of this TA.

A few commenters mentioned that the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will be tentatively meeting this Fall [2010] to review the full range of evidence on ESA benefits and risks. These commenters suggested that the CMS not move forward on a proposed decision until after this meeting takes place.

Several commenters provided literature citations and/or other materials with comments. Full text comments without personal health information can be viewed at: [https://www.cms.gov/medicare-coverage-database/details/nca-view-public-comments.aspx?NCAId=245&ExpandComments=n&ver=6&NcaName=Erythropoiesis+Stimulating+Agents+\(ESAs\)+for+Treatment+of+Anemia+in+Adults+with+CKD+Including+Patients+on+Dialysis+and+Patients+not+on+Dialysis&bc=BEAAAAAAEAAA&](https://www.cms.gov/medicare-coverage-database/details/nca-view-public-comments.aspx?NCAId=245&ExpandComments=n&ver=6&NcaName=Erythropoiesis+Stimulating+Agents+(ESAs)+for+Treatment+of+Anemia+in+Adults+with+CKD+Including+Patients+on+Dialysis+and+Patients+not+on+Dialysis&bc=BEAAAAAAEAAA&).

VIII. CMS Analysis

A. Analysis Framework

National coverage determinations (NCDs) are determinations by the Secretary with respect to whether or not a particular item or service is covered nationally by Medicare (§1869(f)(1)(B) of the Act). In order to be covered by Medicare, an item or service must fall within one or more benefit categories contained within Part A or Part B, and must not be otherwise excluded from coverage. Moreover, with limited exceptions the expenses incurred for items or services must be "reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member." See §1862(a)(1)(A) of the Act. This section presents the agency's evaluation of the evidence considered and conclusions reached for the assessment

B. Analysis

Questions:

A. Is the evidence sufficient to conclude that the underlying cause for anemia in Medicare beneficiaries who have renal disease and are not on dialysis is absolute and irreversible erythropoietin deficiency?

B. If the answer to question A is affirmative, is the evidence sufficient to conclude that erythropoiesis (erythrocyte) stimulating agent (ESA) therapy affects health outcomes (including survival, cardiovascular event rates, exercise capacity, progression of renal disease, quality-of-life, transfusion rates, and ability to receive a transplant) when used by Medicare beneficiaries who have renal disease and are not on dialysis?

C. If the answer to Question B is affirmative, is there sufficient evidence to determine which characteristics of the patient, the disease, or the treatment regimen reliably predict a favorable or unfavorable health outcome when used by Medicare beneficiaries who have renal disease and are not on dialysis?

D. Is the evidence sufficient to conclude that the underlying cause for anemia in Medicare beneficiaries who have renal disease and are on dialysis is absolute and irreversible erythropoietin deficiency?

E. If the answer to question D is affirmative, is the evidence sufficient to conclude that erythropoiesis (erythrocyte) stimulating agent (ESA) therapy affects health outcomes (including survival, cardiovascular event rates, exercise capacity, quality of life, transfusion rates, and ability to receive a transplant) when used by Medicare beneficiaries who have renal disease and are on dialysis?

F. If the answer to Question E is affirmative, is there sufficient evidence to determine which characteristics of the patient, the disease, or the treatment regimen reliably predict a favorable or unfavorable health outcome when used by Medicare beneficiaries who have renal disease and are on dialysis?

In seeking to address these questions, CMS sought evidence on the underlying clinical science

1. For anemia in general, what are the physiologic criteria for intervention?
2. What are the causes for anemia in renal disease?
 - a. Do the causes differ along the spectrum of renal dysfunction?
 - b. When is anemia erythropoietin-mediated?
3. Are there validated criteria for transfusion?
 - a. For what reasons do renal patients receive transfusions?
 - b. Is there evidence that ESAs eliminate/reduce the need for transfusion when validated criteria for transfusion are employed?
4.
 - a. Is there evidence of improved clinical outcomes from ESA therapy?
 - b. Is there evidence of potential harm from ESA therapy?
5. Do we have sufficient data to determine whether the hemoglobin level or ESA dose contributes to benefit or harm?
6. How do ESA dose levels in the U.S. compare to dose levels elsewhere?
7. If ESA resistance, i.e. requirement of more than physiologic replacement, is present, is there evidence that patient outcomes are improved by continued/increased ESA dosing?

Our analysis is made more complex because of certain historical assumptions that have been recently challenged. In the late 1980s, erythropoietin was developed to treat anemia and reduce the need for transfusions, especially with the advent of AIDS and a limited ability to screen the blood supply. (OTA 1985, OTA 1990) It was presumed that many complications of renal disease were related to anemia rather than to the underlying disease or comorbidities. The renal failure population was relatively small, thus the orphan drug designation, and homogenous. (Coster 1992, OTA 1990)

CMS has carefully reviewed the historical context of renal disease, anemia management, secular changes in the renal patient population, and an evolving ESA database in which hypothesized benefits have been assessed more rigorously.

1. Physiology and Hemoglobin Requirements

Hemoglobin level requirements for physiologic function remain poorly understood. Most of the observational and interventional data are from the acute care setting. In one of the few controlled studies, Hebert found that 30 day mortality rates were not improved by liberal transfusion policies (transfusion for hemoglobin levels less 10 g/dl and maintenance with hemoglobin levels between 10 and 12 g/dl) compared to restrictive transfusion policies (transfusion for hemoglobin levels less 7g/dl and maintenance with hemoglobin levels between 7 and 9 g/dl) in 838 euvoletic, anemic, critically ill intensive care patients stratified by disease severity (APACHE II score). (Hebert 1999) Mortality was actually increased in relatively healthy (APACHE II score < 20) and young (< 55 years) patients. Results did not differ by patient subgroup: cardiovascular disease (n = 357) (Hebert 2001a), head injury (n = 67) (McIntyre 2006), mechanically ventilated (n = 713) (Hebert 2001b), and trauma (n = 204) (McIntyre 2004). In the same way, Hajjar et al. found that 502 cardiac surgery patients transfused to maintain a hematocrit of 30% or higher versus a hematocrit of 24% or higher had equivalent 30 day mortality rates and severe morbidity (cardiogenic shock, acute respiratory distress syndrome, or acute renal injury requiring dialysis or hemofiltration). In the same way, Carson et al. found that 1007 hip-fracture surgical patients with known cardiovascular disease who transfused to hemoglobin levels in excess of 10 g/dl did not have more exercise tolerance at 60 days post-operation than the 1009 restrictive arm patients who were transfused after hemoglobin levels dropped to below 8 g/dl or patients became symptomatic. (Carson 2009-abstract, 2011 MEDCAC presentation, 2011)

Hemoglobin requirements in the chronic setting cannot be directly extrapolated from findings in the acute care setting because there are compensatory such as increases in 2,3 diphosphoglycerate which result in better oxygenation at the tissue level than what would otherwise be expected for a given plasma hemoglobin level. (Aberman 1985, Metivier 2000, McDonald 1977) There are no equivalent randomized trial data to assess the physiologic requirements of renal patients, either pre-dialysis or dialysis treated. The series of papers by the Collins group are frequently cited as the reason for achieving hemoglobin levels between 10 and 12 or higher *“After adjusting for these confounding patient characteristics, our results showed that patients with hematocrit levels < 30% have significantly higher risk of all-cause & cause-specific death, compared to patients with hematocrit levels of 30% to < 33%. ...After adjusting for severity of disease, the impact of hct levels in the 33% to <36% range becomes vulnerable to the number of patients included but still demonstrates a further 4% reduced risk of death. Overall, our findings suggest that sustained increases in hematocrit levels are associated with improved patient survival.”* These papers, however, do not describe either the natural history of renal disease (because most of the population was treated with an ESA) or the specific effects of an intervention (because the presence of an intervention, ESA, and the size of the intervention, ESA dose parameters, were not included in the analyses.) Indeed another author group who performed a similar analysis, Madore et al. specifically cautioned against the extrapolation of such observational data in the absence of correction for therapeutic interventions and co-morbid disease. (Madore 1997)

The most recent systematic reviews conducted by Cochrane (Carliss et al. 2009) and the European Blood Alliance (McClelland et al. 2010) suggest that anemia management with transfusions to maintain or achieve hemoglobin levels > 10 g/dl does not confer physiologic benefit and that anemia management with transfusions is not required until the normovolemic hemoglobin level is below 6 or 7 g/dl unless there is evidence of physiologic decompensation or circulatory risk.

2. Causes of Anemia

Patients with renal disease, especially older patients with co-morbid chronic disease conditions and occult marrow dysfunction, may have anemia for a variety of reasons. Anemia, however, cannot be attributed to renal disease until the GFR is < 30 ml/min/m². Longitudinal data show that as renal function declines in the months prior to dialysis and hemoglobin levels decline, erythropoietin levels actually rise. After dialytic removal of uremic toxins, there is a compensatory increase in hemoglobin levels and decline in erythropoietin levels. These data show that anemia prior to dialysis is not intrinsically mediated by the hormone, erythropoietin. Rather, it generally can be attributed to uremia. In the 6-12 month period after the onset of dialysis, there is further loss of renal tissue in most patients and erythropoietin levels typically permanently decline. In patients with preserved functional tissue, such as those with polycystic kidney disease, residual erythropoietin hormone production may persist. Hormone deficiencies are typically managed by replacement dosing. Physiologic replacement doses approximate 150 U/kg/week or less in normal weight subjects. Higher dose requirements, or resistance, suggest the superimposition of other disease processes such as inflammation, infection, drug-induced marrow fibrosis, or drug-interaction. In many of the registration studies, other causes of anemia were not rigorously excluded. Indeed many studies used only calculated GFR and/or included pre-dialysis subjects whose anemia could not even be attributed to renal dysfunction (uremia) because of filtration values between 30 and 59 ml/min.

3. Transfusions

Although ESAs were developed to reduce transfusion dependence, transfusions can be given for a variety of reasons including chronic anemia management, blood loss due to hemodialysis, bleeding diatheses secondary to uremia, and surgical procedures for renal and non-renal conditions. Unfortunately, the data in support of this indication is poor. To establish this claim, it is necessary to have validated criteria for transfusion, study protocols for transfusion, and documented adherence to such protocols in patients with erythropoietin-mediated anemia. As delineated above, the criteria for anemia intervention are not well established. As such, it was not possible to prepare evidence-based protocols for anemia intervention. The randomized clinical trials did not include criteria for transfusion except "clinical indication." Information on the number of transfusions, number of units transfused (per person transfused), and the reasons for transfusion were not reported. Little is known about the characteristics of patients who received transfusion. Many studies failed to rigorously exclude other causes of anemia. The absence of blinding further complicated interpretation of transfusion data.

In particular it should be noted that only erythropoietin carries the indication for transfusion reduction. The subsequent ESAs used non-inferiority or equivalence data in support of their drug registration applications. As such, they were active controlled, and not placebo controlled studies. There is only one published/publicly available placebo-controlled clinical trial in dialysis patients using an FDA approved product: the Canadian study with 118 patients. These patients were markedly different than the current dialysis population. They were more anemic. They were younger. Their underlying renal disease differed; diabetes was excluded. There is only one published/publicly available placebo controlled clinical trial in pre-dialysis patients using an FDA approved product: the Teehan study with 117 patients. No transfusions were administered during the trial. Because renal patients receive transfusions for reasons other than chronic anemia, ESAs may not be able to eliminate the need for transfusions. The reviewing FDA medical officer for an unpublished darbepoietin registration study in dialysis patients noted "The 27% transfusion rate in the ARANESP group in Study 211 is quite substantial... In any case, the data do not make the case that ARANESP decreased the need for RBC transfusions, given the directionally opposite trend."

4. Other Hypothesized Clinical Benefits

The FDA removed health related quality-of-life claims from the ESA labels after a public hearing in 2007. The sponsor cited evidence from four studies from the initial circa 1988 drug approval application (three small controlled studies (one published EP 86-004, two unpublished 8701 and 8904) and one uncontrolled study 8601). The FDA cited multiple design inadequacies including blinding, failure to prospectively address missing data, post-hoc analysis, and the absence of any correlation (changes in) hemoglobin or hematocrit levels and (changes in) anemia symptoms. The FDA cited deficiencies in the test instruments that were used including problems with content validity and post hoc selection of test items. More recent, larger, and longer studies (CHOIR, CREATE, NHCT, and TREAT) did not demonstrate any clinically significant, durable improvements in (health-related) quality-of-life using validated instruments.

Regarding the effect of ESAs on exercise tolerance, many of the studies were relatively short in duration and small in size. The largest study powered for exercise (Furuland 2003; n = 416) could not be completed because many of the subjects could not perform the testing. despite the near complete penetration of ESA use in the dialysis population, the ability of patients, especially older patients, to ambulate declines during their first year on dialysis. This coupled with studies that suggest that exercise training programs can improve physical function, suggest that exercise performance and fatigue are related to a variety of variables.

ESAs do not appear to alter the rate of renal disease progression. The earliest studies used surrogate markers and attempted to estimate renal function decline using the calculated slope of creatinine clearance or GFR change measured by a variety of methods over variable periods of observation. Only three randomized studies (CHOIR, CREAT, and TREAT) collected data on progression, but were limited because progression to dialysis was not a primary endpoint and the baseline data were not rigorous assessments of renal function. Nonetheless, none of these studies showed that ESA use or randomization to a higher hemoglobin target group decreased the likelihood or onset of dialysis, and the CREATE study suggested increased renal function decline.

The largest and longest randomized studies of intermediate cardiac endpoints, primarily left ventricular mass, did not show improvement. In addition, more definitive studies with cardiovascular events and/or survival (NHCT, CHOIR, CREATE, TREAT, and PEARL) did not show improvement in the higher hemoglobin target treatment arms.

5. Adverse Clinical Outcomes

Some of the earliest studies demonstrated that exogenous erythropoietin could result in fluid retention, hypertension, and vascular thrombosis. Later studies in renal patients suggested that chronic ESA use could result in decreased survival, increased rates of cardiovascular events, and increased rates of thrombosis (arterial and venous) (Table 28). In the TREAT study, there were more deaths in patients with a prior history, but no known active cancer at study entry in the higher hemoglobin target arm. Some of these latter studies suggest harm in the higher hemoglobin target arm, whether or not the target was achieved. These data suggest that dose may be more important than hemoglobin as a mediator of harm for some adverse events. This role for dose is supported by new retrospective studies by Seliger et al. and Zhang et al. (Seliger 2011, Zhang 2011) More definitive conclusions about the degree and nature of the harm cannot be made because of premature discontinuation of the prospective trials before statistical significance was reached and/or the high withdrawal rates and poor follow-up in addition to the confounding introduced by the study design elements such as the absence stratification by ESA-naïve hemoglobin levels and/or absence of fixed dosing. Most of the hundred of studies that have been conducted in thousands of patients since the introduction of ESAs 20 years ago have not been structured to address these fundamental questions.

Table 28: Mortality and Cardiovascular Events in Major Trials

Study	Composite Events	Death	Cardiovascular Other	Other	DC Early	Withdrawal
NHCT Dialysis Epo α	High target 202 Low target 164	High target 183 Low target 150	1st non-fatal MI High target 19 Low target 14	- -	Yes Safety	Not indicated
CHOIR Pre-dialysis Epo α	High target 125 Low target 97	High target 52 Low target 36	CHF+MI+CVA High target 64+18+12 Low target 47+20+12	- -	Yes Ability to show + results unlikely Safety	38%
CREATE Pre- dialysis Epo β	High target 58 Low target 47	High target 31 Low target 21	LV mass Δ yr 1, yr 2 (g/m²) High target -4.6, -6.4 Low target -3.3, -7.8	- -	No	High target 25% Low target 17%
TREAT Pre- dialysis Darbe α	High target 632 Low target 607	High target 31 Low target 21	Stroke High target Low target	Cancer Death High target 39 Low target 25	No	Tx DC but followed 20% DC & followed only for death status 13%

DC = discontinued

Tx = treatment

6. Dosage

In the classic paradigm, physiologic replacement of a missing hormone should result in normalization of function. In the non-classic paradigm, a hormone is used at higher than physiologic levels because of hormone resistance or to supplement endogenous pathways to achieve supraphysiologic or accelerated physiologic responses. It is a well known phenomenon that hormones and related molecules will bind to higher occupancy sites first and lower occupancy (non-classical) sites later—depending on dose and hormonal milieu. Residence time may also be important. Non-classic actions or pleiotropic effects may occur—especially in the setting of high dosing. Toxicology studies in animals, however, appear to have been limited in scope and did not include carcinogenicity studies. (Erythropoietin information limited to that contained in the label.) No fixed dose studies with stratification for co-morbid conditions and ESA-naïve hemoglobin levels have been conducted. None of the primary papers discuss response rate by dose.

Despite these deficiencies in the data, it is clear that administered ESA doses have increased markedly over time in the U.S (Figure 8). ESA dosing in the U.S. exceeds physiologic replacement and is approximately twice that in Europe despite equivalent hemoglobin results, and hemoglobin levels that exceed physiologic requirements and known to confer any beneficial clinical outcome (Tables 29, 30, and 31). The doses of this hormone that are being given are by definition supraphysiologic—more than replacement—especially immediately after IV administration dose. (Figures 1 and 2) The reasons for these differences in dosing practice remain unclear.

Recent retrospective studies suggest that acute stroke is more frequent in renal insufficiency patients, especially those with concomitant cancer (Seliger 2011), and mortality is greater in end stage renal disease patients, especially those with diabetes, when using higher ESA doses (Zhang 2011 in press).

Table 29: Hemoglobin Level and Erythropoietin Dose in the 2003 ESAM Cross-sectional Survey on Anaemia Management (Jacob 2005)

Location	Mean Epo Dose (U/wk)	Hb < 11 g/dl (%)	Mean Epo Dose (U/wk)	Hb > 11 g/dl (%)	Ratio Epo Dose Hb< 11 g/dl/> 11g/dl	Mean Epo Dose (U/wk)
Belgium	16,477	23.6	10,023	76.4	1.6	11,546
Israel	15,310	28.7	9,358	71.3	1.6	11,064
Sweden	15,649	23.8	9,744	76.2	1.6	11,147
Austria	14,049	28.6	7,653	71.4	1.8	9,483
Finland	12,095	27.1	6,835	72.9	1.8	8,261
Switzerland	11,943	21.1	7,923	78.9	1.5	8,771
Netherlands	11,623	32.1	7,038	67.9	1.65	8,511
United Kingdom	11,196	34.6	7,503	65.4	1.5	8,782
Greece	10,335	42.4	7,109	57.6	1.45	8,476
Slovenia	9,940	32.3	6,245	67.7	1.6	7,437
Germany	8,628	34.6	5,532	65.4	1.6	6,603
Poland	4,420	62.9	2,583	37.1	1.7	3,738

Location	Mean Epo Dose (U/wk)	Hb < 11 g/dl (%)	Mean Epo Dose (U/wk)	Hb > 11 g/dl (%)	Ratio Epo Dose Hb< 11 g/dl/> 11g/dl	Mean Epo Dose (U/wk)
Overall Mean	9,836	33.9	6,781	66.1	1.45	7,817

N = 8100, 284 centers 12 countries

Table 30: Hemoglobin Level and Erythropoietin Dose in the 2002-3 DOPPS Cross-sectional Survey in Hemodialysis Patients (Pisoni 2004)

Location	Mean Epo Dose (U/wk)	Weekly Epo Dose 1K-18 K (%)	Mean Hb (g/dl)	Hb > 11 g/dl (%)	Epo Use b/f Dialysis (%)*	Mean Hb b/f Dialysis (g/dl)*
United States	17360	69	11.7	76	27	10.4
Belgium	12312	85	11.5	68	33	10.3
Sweden	12202	78	11.8	74	65	10.7
Canada	10808	86	11.4	66	43	10.1
Australia/New Zealand	8725	91	11.5	63	50	10.1
Italy	8118	95	11.1	56	59	10.2
United Kingdom	8010	96	11.2	58	44	10.2
Spain	7607	96	11.5	67	56	10.6
France	7401	96	11.0	51	43	10.1
Germany	6846	99	11.3	61	46	10.5

Location	Mean Epo Dose (U/wk)	Weekly Epo Dose 1K-18 K (%)	Mean Hb (g/dl)	Hb > 11 g/dl (%)	Epo Use b/f Dialysis (%)*	Mean Hb b/f Dialysis (g/dl)*
Japan	4875	98	10.2	19	62	8.3
Overall Mean	N = 11,041				N = 1886	

Table 31: Hemoglobin Level and Erythropoietin Dose in the UK Renal Registry Surveys in 1997 and 2007 (Burton 2000, Richardson 2009)

Type Dialysis/ Time Survey	ESA Dose (U/wk)	ESA Use (%)	No ESA+Hb > 10g/dl (%)	Hb (g/dl)	Hb > 10 g/dl (%)	Hb > 11 g/dl (%)
Hemodialysis-2007	9299	92	7	11.6 mean	86	68
Peritoneal Dialysis-2007	6101	75	20	11.9 mean	91	76
Hemodialysis-1997	-	73	18	10.5 median	62	-
Peritoneal Dialysis-1997	-	48	39	11.0 median	76	-

ESA Resistance

As we noted above, in the classic paradigm, physiologic replacement of a missing hormone should result in normalization of function. Indeed many, albeit not all, patients with end-stage renal disease are deficient in erythropoietin because of damage to the renal parenchyma. Their anemia is secondary to and highly responsive to low doses of ESAs. In the non-classic paradigm, a hormone is used at higher than physiologic levels because of hormone resistance or to supplement endogenous pathways to achieve supraphysiologic or accelerated physiologic responses.

Poor drug response, i.e., resistance, suggests the presence of other clinical factors. Infection (frank or occult), inflammation (from a variety of causes including occult malignancy and adipose-related cytokines), impaired bone marrow reserve, dialysis adequacy, concomitant anemia from other causes (including iron deficiency and the anemia of chronic disease associated with type 2 diabetes mellitus), and drug products (interactions with endogenous erythropoietin or exogenous ESAs or ESA direct effects on the marrow or ESA drug-packaging induction of autoantibodies) have all been implicated in ESA resistance. Rossert et al. (OrthoBiotech) conducted a post hoc analysis in a subset of the ECAP study population and reported that greater body mass (BMI), older age, attribution of diabetes as the underlying cause of renal disease, anemia, and use of angiotensin-converting enzyme (ACE) or angiotensin II receptor blocking (ARB) anti hypertensive drugs were associated with higher erythropoietin dose requirements although these variables did not account for all of the variability in erythropoietin dosing.

Exploration of the underlying cause of ESA resistance is important for patient outcomes. Kilpatrick et al. (Amgen) conducted a post hoc analysis of 1-year mortality in dialysis and ESA responsiveness in NHCT dialysis patients with pre-study hematocrit levels of 30 ±3 vol%. The authors defined erythropoietin response as the weekly hematocrit change/erythropoietin dose increase. The patients in the lowest response rate quartile had the highest mortality (Table 32).

Table 32: Erythropoietin Resistance and Mortality (NHCT)

	Least Responsive Quartile 1	Quartile 2	Quartile 3	Most Responsive Quartile 4
Mortality %	34	28	25	14

Unfortunately, none of the published studies or FDA reviews discuss hemoglobin response rate by dose after stratifying by ESA-naïve baseline hemoglobin level. None of the studies were designed to prospectively assess erythropoietin resistance and putative variables. Many of the exclusion criteria for registration studies specifically excluded patients with high ESA dosing requirements or risk factors for resistance. The pivotal studies for pegylated erythropoietin excluded patients with elevated C-reactive protein (CRP) levels. The Resistance to ErythroPoietin Effectiveness Trials (REPEAT) (ClinicalTrials.gov identifier: NCT00319150)(Principal investigator K E Yeates; Sponsor OrthoBiotech) which was initiated in 2006 was terminated. (www.clinicaltrials.gov/ct2/show/NCT00319150?term=yeates+and+erythropoietin&rank=1; accessed February 11, 2011). There have been no drug interaction studies for medications such as ACE inhibitors, which are frequently used in the renal and diabetic patient populations. There are no long-term studies with bone marrow biopsies (published in entirety) to assess drug-induced fibrosis although early unpublished toxicology data and more recent molecular biologic data have suggested this possibility.

Conclusion

ESAs are being used with supraphysiologic dosing at hemoglobin/hematocrit levels higher than those used to avoid transfusions. Despite an exhaustive search, we identified no high quality, randomized clinical trials that were of sufficient design, duration, and power to definitely determine that ESAs provided clinical benefits other than increasing hemoglobin, a putative intermediate clinical surrogate in patients with documented erythropoietin-mediated anemia. The evidence for transfusion reduction is limited because of the absence of validated criteria for transfusion, the absence of defined study protocols for transfusion, and the use of non-inferiority (or equivalence) study designs that lacked a placebo arm.

We identified no randomized clinical trials that used fixed doses and stratification by ESA-naïve hemoglobin levels to better define the response rate to physiologic dosing, assess dose-related safety, and exclude the confounding associated with hemoglobin levels and targets. We identified no good drug interaction studies. Despite the absence of complete publications in easily accessible medical journals, we did identify emerging evidence for harm including increased mortality, tumor progression, cardiovascular-thromboembolic events, and stroke in patients with renal insufficiency and/or renal failure. Although there are a plethora of studies comparing ESA preparations, dosing regimens and routes of administration, important fundamental data about ESA and their use are lacking. Optimal patient management dictates that patients with either primary (e.g. infection, occult cancer, dialysis inadequacy, or dysplastic marrow) or secondary (e.g., anti-erythropoietin antibody mediated pure red cell aplasia or drug-induced marrow fibrosis) ESA resistance be identified and the underlying causes addressed prior to dose increases. The current published studies are insufficient to delineate risk:benefit for the various patient populations, particularly the Medicare population.

IX. Proposed Decision

Given the totality of the currently available evidence, we propose that CMS not issue a national coverage determination at this time for Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on Dialysis (CAG-00413N).

In order to maintain an open and transparent process, we are seeking comments on our proposal that no national coverage determination is appropriate at this time. We will respond to public comments in a final decision memorandum, consistent with the spirit of §1862(l)(3).

APPENDIX A

General Methodological Principles of Study Design

(Section VI of the Decision Memorandum)

When making national coverage determinations, CMS evaluates relevant clinical evidence to determine whether or not the evidence is of sufficient quality to support a finding that an item or service is reasonable and necessary. The overall objective for the critical appraisal of the evidence is to determine to what degree we are confident that: 1) the specific assessment questions can be answered conclusively; and 2) the intervention will improve health outcomes for patients.

We divide the assessment of clinical evidence into three stages: 1) the quality of the individual studies; 2) the generalizability of findings from individual studies to the Medicare population; and 3) overarching conclusions that can be drawn from the body of the evidence on the direction and magnitude of the intervention's potential risks and benefits.

The methodological principles described below represent a broad discussion of the issues we consider when reviewing clinical evidence. However, it should be noted that each coverage determination has its unique methodological aspects.

Assessing Individual Studies

Methodologists have developed criteria to determine weaknesses and strengths of clinical research. Strength of evidence generally refers to: 1) the scientific validity underlying study findings regarding causal relationships between health care interventions and health outcomes; and 2) the reduction of bias. In general, some of the methodological attributes associated with stronger evidence include those listed below:

- Use of randomization (allocation of patients to either intervention or control group) in order to minimize bias.
- Use of contemporaneous control groups (rather than historical controls) in order to ensure comparability between the intervention and control groups.
- Prospective (rather than retrospective) studies to ensure a more thorough and systematic assessment of factors related to outcomes.
- Larger sample sizes in studies to demonstrate both statistically significant as well as clinically significant outcomes that can be extrapolated to the Medicare population. Sample size should be large enough to make chance an unlikely explanation for what was found.
- Masking (blinding) to ensure patients and investigators do not know to which group patients were assigned (intervention or control). This is important especially in subjective outcomes, such as pain or quality of life, where enthusiasm and psychological factors may lead to an improved perceived outcome by either the patient or assessor.

Regardless of whether the design of a study is a randomized controlled trial, a non-randomized controlled trial, a cohort study or a case-control study, the primary criterion for methodological strength or quality is the extent to which differences between intervention and control groups can be attributed to the intervention studied. This is known as internal validity. Various types of bias can undermine internal validity. These include:

- Different characteristics between patients participating and those theoretically eligible for study but not participating (selection bias).
- Co-interventions or provision of care apart from the intervention under evaluation (performance bias).
- Differential assessment of outcome (detection bias).
- Occurrence and reporting of patients who do not complete the study (attrition bias).

In principle, rankings of research design have been based on the ability of each study design category to minimize these biases. A randomized controlled trial minimizes systematic bias (in theory) by selecting a sample of participants from a particular population and allocating them randomly to the intervention and control groups. Thus, in general, randomized controlled studies have been typically assigned the greatest strength, followed by non-randomized clinical trials and controlled observational studies. The design, conduct and analysis of trials are important factors as well. For example, a well designed and conducted observational study with a large sample size may provide stronger evidence than a poorly designed and conducted randomized controlled trial with a small sample size. The following is a representative list of study designs (some of which have alternative names) ranked from most to least methodologically rigorous in their potential ability to minimize systematic bias:

Randomized controlled trials
Non-randomized controlled trials
Prospective cohort studies
Retrospective case control studies
Cross-sectional studies
Surveillance studies (e.g., using registries or surveys)
Consecutive case series
Single case reports

When there are merely associations but not causal relationships between a study's variables and outcomes, it is important not to draw causal inferences. Confounding refers to independent variables that systematically vary with the causal variable. This distorts measurement of the outcome of interest because its effect size is mixed with the effects of other extraneous factors. For observational, and in some cases randomized controlled trials, the method in which confounding factors are handled (either through stratification or appropriate statistical modeling) are of particular concern. For example, in order to interpret and generalize conclusions to our population of Medicare patients, it may be necessary for studies to match or stratify their intervention and control groups by patient age or co-morbidities.

Methodological strength is, therefore, a multidimensional concept that relates to the design, implementation and analysis of a clinical study. In addition, thorough documentation of the conduct of the research, particularly study selection criteria, rate of attrition and process for data collection, is essential for CMS to adequately assess and consider the evidence.

Generalizability of Clinical Evidence to the Medicare Population

The applicability of the results of a study to other populations, settings, treatment regimens and outcomes assessed is known as external validity. Even well-designed and well-conducted trials may not supply the evidence needed if the results of a study are not applicable to the Medicare population. Evidence that provides accurate information about a population or setting not well represented in the Medicare program would be considered but would suffer from limited generalizability.

The extent to which the results of a trial are applicable to other circumstances is often a matter of judgment that depends on specific study characteristics, primarily the patient population studied (age, sex, severity of disease and presence of co-morbidities) and the care setting (primary to tertiary level of care, as well as the experience and specialization of the care provider). Additional relevant variables are treatment regimens (dosage, timing and route of administration), co-interventions or concomitant therapies, and type of outcome and length of follow-up.

The level of care and the experience of the providers in the study are other crucial elements in assessing a study's external validity. Trial participants in an academic medical center may receive more or different attention than is typically available in non-tertiary settings. For example, an investigator's lengthy and detailed explanations of the potential benefits of the intervention and/or the use of new equipment provided to the academic center by the study sponsor may raise doubts about the applicability of study findings to community practice.

Given the evidence available in the research literature, some degree of generalization about an intervention's potential benefits and harms is invariably required in making coverage determinations for the Medicare population. Conditions that assist us in making reasonable generalizations are biologic plausibility, similarities between the populations studied and Medicare patients (age, sex, ethnicity and clinical presentation) and similarities of the intervention studied to those that would be routinely available in community practice.

A study's selected outcomes are an important consideration in generalizing available clinical evidence to Medicare coverage determinations. One of the goals of our determination process is to assess health outcomes. These outcomes include resultant risks and benefits such as increased or decreased morbidity and mortality. In order to make this determination, it is often necessary to evaluate whether the strength of the evidence is adequate to draw conclusions about the direction and magnitude of each individual outcome relevant to the intervention under study. In addition, it is important that an intervention's benefits are clinically significant and durable, rather than marginal or short-lived. Generally, an intervention is not reasonable and necessary if its risks outweigh its benefits.

If key health outcomes have not been studied or the direction of clinical effect is inconclusive, we may also evaluate the strength and adequacy of indirect evidence linking intermediate or surrogate outcomes to our outcomes of interest.

Assessing the Relative Magnitude of Risks and Benefits

Generally, an intervention is not reasonable and necessary if its risks outweigh its benefits. Health outcomes are one of several considerations in determining whether an item or service is reasonable and necessary. CMS places greater emphasis on health outcomes actually experienced by patients, such as quality of life, functional status, duration of disability, morbidity and mortality, and less emphasis on outcomes that patients do not directly experience, such as intermediate outcomes, surrogate outcomes, and laboratory or radiographic responses. The direction, magnitude, and consistency of the risks and benefits across studies are also important considerations. Based on the analysis of the strength of the evidence, CMS assesses the relative magnitude of an intervention or technology's benefits and risk of harm to Medicare beneficiaries.

[Back to Top](#)

Bibliography

42nd Annual Meeting of the Drug Information Association. June 19, 2006. Patient-reported outcome instruments: overview and comments on the FDA draft guidance. <http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm118795.pdf>.

Aalten J, Bemelman FJ, van den Berg-Loonen EM, Claas FH, Christianns MH, de Fijter JW, et al. Pre-kidney-transplant blood transfusions do not improve transplantation outcome: a Dutch national study. *Nephrol Dial Transplant*. 2009;24:2559-2566.

Aarup M, Bryndum J, Dieperink H, Joffe P. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. *Nephrol Dial Transplant*. 2006;21:1312-1316.

Abdu A, Arogundade F, Adamu B, Dutse AI, Sanusi A, Sani MU, et al. Anaemia and its response to treatment with recombinant human erythropoietin in chronic kidney disease patients. *WJMJ*. 2009;28(5):295-299.

Abdulhadi MH, Fouad-Tarazi FM, Thomas T, Bravo EL, Paganini EP. The haemodynamic effects of correction of anaemia in haemodialysis patients using recombinant human erythropoietin. *Nephrol Dial Transplant*. 1990;Suppl1:102-108.

Abels R. Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin. *Seminars in Nephrology*. 1990;10(2)Suppl 1:20-25.

Aberman A, Hew E. Clarification of the effects of changes in P50 on oxygen transport. *Acute Care*. 1985;11:216-221.

Abraham PA. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects. *Am J Nephrol*. 1990;10(suppl 2):7-14.

Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. *J Am Soc Nephrol*. 1991;2:927-936.

Abraham PA, Opsahl JA, Keshaviah PR, Collins AJ, Whalen JJ, Asinger RW, et al. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. *Am J Kidney Dis*. 1990;1695:438-446.

Abraham PA, Opsahl JA, Rachael KM, Asinger R, Halstenson CE. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. *Am J Nephrol*. 1990;10:128-136.

Abraham PA, St Peter WL, Redic-Kill KA, Halstenson CE. Controversies in determination of epoetin (recombinant human erythropoietin) dosages. *Clin Pharmacokinet*. 1992;22(6):409-415.

Abu-Alfa, AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. *American Journal of Kidney Diseases*. 2000;35(6):1076-1082.

Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlatt D, Globe D, Audhya P. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. *Current Medical research and opinion*. 2008;24(4):1091-1100.

Acchiardo SR, Quinn BP, Burk LB, Moore LW. Are high flux dialysis and erythropoietin treatment in a collision course? *ASAIO Transactions*. 1989;35:308-310.

Acchiardo SR, Quinn BP, Moore LW, Burk LB, Miles DE. Evaluation of hemodialysis patients treated with erythropoietin. *Am J Kidney Dis*. 1991;17(3):290-294.

Adamson JW. The promise of recombinant human erythropoietin. *Seminars in Hematology*. 1989;26(2)Suppl 2:5-8.

Adamson JW, Eschbach J. Erythropoietin for end-stage renal disease. *NEJM*. 1998;339(9):624-629.

Adamson JW, Eschbach J. Management of the anaemia of chronic renal failure with recombinant erythropoietin. *Quarterly Journal of Medicine*. 1989;272(73):1093-1101.

Adamson W, Egrie JC, Browne JK, Downing MR, Eschbach W. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report. *Behring Inst Mitt*. 1988;83:188-192.

Agarwal R, Davis JL, Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. *Clin J Am Soc Nephrol*. 2008;3(1):98-104.

Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. *Kidney International*. 2007;72:638-642.

Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. *Seminars in Nephrology*. 2002;22(6):479-487.

Affarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. *J Assoc Physicians India*. 2003;51:170-174.

Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, et al. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. *Journal of Pharmaceutical Sciences*. 2009;98(6):2198-2211.

Akada H, Yan D, Zou H, Fiering S, Hutchinson RE, Mohi G. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera like disease. *Blood*. 2010;115:3589-3597.

Akarsu S, Taskin E, Yilmaz E, Yilmaz H, Kilic M, Denizmen Aygun A. Treatment of iron deficiency anemia with intravenous iron preparations. *Acta Haematol*. 2006;1161:51-57.

Aktekin LA, Eser F, Malhan S, Öksüz E, Keskin D, Bodur H. A comparison of four different HRQoL generic questionnaire in five different patient groups. *Rheumatol Int.* 2009;30:63-67.

Akinci F, Yildirim A, Ogutman B, Ates M, Gozu H, Deyneli O, et al. Translation, cultural adaptation, initial reliability, and validation of Turkish 15d's version. *Evaluation & the Health Professions.* 2005;28(1):53-66.

Akizawa T, Koshikawa S, Iwasaki M, and the KRN321 A08 Study Group. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. *Therapeutic Apheresis and Dialysis.* 2007;11(3):220-226.

Al-Muzairai IA, Innes A, Hillis A, Stewart KN, Bone JM, Catto GR, Macleod AM. Renal transplantation: cyclosporine A and antibody development after donor-specific transfusion. *Kidney International.* 1989;35:1057-1063.

Alam MG, Krause MW, Shah SV. Parental iron therapy: beyond anaphylaxis. *Kidney International.* 2004;66:457-458.

Alcázar R, Tato A, García F, Barrios V, Quereda C. [Would prescription of erythropoiesis-stimulating agents in pre-dialysis change after results from TREAT study?] *Nefrologia.* 2010;30(1):114-118.

Alexander M, Kewalramani R, Agodoa I, Globe D. Association of anemia correction with health related quality of life in patients not on dialysis. *Current Medical Research and Opinion.* 2007;23(12):2997-3006.

Alexanian R. Erythropoietin excretion in bone marrow failure and hemolytic anemia. *J Lab Clin Med.* 1973;82(3):438-445.

Albertazzi A, Di Liberato L, Daniele F, Battistel V, Colombi L. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. *The International Journal of Artificial Organs.* 1998;21(1):12-18.

Albrechtsen D, Flatmark A, Lundgren G, Brynner H, Frödin, Groth CG, Gäbel H. Retransplantation of renal grafts: prognostic influence of previous transplantation. *Transplantation Proceedings.* 1987;19(5):3619-3621.

Alexander JW, Babcock GF, First MR, Davies CB, Madden RL, Munda R, et al. The induction of immunologic hyporesponsiveness by preoperative donor-specific transfusions and cyclosporine in human cadaveric transplants. *Transplantation.* 1992;53(2):423-427.

Alexander M, Kewalramani R, Agodoa I, Globe D. Association of anemia correction with health related quality of life in patients not on dialysis. *Current Medical Research and Opinion.* 2007;23(12):2997-3008.

Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. *Clin Pharmacol Ther.* 2002;72:546-555.

Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. *Blood.* 2008;112(7):2617-2626.

Amar M, Neto MC, Canziani MEF, Nadaletto MAJ, Ajzen H, Draibe SA. Correction of anemia in chronic renal failure with lyophilized recombinant human erythropoietin using a subcutaneous approach. *Rev Ass Med Brasil.* 1994;40(2):101-107.

Anaemia Management in Chronic Kidney Disease. Rapid Update 2011 (Original publication 2006) Commissioned by the National Institute for Health and Clinical Excellence (NICE). Published by the National Clinical Guideline Centre (NCGC) at the Royal College of Physicians, London, UK.

Anandh U, Thomas PP, Shastry JCM, Jacob CK. A randomized controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin. *JAPI.* 2000;48:1061-1063.

Anderson CB, Brennan D, Keller C, Goss J, Shenoy S, Burton K, Sicard G, Flye MW. Beneficial effects of donor-specific transfusions on long-term renal allograft function. *Transplantation Proceedings.* 1989;21:1828-1831.

Anderson CB, Jendrisak MD, Flye MW, Hanto DW, Anderman CK, Rodey GE, Sicard GA. Concomitant immunosuppression and donor-specific transfusions prior to renal transplantation. *Transplantation Proceedings.* 1989;21(1):1828-1831.

Andrassy K, Ritz E. Uremia as a cause of bleeding. *Am J Nephrol.* 1985;5:313-319.

André J, Deschênes G, Boudailliez B, Broux F, Fischbach M, Gagnadoux M, et al. Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure. *Pediatr Nephrol.* 2007;22:708-714.

Ansell D. UK Renal Registry 11th Annual Report (Dec 2008): Chapter 1 Summary of findings in the 2008 UK renal registry report. *Nephron Clin Pract.* 2009;111(Suppl1):c1-2.

Ansell D. UK Renal Registry 11th Annual Report: Chapter 2 Introduction to the 2008 UK Renal Registry Report. *Nephron Clin Pract.* 2009;111 (Suppl.1):c3-c12.

Arabul M, Gullulu M, Yilmaz Y, Eren MA, Baran B, Gul CB, et al. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients. *Med Sci Monit.* 2009;15(11):CR583-587.

Arcasoy MO, Jiang X. Co-operative signaling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. *British Journal of Haematology.* 2005;130:121-129.

Aronoff GR, Bennett WM, Blumenthal S, Charytan C, Pennell JP, Reed J, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. *Kidney International.* 2004;66:1193-1198.

Aronoff GR, Bennett WM, Blumenthal S, Charytan C, Pennell JP, Reed J, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. *Kidney International.* 2004;66:1193-1198.

Aronoff GR, Duff DR, Sloan RS, Brier ME, Maurice B, Erickson B, Golper TA. The treatment of anemia with low-dose recombinant human erythropoietin. *Am J Nephrol.* 1990;10(Suppl 2):40-43.

Asbury CH. The orphan drug act: the first 7 years. *JAMA.* 1991;265(7):893-897.

Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. *The Lancet.* 2007;369:1502-1504.

Aunsholt NA, Ahlbom G, Steffensen G, Glud T. Fibrinolytic capacity in hemodialysis patients treated with recombinant human erythropoietin. *Nephron.* 1992;62:284-288.

Ayli D, Ayli M, Azak A, Yüksel C, Kosmaz GP, Atilgan G, et al. The effect of high-flux hemodialysis on renal anemia. *J Nephrol.* 2004;17:701-706.

Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. *Kidney Intl.* 2005;68(2):788-795.

Bader R, Bode G, Rebel W, Lexa P. Stimulation of bone marrow by administration of excessive doses of recombinant human erythropoietin. *Path Res Pract.* 1992;188:676-679.

Bahlmann J, Schöter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. *Contrib Nephrol.* 1991;88:90-106.

Baillie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. *Nephrol Dial Transplant.* 2005;20:1443-1449.

Baj Z, Pokoca L, Majewska E, Luciak M, Tchórzewski H. T lymphocyte subsets and NK cell cytotoxicity in chronic hemodialysis patients. The effect of recombinant human erythropoietin (rHu-EPO) treatment. *Archivum Immunologiae et Theraphiae Experimentalis.* 1992;40:201-206.

Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. *American Journal of Kidney Diseases.* 1991;XVII(1):29-33.

Barber WH, Hudson SL, Deierhoi MH, Laskow DA, Gaston RS, Julian BA, Curtis JJ, Diethelm AG. Donor antigen-specific immunosuppression in cadaveric and living-related donor kidney allograft recipients. *Clinical Transplants.* 1990;289-300.

Bargman JN, Jones JE, Petro JM. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. *Peritoneal Dialysis International.* 1992;12:369-372.

Barosi G, Hoffman R. Idiopathic myelofibrosis. *Semin Hematol.* 2005;42:248-258.

Bastani B, Rahman S, Gellens M. Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran. *ASAIO Journal.* 2002;48:404-406.

Bedani PL, Verzola A, Bergami M, Stabellini G, Gilli P. Erythropoietin and cardiocirculatory condition in aged patients with chronic renal failure. *Nephron.* 2001;89:350-353.

Belonje Am, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ. Endogenous erythropoietin and outcome in heart failure. *Circulation.* 2010;121:245-251.

Bennett CL, Lai SY, Henke M, Barnato SE, Armitage JO, Sartor O. Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. *Arch Intern Med.* 2010;170(16):1490-1498.

Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. *J Am Soc Nephrol.* 1991;1:990-998.

Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. *Clin J Am Soc Nephrol*. 2007;2:215-221.

Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. *Medical Care*. 1981;19(8):787-805.

Bergner M, Bobbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. *International Journal of Health Services*. 1976;6(3):393-415.

Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. *Clinical Nephrology*. 1992;37(5):264-267.

Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. *Kidney International*. 1999;56:253-260.

Berridge MV, Fraser JK, Carter JM, Lin F. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. *Blood*. 1988;72(3):970-977.

Berthoux F, Rychelynck JP, Rouanet S, Gelu-Mantoulet S, Montestruc F, Mouchel P, Choukroun G. A trial comparing local pain after subcutaneous injection of epoetin- β versus darbepoetin- α in healthy volunteers. *Clinical Nephrology*. 2008;70(1):33-40.

Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *NEJM*. 1998;339(9):584-590.

Besarab A, Goodkin DA, Nissenson AR. The normal hematocrit study—follow up. *NEJM*. 2008;358(4):433-434.

Besarab A, Medina F, Musial E, Picarello N, Michael H. Recombinant human erythropoietin does not increase clotting in vascular accesses. *ASAIO Transactions*. 1990;36:M749-M753.

Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. *Clinical Therapeutics*. 2007;29(4):626-639.

Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. *J Am Soc Nephrol.* 1996;7:763-773.

Bia MJ, Cooper K, Schnall S, Duffy T, Hendler E, Malluche H, Solomon L. Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. *Kidney International.* 1989;36:852-858.

Birgegård G, Hällgren R, Caro J. Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: relationship to anaemia and the effect of anti-inflammatory treatment. *British Journal of Haematology.* 1987;65:479-483.

Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. *Clin J Am Soc Nephrol.* 2006;1:S19-S23.

Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, Ferrucci L. Renal function, erythropoietin, and anemia of older persons. *Arch Intern Med.* 2005;165:2222-2227.

Bock HA, Hirt-Minkowski P, Brünisholz M, Keusch G, Rey S, von Albertini B. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. *Nephrol Dial Transplant.* 2008;23:301-308.

Boddana P, Caskey F, Casula A, Ansell D. Chapter 14: UK Renal Registry and international comparisons. *Nephron Clin Pract.* 2009;111(suppl 1):c269-276.

Boelaert JR, Schurgers ML, Matthys EG, Belpaire FM, Daneels RF, De Cre MJ, Bogaert MG. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. *Peritoneal Dialysis International.* 1989;9:95-98.

Bommer J, Asmus G, Wenning M, Bommer G. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alpha: a German prospective, randomized, multicentre study. *Nephrol Dial Transplant.* 2008;23:4002-4008.

Bommer J, Kugel M, Schoeppe W, Brunkhorst R, Samtleben W, Bramsiepe P, Scigalla P. Dose-related effects of recombinant human erythropoietin on erythropoiesis. *Contr Nephrol.* 1988;66:85-93.

Bommer J, Samtleben W, Koch KM, Baldamus CA, Grützmacher P, Scigalla P. Variations of recombinant human erythropoietin application in hemodialysis patients. *Contributions to Nephrology.* 1989;76:149-158.

Boran M, Dalva I, Yazicioğlu A, Cetin S. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients. *Nephron*. 1993;63:113-114.

Bou-Habib JC, Krams S, Colombe BW, Bubar OT, Yousif B, Amend WJC, et al. Impaired kidney graft survival in flow cytometric crossmatched positive donor-specific transfusion recipients. *Transplantation Proceedings*. 1991;23(1):403-404.

Boudville NC, Djurdjev O, Macdougall IC, de Francisco ALM, Deray G, Besarab A, et al. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. *Clin J Am Soc Nephrol*. 2009;4:1176-1182.

Bovan K, Knight J, Bader F, Rossert J, Eckardt K, Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. *Nephrol Dial Transplant*. 2005;20[Suppl 3]:iii33-iii40.

Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. *Am J Kidney Dis*. 2008;51(1):62-70.

Brandt JR, Avner ED, Hickman RO, Watkins SL. Safety and efficacy of erythropoietin in children with chronic renal failure. *Pediatr Nephrol*. 2000;14(1):84-5.

Brewster US, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. *Seminars in Dialysis*. 2004;17(1):57-60.

Breyman C, Rohling R, Huch A, Huch R. Intraoperative endogenous erythropoietin levels and changes in intravenous blood volume in healthy humans. *Ann Hematol*. 2000;79:183-186.

Brier ME, Gaweda AE, Dailey A, Aronoff GR, Jacobs AA. Randomized trial of model predictive control for improved anemia management. *Clin J Am Soc Nephrol*. 2010;5:814-820.

Brockmöller J, Köchling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. *Br J Clin Pharmacol*. 1992;34:499-508.

Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayr WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. 2010;303(9):857-862.

Brosnahan G, Fraer M. Management of chronic kidney disease: what is the evidence? Southern Medical Journal. 2010;10(20):1-9.

Brown S, Caro J, Erslev AJ, Murray TG. Spontaneous increase in erythropoietin and hematocrit value associated with transient liver enzyme abnormalities in an anephric patient undergoing hemodialysis. Am J Med. 1980;68:280-284.

Brown CD, Zhao ZH, Thomas LL, deGroof R, Friedman EA. Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients. Am J Kidney Dis. 2001;38(6):1414-1420.

Buckingham JE. Human recombinant erythropoietin does not induce bone marrow fibrosis in haemodialysed patients. Nephrol Dial Transplant. 1989;4:674-679.

Buemi M, Allegra A, Laganá A, Aloisi C, Privitera M, Morabito N, Frisina N. Effects of the evening IV administration of erythropoietin in haemodialyzed patients. European Review for Medical and Pharmacological Sciences. 1993;15:195-197.

Burgess ED. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol. 1991;23-26.

Buur T, Lundberg M. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients. Clinical Nephrology. 1990;34(3):230-235.

Cambridge GW, McDonald FF. The influence of diet on the acute toxicity of injectable iron preparations in the mouse. Br J Pharmac Chemother. 1966;27:114-119.

Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J. 1990;300:573-578.

Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol. 1991;11:23-26.

Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008;23:3654-3661.

Caravaca F, López-Minguez R, Arrobas M, Cubero J, Pizarro JL, Cid MC, et al. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. *Nephrol Dial Transplant*. 1995;10:1720-1724.

Cardiovascular and renal drugs advisory committee (CRDAC) in joint session with drug safety and risk management advisory committee (DSARM) meeting. Sept 11, 2007. Gaithersburg, MD.

Carless PA, Henry DA, Carson JL, Herbert PPC, McClelland B, Ker K. Transfusion thresholds and other strategies for guiding allogenic red blood cell transfusion (Review). *Cochrane Database of Systematic Reviews* 2010, Issue 10.

Caro J, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. *Cancer*. 2001;91:2214-2221.

Caro J, Erslev AJ. Erythropoietin assays and their use in the study of anemias. *Contr Nephrol*. 1988;66:54-62.

Carracedo J, Madueno JA, Ramirez R, Martin-Malo A, de Francisco AL, Aljama P. Antibody-mediated pure red-cell aplasia (PRCA): the Spanish experience. *J Nephrol*. 2005;18:382-387.

Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. *Nephrol Dial Transplant*. 2006;21:2846-2850.

Carson JL, Terrin ML, Magaziner J, Chaitman BR, Apple FS, Heck DA, Sanders D. Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS).

Carson JL, Reynolds RC, Klein HG. Bad bad blood? *Crit Care Med*. 2008;36(9):2707-2708.

Carter WB, Bobbitt RA, Bergner M, Gilson BS. Validation of an interval scaling: the sickness impact profile. *Health Services Research*. 1976:516-528.

Case DC, Bukowski RM, Casey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. *Journal of the National Cancer Institute*. 1993;85(10):801-806.

Cervelli MJ, Gray N, McDonald S, Gentgall MG, Disney AP. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. *Nephrology*. 2005;10:129-135.

Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. *American Journal of Kidney Diseases*. 2001;38(5):988-991.

Charnow JA. Hemoglobin levels linked to vitamin D in diabetic CKD patients. 2009 Oct [cited 2009 Oct 31];[2 pgs.]. Available from: <http://www.renalandneurologynews.com/hemoglobin-levels-linked-to-vitamin-D-in-diabetic-CKD-patients/>.

Charnow JA. Wasting, inflammation hike death risk in dialysis patients with EPO resistance. 2009 Oct [cited 2009 Oct 31];[1 p.]. Available from: <http://www.renalandneurologynews.com/wasting-inflammation-hike-death-risk-in-dialysis-patients-with-EPO-resistance/>.

Charnow JA. Anemia hikes long-term mortality in non-diabetic CKD patients. 2009 Nov [cited 2009 Nov 1];[2 pgs.]. Available from: <http://www.renalandurologynews.com/anemia-hikes-long-term-mortality-in-non-diabetic-CKD-patients/>.

Charnow JA. Why large doses of IV iron decreases HD patient survival is unclear. 2009 Nov[cited 2009 Nov];[1 p.]. Available from: <http://www.renalandneurologynews.com/why-large-doses-of-IV-iron-decreases-HD-patient-survival-is-unclear/>.

Charytan C, Schwenk MH, Al-Saloum MM, Spinowitz BS. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. *Nephron Clin Pract*. 2004;96:c63-c66.

Chavers BM, Sullivan EK, Tejani A, Harmon WE. Pre-transplant blood transfusion and renal allograft outcome: a report of the north American pediatric renal transplant cooperative study. *Pediatr Transplantation*. 1997;1:22-28.

Chazot C, Terrat JC, Dumoulin A, Ang K, Gassia JP, Chedid K, Maurice F, Canaud B. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. *The Annals of Pharmacotherapy*. 2009;43:228-234.

Cheigh JS, Suthanthiran M, Stubenbord WT, Fotino M, Riggio RR, Schechter N, Stenzel KH, Rubin AL. Optimization of donor specific blood transfusion in kidney transplantation. *Transplantation Proceedings*. 1987;19(1):2250-2251.

Chen H, Tarng D, Lee K, Wu C, Chen Y. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. *J Nephrol*. 2008;21:543-549.

Chew CG, Weise MD, Disney APS. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. *Nephrol Dial Transplant*. 1999;14:2047-2049.

Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, Shimizu A, Smith EKM. Measurement of quality of life in end-stage renal disease: the time trade-off approach. *Clinical and Investigative Medicine*. 1987;10(1):14-20.

Clibon U, Bonewald L, Caro J, Roodman D. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. *Exp Hematol*. 1990;18:438-441.

Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. *Nephron*. 1992;60:390-396.

Cody JD, Daly C, Campbell MK, Khan I, Radindranath KS, Vale L, Wallace SA, MacLeod AM, Grant A, Pennington S. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis (review). *Cochrane Database of Systematic Reviews* 2009, Issue 3.

Collart FE, Dratwa M, Wittek M, Wens R. Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients. 1990;36(3):M219-223.

Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. *Seminars in Nephrology*. 2000;20(4):345-349.

Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. *American Journal of Kidney Diseases*. 1998;32(6)(Suppl 4):S133-S141.

Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. *Renal Failure*. 2000;22(4):435-444.

Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, MacDougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN- γ , TNF- α , IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. *J Am Soc Nephrol*. 2003;14:1776-1784.

Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. *JAMA*. 2007;298(17):2038-2047.

Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. *NEMJ*. 2007;357(10):965-976.

Coster JM. Recombinant erythropoietin: orphan product with a silver spoon. *International Journal of Technology Assessment in Health Care*. 1992;8(4):635-646.

Cotes PM, Pippard MJ, Reid CDL, Winearls CG, Oliver DO, Royston JP. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. *Quarterly Journal of Medicine*. 1989;70(262):113-137.

Crawley J. Iron absorption tests in anaemia: the use of intravenous iron preparations. *Edinburgh Medical Journal*. 1952;59(10):478-491.

Cruz DN, Cal ME, Garzotto F, Brendolan A, Nalesso F, Corradi V, Ronco C. Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study. *The International Journal of Artificial Organs*. 2008;31(6):545-552.

Cruz DN, de Cal M, Ronco C (eds): Hemodialysis-from basic research to clinical trials. *Contrib Nephrol*. Basel, Karger, 2008, vol 161, pp 89-98.

Daniell HW. Erythropoietin resistance during androgen deficiency. *Arch Intern Med*. 2006;166:1923-1924.

Davies CB, Alexander JW, Cofer BR, First MR, Schroeder TJ. Efficacy of a single pretransplant donor-specific transfusion and cyclosporine A administered 24 to 48 hours before one-haplotype-mismatched living related donor kidney transplant. *Ann Surg*. 1992; 215(6): 618-626

De Francisco ALM, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, et al. Continuous erythropoietin receptor activator (c.e.r.a.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomized, multicentre, multi-dose, phase II study. *Int J Clin Pract*. 2006;60(12):1687-1696.

De Klerk G, Wilink JM, Rosengarten PCJ, Vet RJWM, Goudsmit R. Serum erythropoietin (ESF) titers in anemia of chronic renal failure. *J Lab Clin Med*. 1982;100:720-734.

De Lurdes Agostinho Cabrita A, Pinho A, Malho A, Morgado E, Faísca M, Carrasquiera H, et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. *Int Urol Nephrol*. 2010;1-6.

De Marchi S, Cecchin E. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin. *Clinical Science*. 1991;81:113-121.

De Marchi S, Cecchin E, Villalta D, Sepiacchi G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. *NEJM*. 1992;326(15):969-974.

De Nicola L, Minutolo R, Conte G. Anaemia management in non-dialysis chronic kidney disease: flexibility of target to target stability? *Nephron Clin Prac*. 2010;114:c236-c241.

De Schoenmakere G, Lameire N, Dhondt A, Van Loo A, Van der Goten J, Duym P, Vanholder R. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). *Nephrol Dial Transplant*. 1998;13:1770-1775.

Del Vecchio L, Cavalli A, Locatelli F. Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease. *Drugs of Today*. 2008;44(8):577-584.

Del Vecchio L, Cavalli A, Tucci B, Locatelli F. Chronic kidney disease-associated anemia: new remedies. *Current Opinion in Investigational Drugs*. 2010;11(9):1030-1038.

DePaul V, Moreland J, Eager T, Clase CM. The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: a randomized controlled trial. *Am J Kid Dis*. 2002;40(6):1219-1229.

Deicher R, Hörl WH. Vitamin C for hyporesponsiveness to epo: a cure for all? *Am J Kidney Dis*. 2003;42(4):848-849.

Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. *Am J Kidney Dis*. 1989;14(2)(Suppl 1):14-18.

Delwiche F, Segal GM, Eschbach JW, Adamson JW. Hematopoietic inhibitors in chronic renal failure: lack of in vitro specificity. *Kidney International*. 1986;29:641-648.

Deniston OL, Luscombe FA, Buesching DP, Richner RE, Spinowitz BS. Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients. *ASAIO Transactions*. 1990;36:M157-M160.

Deray G. Dosing darbepoetin alfa continued. *Am J Kidney Dis*. 2003;41(6):1334-1336.

Devins GM, Binik YM, Mandin H, Letourneau PK, Hollomby DJ, Barre PE, Prichard S. The kidney disease questionnaire: a test for measuring patient knowledge about end-stage renal disease. *J Clin Epidemiol*. 1990;43(3):297-307.

Dittrich E, Puttinger H, Schneider B, Hörl WH, Haag-Weber M, Vychytil A. Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients? *Peritoneal Dialysis International*. 2000;20:667-673.

Dokal I, Pagliuca A, Deenmamode M, Mufti GJ, Lewis SM. Development of polycythaemia vera in a patient with myelofibrosis. *Eur J Haematol* 1989;42:96-98.

Donnelly SM, Ali M, Churchill DN. Bioavailability of iron in hemodialysis patients treated with erythropoietin: evidence for the inhibitory role of aluminum. *American Journal of Kidney Diseases*. 1990;16(5):447-451.

Doxiadis II, Persijn GG, Claas FH. The crossmatch policy of the transplantation center influences graft survival in cadaver kidney transplantation. *Clinical Transplants*. 2003;143-147.

Drüeke T, Locatelli F, Clyne N, Eckardt K, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *NEJM*. 2006;355(20):2071-2084.

Drüeke T, Massy ZA. Intravenous iron: how much is too much? *J Am Soc Nephrol*. 2005;16:2833-2835.

Drüeke T, Zins B, Naret C, Casadevall N, Goureau Y, Bererhi L, et al. Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure. *Adv Nephrol*. 1989;18:187-206.

Duarte PS, Ciconelli RM, Sesso R. Cultural adaptation and validation of the "kidney disease and quality of life-short form (KDQOL-SF™ 1.3)" in Brazil. *Brazilian Journal of Medical and Biological Research*. 2005;38:261-270.

Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT. Dosing patterns and treatment costs of erythropoietin agents in elderly patients with pre-dialysis chronic kidney disease in managed care organizations. *Drugs Aging*. 2006;23(12):969-76.

Duff DR, Golper TA, Sloan RS, Brier ME, Aronoff GR. Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. *American Journal of Kidney Diseases*. 1991;18(1):60-64.

EI-Komy MH, Widness JA, Veng-Pedersen. Pharmacokinetic analysis of C.E.R.A. disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology. *Drug Metab Dispos*. 2001;42.

Eckardt K. The CREATE trial—building the evidence. *Nephrol Dial Transplant*. 2001;16[Suppl 2]:16-18.

Eckardt K, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B. Hemoglobin variability does not predict mortality in European hemodialysis patients. *J Am Soc Nephrol*. 2010;21:1765-1775.

Eckardt K, Drüeke T, Leski M, Kurtz A. Unutilized reserves: the production capacity for erythropoietin appears to be conserved in chronic renal disease. *Contrib Nephrol*. 1991;88:18-34.

Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. *Nutrition Society*. 2007;66:82-95.

Eder AF, Chambers LA. Noninfectious complications of blood transfusion. *Arch Pathol Lab Med*. 2007;131:708-718.

Edgell ET, Coons SJ, Carter WB, Kallich JD, Mapes D, Damush TM, Hays RD. A review of health-related quality-of-life measures used in end-stage renal disease. *Clinical Therapeutics*. 1996;18(5):887-1111.

Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). *British Journal of Cancer*. 2001;84(Suppl 1):3-10.

Egrie JC, Browne JK. Development and characterization of darbepoetin alfa. *Oncology*. 2002;16(10 Suppl 11):13-22.

Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. *Experimental Hematology*. 2003;31:290-299.

Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B, Halloran PF. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. *American Journal of Transplantation*. 2009;9:2520-2531.

Eklund SG, Johansson SV, Strandberg O. Anemia in uremia. *Acta Med Scand*. 1971;190:435-443.

Elliott S, Busse L, McCafferty I, Rossi J, Sinclair A, Spahr C, Swift S, Begley CG. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. *Journal of Immunological Methods*. 2010;352:126-139.

Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I. Control of rHuEPO biological activity: the role of carbohydrate. *Experimental Hematology*. 2004;32;1146-1155.

Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. *Advances in Chronic Kidney Disease*. 2009;16(2):94-100.

Epogen, Procrit (1990-2010) in *Physicians' Desk Reference*. San Francisco, CA: Medical Economics.

Erbes PM, Radtke HW, Schoeppe W, Koch KM. Sustained negative feedback between haematocrit and serum erythropoietin concentration in end-stage renal failure. *Proc Eur Dial Transplant Assoc*. 1978;15;442-448.

Erslev AJ, Caro J. Erythropoietin titers in anemic, nonuremic patients. *J Lab Clin Med*. 1987;109(4):429-433.

Erslev AJ, Caro J. Erythropoietin titers in response to anemia or hypoxia. *Blood Cells*. 1987;13:207-216.

Erslev AJ, Caro J. Erythropoietin: from mountain top to bedside. *Adv Exp Med Biol*. 1989;271:1-7.

Erslev AJ, Caro J, Miller O, Silver R. Plasma erythropoietin in health and disease. *Annals of Clinical and Laboratory Science*. 1980;10(3):250-257.

Erythropoietin (Epogen/Procrit): FDA label; http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf.

Escbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. *Annals of Internal Medicine*. 1989;111:992-1000.

Escbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. The safety of epoetin-alpha: results of clinical trials in the united states. *Contrib Nephrol*. 1991;88:72-80.

Escbach JW, Kelly MR, Haley R, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. *N Engl J Med*. 1989;321:158-163.

Espósito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. *European Journal of Clinical Investigation*. 2002;32(Suppl I):42-49.

Essink-Bot ML, Krabbe PFM, van Agt HME, Bonse GJ. NHP or SIP-a comparative study in renal insufficiency associated anemia. *Quality of Life Research*. 1996;5:91-100.

Evatt BL, Spivak JL, Levin J. Relationships between thrombopoiesis and erythropoiesis: with studies of the effects of preparations of thrombopoietin and erythropoietin. *Blood*. 1976;48:547-558.

FDA: Aranesp (darbepoetin). BLA: 103951: Complete on-line reviews and approval letter. 2001. (www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080442.htm). Subsequent review history and REMS safety program information. (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist) (www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM200104.pdf)

FDA: Epogen, Procrit (erythropoietin). BLA 103234: Summary Basis of Approval. 1989. Reviews from individual disciplines not available. Subsequent review history (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist) and REMS safety program information (www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM200105.pdf)

FDA: Mircera (methoxy polyethylene glycol-epoetin-beta). BLA: 125164: Complete on-line reviews and approval letter. (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist)

Farrington K, Udayaraj U, Gilg J, Feehally J. ESRD incident rates in 2007 in the UK: national and centre-specific analyses (Ch 3). 2008;13-41.

Farrington K, Hodsman A, Casula A, Ansell D, Feehally J. ESRD prevalent rates in 2007 in the UK: national and centre-specific analyses (Ch 4). 2008;43-68.

Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin) a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemias and the stimulation of erythropoietin. *Drugs*. 1989;38(6):863-899.

Festenstein H, Sachs JA, Paris AMI. Influence of HLA matching and blood-transfusion on outcome of 502 London transplant group renal-graft recipients. *The Lancet*. 1976;307(7952):157-161.

Fields R. God help you. You're on dialysis. *The Atlantic*. 2010. <http://www.theatlantic.com/magazine/archive/2010/12/-8220-god-help-you-you-39-re-on-dialysis-8221/8308/>.

Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. *Am J Kidney Dis.* 1995;26(1):41-46.

Fishbane S, Miyawaki N, Sczech LA. Hypothesis: an erythropoietin honeymoon phase exists. *Kidney International.* 2010;78:646-649.

Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. *J Clin Pharmacol.* 2007;47:1390-1397.

Fisher JW. Control of erythropoietin production. *Proceedings of the society for experimental biology and medicine.* 1983;173:289-305.

Fisher JW, Bommer J, Eschbach J, Fried W, Lange RD, Massry S, et al. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. *American Journal of Kidney Diseases.* 1989;14(3):163-169.

Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. *Clin Pharmacol Ther.* 1990;47:557-564.

Fletes R, Lazarus M, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. *American Journal of Kidney Diseases.* 2001;37(4):743-749.

Flye MW, Burton K, Mohanakumar T, Brennan D, Keller C, Goss JA, Sicard GA, Anderson CB. Donor-specific transfusions have long-term beneficial effects for human renal allografts. *Transplantation.* 1995;60(12):1395-1401.

Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. *Clin J Am Soc Nephrol.* 2009;4:726-733.

Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. *Clin J Am Soc Nephrol.* 2008;3(6):1669-1675.

Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. *Clin J Am Soc Nephrol.* 2010;5:805-813.

Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, Coyle D, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. *Kidney International*. 2000;58:1325-1335.

Frank H, Heusser K, Höffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. *Kidney International*. 2004;66:832-840.

Freedman MH, Cattran DC, Saunders EF. Anemia of chronic renal failure: inhibition of erythropoiesis by uremic serum. *Nephron*. 1983;35:15-19.

Frei U, Kwan JTC, Spinowitz BS, the Epoetin Delta 3002 study group. Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study. *BMC Nephrology*. 2009;10:5.

Frenkel EP, Douglass CC, McCall MS. Hypoerythropoietinemia and anemia. *Arch Intern Med*. 1970;125:1050-1055.

Frenken LAM, van Lier HJJ, Gerlag PGG, den Hartog M, Koene RAP. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. *BMJ*. 1991;303:288.

Freudenthaler SM, Schreeb KH, Körner T, Gleiter CH. Angiotensin II increases erythropoietin production in health human volunteers. *European Journal of Clinical Investigation*. 1999;29:816-823.

Frifelt JJ, Tvedegaard E, Bruun K, Steffensen G, Cintin C, Breddam M, et al. Efficacy of recombinant human erythropoietin administered subcutaneously to capd patients once weekly. *Peritoneal Dialysis International*. 1996;16:594-598.

Frisan E, Pawlikowska P, Pierre-Eugène C, Viallon V, Gibault L, Park S. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. *Haematologica*. 2010[Epub ahead of print].

Fritschka E, Neumayer HH, Seddighi S, Thiede HM, Distler A, Philipp T. Effect of erythropoietin on parameters of sympathetic nervous activity in patients undergoing chronic haemodialysis. *Br J Clin Pharmacol*. 1990;30:135S-138S.

Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. *Blood*. 1989;73(1):84-89.

Fukuhara S, Akizawa T, Morita S, Koshikawa S, KRN321 A08 Study Group. Quality of life improvements in dialysis patients receiving darbepoetin alfa. *Therapeutic Apheresis and Dialysis*. 2008;12(1):72-77.

Fukushima Y, Fukuda M, Yoshida K, Yamaguchi A, Nakamoto Y, Miura AK, Harada T, Tsuchida S. Serum erythropoietin levels and inhibitors of erythropoiesis in patients with chronic renal failure. *Tohoku J. exp. Med.* 1986;150:1-15.

Furuland H, Linde T, Ahlmén J, Christensson A, Strómbom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. *Nephrol Dial Transplant*. 2003;18:353-361.

Furuland H, Linde T, Sandhagen B, Andrén B, Wikström B, Danielson BG. Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin- α . *Scandinavian Journal of Urology and Nephrology*. 2005;39:399-404.

Fusté B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. *Thromb Haemost*. 2002;88:678-685.

Gallieni M, Corsi C, Brancaccio D. Hyperparathyroidism and anemia in renal failure. *Am J Nephrol*. 2000;20:89-96.

Galvão MM, Peixinho ZF, Mendes NF, Sabbaga E. Stored blood-an effective immunosuppressive method for transplantation of kidneys from unrelated donors. An 11-year follow-up. *Brazilian Journal of Medical and Biological Research*. 1997;30:727-734.

Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. *Am J Kidney Dis*. 2010;55(3):519-534.

Gaughan WJ, Liss KA, Dunn SR, Mangold A, Buhsmer JP, Michael B, Burke JF. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. *Am J Kidney Dis*. 1997;30(4):495-500.

Geary DF, Keating LE, Vigneux A, Stephens D, Hébert D, Harvey EA. Darbepoetin alfa (Aranesp™) in children with chronic renal failure. *Kidney International*. 2005;68:1759-1765.

Gebel HM, Halloran PF. Making sense of desensitization. *American Journal of Transplantation*. 2010;10:443-444.

Geisser P, Baer M, Schaub E. Structure/Histotoxicity relationship of parenteral iron preparations. *Arzneim-Forsch/Drug Res*. 1992;42(II):1439-1452.

Geisser P, Müller A. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats. *Arzneim-Forsch/Drug Res.* 1984;34(II):1560-1569.

Ghezzi P, Bernaudin M, Bianchi R, Blomgren, et al. Erythropoietin: not just about erythropoiesis. *Lancet.* 2010;375:2142.

Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. *J Nephrol.* 2000;13:444-449.

Gilson BS, Gilson JS, Bergner M, Bobbitt RA, Kressel S, Pollard WE, Vesselago M. The sickness impact profile: development of an outcome measure of health care. *AJPH.* 1975;65(12):1304-1310.

Gimenez LF, Watson AJ, Spivak JL. Serum Immunoreactive erythropoietin in patients with end stage renal disease. *Prog Clin Biol Res.* 1990;352:493-504.

Goh B, Ong L, Sivanandam S, Lim T, Morad Z. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. *Nephrology.* 2007;12:431-436.

Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perez-Garcia R, Valderrábano F. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. *Nephron.* 1998;78:23-27.

Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. *J Am Soc Nephrol.* 2011;22:358-365.

Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. *Blood.* 2000;96(3):823-833.

Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. *Kidney Int.* 2004;66(2):753-760.

Graf H. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. *Nephron.* 1992;61:399-403.

Granolleras C, Leskoff W, Shaldon S, Fourcade J. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. *Clinical Nephrology*. 1991;36(6):294-298.

Greenwood RN, Ronco C, Gastaldon F, Brendolan A, Homel P, Usvyat L, et al. Erythropoietin dose variation in different facilities in different countries and its relationship to drug resistance. *Kidney International*. 2003;64(Suppl 87):S78-S86.

Grützmacher P, Bergmann M, Weinreich T, Nattermann U, Reimers E, Pollok M. Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. *Contr Nephrol*. 1988;66:104-113.

Grützmacher P, Radtke HW, Fassbinder W, Koch K-M, Schoeppe. Effect of secondary hyperparathyroidism on the anaemia of end-stage renal failure: in vivo and in vitro studies. *Proc EDTA*. 1983;20:739-745.

Grützmacher P, Scheuermann E, Löw I, Bergmann M, Rauber K, Baum R. Correction of renal anaemia by recombinant human erythropoietin: effects on myocardial function. *Contr Nephrol*. 1988;66:176-184.

Gurney CW, Goldwasser E, Pan C. Studies on erythropoiesis. VI. Erythropoietin in human plasma. *J Lab Clin Med*. 1957;50(4):534-542.

Guthrie M, Cardenas D, Eschbach JW, Haley NR, Robertson HT, Evans RW. Effects of erythropoietin on strength and functional status of patients on hemodialysis. *Clin Nephrol*. 1993;39(2):97-102.

Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. *Clinical Nephrology*. 2009;72(5):380-390.

Hajeer AH. Panel reactive antibody test (PRA) in renal transplantation. *Saudi J Kidney Dis Transplant*. 2006;17(1):1-4.

Hajjar LA, Vincent J, Galas FR, Nakamura RE, Silva CMP, Santos MH, et al. Transfusion requirements after cardiac surgery. *JAMA*. 2010;304(14):1559-1567.

Halloran PF. T cell mediated rejection of kidney transplants: a personal viewpoint. *American Journal of Transplantation*. 2010;10:1126-1134.

Halstead SB. Nosocomial dengue in health-care workers. *The Lancet*. 2008;371:299.

HAMPL H, RIEDEL E, WENDEL G, SCIGALLA P. Red blood cell density distribution in uremic patients on acetate and bicarbonate hemodialysis. *Blood Purif.* 1990;8:260-267.

HANDELMAN GJ. Newer strategies for anemia prevention in hemodialysis. *The International Journal of Artificial Organs.* 2007;30(11):1014-1019.

HANDELMAN GJ, LEVIN NW. Red cell survival: relevance and mechanism involved. *Journal of Renal Nutrition.* 2010;20(55):S84-S88.

HARDY S, LEE S, TERASAKI PI. Chapter 24: Sensitization 2001. *Clinical Transplants.* 2001:271-278.

HARMON WE, ALEXANDER SR, TEJANI A, STABLEIN D. The effect of donor age on graft survival in pediatric cadaver renal transplant recipients-a report of the north American pediatric renal transplant cooperative study. *Transplantation.* 1992;54(2):232-237.

HARRIS AM, ATTERBURY CLJ, CHAFFE B, ELLIOTT C, HAWKINS T, HENNEM SJ, et al. Guideline on the administration of blood components. *British Committee for Standards in Haematology.* 2002;1-59.

HARRIS DCH, CHAPMAN JR, STEWART JH, LAWRENCE S, ROGER SD. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. *Aust NZ J Med.* 1991;21:693-700.

HAYASHI K, HASEGAWA K, KOBAYASHI S. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin. *Kidney International.* 2001;60:1910-1916.

HAYASHI N, KINOSHITA H, YUKAWA E, HIGUCHI S. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. *Br J Pharmacol.* 1998;46:11-19.

HAYAT A, HARIA D, SALIFU M. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. *Patient Preference and Adherence.* 2008;2:195-200.

HAYS RD, KALLICH JD, MAPES DL, COONS SJ, CARTER WB. Development of the kidney disease quality of life (KDQOL™) instrument. *Quality of Life Research.* 1994;3:329-338.

HÉBERT PC, VAN DER LINDEN P, BIRO G, HU LQ. Physiologic aspects of anemia. *Crit Care Clin.* 2004;20:187-212.

Heim MU. Guidelines of the German Medical Association for therapy with blood components and plasma derivatives an introduction. Evidence-based recommendations for the risk-benefit analysis in hemotherapy. *Anesthesiol IntensiveMed Notfallmed Schmerzther*. 2009; Mar;44:186-97.

Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. *JAMA*. 2010;303(5):423-429.

Hébert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular disease? *Crit Care Med*. 2001;29(2):227-234.

Herrera J, Nava M, Biol L, Romero F, Biol L, Rodríguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. *Am J Kidney Dis*. 2001;37(4):750-757.

Hiesse C, Busson M, Buisson C, Farahmand H, Bierling P, Benbunan M, et al. Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. *Kidney International*. 2001;60:341-349.

Hillis AN, MacLeod AM, Al-Muzairai IA, Innes A, Stewart KN, Power DA, et al. Antidiotypic activity and sensitization after donor-specific transfusion (DST) given with and without cyclosporine (CsA). *Transplantation Proceedings*. 1989;21(1):1820-1821

Hiramatsu M, Kubota M, Iwasaki M, Akizawa T, Koshikawa S, KRN321 A09 Study Group. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients. *Therapeutic apheresis and dialysis*. 2008;12(1):19-27.

Hodsman A, Lamb EJ, Steenkamp R, Warwick G. Biochemistry profile of patients receiving dialysis in the UK in 2007: national and centre-specific analyses(Ch 10). 2008:185-222.

Hon G, Vaziri ND, Kaupke CJ, Tehranzadeh A, Barton C. Lack of fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. *Artif Organs*. 1995;19(2):188-191.

Horemans HL, Nollet F, Beelen A, Lankhorst GJ. A comparison of 4 questionnaires to measure fatigue in postpoliomyelitis syndrome. *Arch Phys Med Rehabil*. 2004;85:392-398.

Hörl WH. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous. *Acta Haematologica*. 1992;87(suppl 1):16-19.

- Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. *Nephrol Dial Transplant*. 2007;22:1462-1464.
- Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. *Clinical Therapeutics*. 2001;23(10):1637-1671.
- Hughes RT, Cotes PM, Oliver DO, Pippard MJ, Royston P, Stevens JM, Strong CA, Tam RC, Winearls CG. Correction of the anaemia of chronic renal failure with erythropoietin: pharmacokinetic studies in patients on haemodialysis and CAPD. 1989;76(1):122-130.
- Hughes RT, Smith T, Hesp R, Hulme B, Dukes DC, Bending MB, Pearson J, et al. Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores. *British Journal of Haematology*. 1992;82:445-454.
- Hung S, Tung T, Yang C, Tarng D. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients. *Am J Kidney Dis*. 2005;45(6):1073-1083.
- Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E. A quantitative approach to perceived health status: a validation study. *Journal of Epidemiology and Community Health*. 1980;34:281-286.
- Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham health profile: subjective health status and medical consultations. *Soc Sci Med*. 1981;15A:221-229.
- Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O. Different involvement of the megakaryocytic lineage by the JAK2(V617F) mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. *Ann Hematol*. 2007;86:245-253.
- Icardi A, Sacco P, Salvatore F, Romano U. Long-term intravenous epoetin- α /darbepoetin- α ratio in iron-replete hemodialysis patients. *J Nephrol*. 2007;20:73-79.
- Ifudu O, Chan E, Paul H, Mayers JD, Cohen LS, Brezsnayk WF, et al. Anemia severity and missed dialysis treatments in erythropoietin-treated hemodialysis patients. *ASAIO Journal*. 1996;42:146-149.
- Imamura K. Effects of intravenous administration of iron preparations on the metabolism of phosphorus. *Acta Med*. 1984;75(6):316-326.

Islam S, Rahman H, Rashis HU. Effect rHuEpo on predialysis CRF patients: study of 45 cases. *Bangladesh Med Res Counc Bull.* 2005;31(2):83-87.

Ingley E, Tilbrook PA, Klinken SP. New insights into the regulation of erythroid cells. *IUBMB Life.* 2004;56:177-184.

Jacobs C, Frei D, Perkins AC. Results of the European survey on anaemia management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. *Nephrol Dial Transplant.* 2005;20[Suppl 3]:iii3-iii24.

Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT, Lewis T. Circulating erythropoietin in patients with myelodysplastic syndromes. *British Journal of Haematology.* 1989;73:36-39.

Jagsch R, Pils K. Which instrument is more suitable to assess health-related quality of life: Nottingham Health Profile or Short-Form-36? *Wien Med Wochenschr.* 2006;156:149-157.

Janssen MJA, van der Kuy A, ter Wee PM, van Boven WPL. Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients. *Nephrol Dial Transplant.* 1995;10:2321-2324.

Jelkmann W. Biosimilar epoteins and other "follow-on" biologics: update on the European experiences. *Am J Hematol.* 2010;85:771-780.

Jenkinson C. Why are we weighting? A critical examination of the use of item weights in a health status measure. *Soc Sci Med.* 1991;32(12):1413-146.

Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. *Eur J clin Pharmacol.* 1996;50:171-177.

Jensen GV, Nielsen B. Adverse effects of subcutaneous administration of erythropoietin solution versus lyophilisate in patients receiving hemodialysis. *Ugeskr Laeger.* 1994;156(2):183-184.

The Johns Hopkins Comprehensive Transplant Center Incompatible Kidney Transplant Programs.
http://www.hopkinsmedicine.org/bin/w/h/InKTP_brochure.pdf.

Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, Mayne TJ. Systematic review and meta-analysis of exercise tolerance with physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. *Am J Kidney Dis.* 2010;55(3):535-548.

Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. *Biochemistry*. 1998;37:3699-3710.

Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. *Blood*. 1989;74(1):130-138.

Jones MC, Stewart N, Propper DJ, Catto GRD, Power DA. The effect of cyclosporine administered during a third-party blood transfusion protocol on humoral immune responses. *Nephrol Dial Transplant*. 1991;6:125-130.

Kainz A, Mayer B, Kramar R, Oberbauer. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. *Nephrol Dial Transplant*. 2010;1-6.

Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, Numata A, et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. *Leukemia Research*. 2005;29:761-769.

Kalanta-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. *Am J Kidney Dis*. 2009;53(5):823-834.

Kallich JD, Hays RD. The benefits and pitfalls of health services research funded by proprietary firms. *Quality of Life Research*. 1994;3:231-233.

Kallich JD, Hays RD, Mapes DL, Coons SJ, Carter WB. The RAND kidney disease and quality of life instrument. *Nephrology News & Issues*. 1995;9(9):29,36.

Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. *Nephron*. 1992;61:393-398.

Kampf D, Kahl A, Passlick J, Pustelnik A, Eckardt K, Ehmer B, et al. Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. *Contrib Nephrol*. 1989;76:106-111.

Kanbay M, Akcay A, Delibasi T, Uz B, Kaya A, Koca C, et al. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. *Advances in Therapy*. 2007;24(2):346-352.

- Kang D, Yoon K, Han D. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. *Nephrol Dial Transplant*. 1998;13:2877-2883.
- Kang JY. The gastrointestinal tract in uremia. *Digestive Diseases and Sciences*. 1993;38(2):257-268.
- Kang JY, Ho K, Yeoh K, Guan R, Wee A, Lee E, et al. Peptic ulcer and gastritis in uraemia, with particular reference to the effect of helicobacter pylori infection. *Journal of Gastroenterology and Hepatology*. 1999;14:771-778.
- Kang JY, Wee A, Choong HI, Wu AYT. Erosive prepyloric changes in patients with end-stage renal failure undergoing maintenance dialysis treatment. *Scand J Gastroenterol*. 1990;25:746-750.
- Karpinski M, Pochinco D, Dembinski I, Laidlaw W, Zacharias J, Nickerson P. Leukocyte reduction of red blood cell transfusion does not decrease allosensitization rates in potential kidney transplant candidates. *J Am Soc Nephrol*. 2004;15:818-824.
- Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. *NEJM*. 1998;339:578-583.
- Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. Diagnostic value of iron indices in hemodialysis patients receiving epoetin. *Kidney International*. 2001;60:300-308.
- Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. *J Am Soc Nephrol*. 1993;3(10):1672-1679.
- Kawakami K, Takama H, Nakashima D, Tanaka H, Uchida E, Akizawa T. Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. *Eur J Clin Pharmacol*. 2009;65(2):169-178.
- Keane WF, Lyle PA. Recent advances in management of Type 2 diabetes and nephropathy: lessons from the RENAAL study. *Am J Kidney Dis*. 2003;41(3)(Suppl 1):S22-S25.
- Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. *Kidney Int*. 2008;74(6):695-697.

- Kelly S, Jessop EG. A comparison of measures of disability and health status in people with physical disabilities undergoing vocational rehabilitation. *Journal of Public Health Medicine*. 1996;18(2):169-174.
- Kendall RG, Jeffries R, Cavill I, Norfolk DR. Relationship between endogenous erythropoietin levels, reticulocyte count, and reticulocyte RNA distribution. *Ann NY Acad Sci*. 1994;718:353-355.
- Keown PA. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. *Contrib Nephrol*. 1991;88:81-86;discussion 87-89.
- Keown PA, Churchill DN, Poulin-Costello M, Lei L, Gantotti S, Agodoa I, et al. Dialysis patients treated with epoetin alfa show improved anemia symptoms: a new analysis of the Canadian erythropoietin study group trial. *Hemodialysis International*. 2010;14:168-173.
- Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty F, Beyer U. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: the ARCTOS extension study. *Hemodialysis International*. 2010;14:233-239.
- Keven K, Kutlay S, Nergizoglu G, Ertürk S. Randomized, crossover study of the effect of vitamin c on EPO response in hemodialysis patients. *Am J Kidney Dis*. 2003;41:1233-1239.
- Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. *Clin J Am Soc Nephrol*. 2008;3(4):1077-1083.
- Kim CD, Park SH, Kim DJ, Park JW, Do JY, Shin SK, et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. *Nephrology*. 2009;14(5):482-487.
- Kirkley SA. Proposed mechanisms of transfusion-induced immunomodulation. *Clinical and Diagnostic Laboratory Immunology*. 1999;652-657.
- Klarenback S, Heidenheim AP, Leitch R, Lindsay RM, the Daily/Nocturnal Dialysis Study Group. Reduced requirement for erythropoietin with Quotidian hemodialysis therapy. *ASAIO Journal*. 2002;48:57-61.
- Klein HG. How safe is blood, really? *Biologicals*. 2010;38:100-104.

Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. *The Lancet*. 2007;370:415-426.

Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. *American Journal of Kidney Diseases*. 1989;14(6):486-495.

Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered over 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. *Am J Kidney Dis*. 2007;50(6):989-1000.

Klinkmann H, Wieczorek, Scigalla P. Adverse effects of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study. *Artificial Organs*. 1993;17(4):219-225.

Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM. Erythropoietin response to critical illness. *Crit Care Med*. 1994;22:821-826.

Koch KM, Koene RAP, Messinger D, Quarder O, Scigalla P. The use of epoetin beta in anemic predialysis patients with chronic renal failure. *Clinical Nephrology*. 1995;44(3):201-208.

Koch KM, Radtke HW. Role of erythropoietin deficiency in the pathogen of renal anemia. *Klin Wochenschr*. 1979;57(19):1031-1036.

Kong JM, Jeong JH, Kang JK, Seong IG, Kim BC. Donor-specific transfusion in living related and unrelated donor kidney transplantation: minimal sensitization and excellent graft outcome. *Transplantation Proceedings*. 1995;27(1):1036-1037.

Kontos PC, Miller K, Brooks D, Jassal SV, Spanjevic L, Devins GM, et al. Factors influencing exercise participation by older adults requiring chronic hemodialysis: a qualitative study. *Int Urol Nephrol*. 2007;39:1303-1311.

Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM. Anemia and outcomes in patients with heart failure. *Arch Intern Med*. 2005;165:2237-2244.

Kotaki M, Uday K, Henriquez M, Blum S, Dave M. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. *Clinical Nephrology*. 1997;48(1):63-64.

Kouidi E, Albani M, Natsis K, Megalopoulos A, Gigis P, Guiba-Tziampiri O. The effects of exercise training on muscle atrophy in haemodialysis patients. *Nephrol Dial Transplant*. 1998;13:685-699.

Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. *Blood*. 1989;74(2):645-651.

Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemia. *Blood*. 1997;90(5):2057-2061.

Kraus ES, Parekh RS, Oberai P, Lepley D, Segev DL, Bagnasco S, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. *American Journal of Transplantation*. 2009;9:1826-1834.

Krishnan G, Thacker L, Angstadt JD, Capelli JP. Multicenter analysis of renal allograft survival in lupus patients. *Transplantation Proceedings*. 1991;23(2):1755-1756.

Krivoshiev S, Todorov VV, Manitus J, Czekalski S, Scigalla P, Koytchev R. Comparison on the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. *Current Medical Research and Opinion*. 2008;24(5):1407-1415.

Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Plješa S, Wolf-Pflugmann M, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. *Adv Ther*. 2010;27(2):105-117.

Krumwieh D, Arnold I, Seiler FR. Comparison of relevant biological assays for the determination of biologically active erythropoietin. *Develop Biol Standard*. 1988;69:15-22.

Kudasheva DS, Lai J, Ulman A, Cowman MK. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. *Journal of Inorganic Biochemistry*. 2004;98:1757-1769.

Kühn K, Nonnast-Daniel B, Grützmacher P, Grüner J, Pfaffl W, Baldamus CA, Scigalla P. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. *Contr Nephrol*. 1988;66:94-103.

Kulzer P, Schaefer RM, Krahn R, Schaefer L, Heidland A. Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. European Multicentre Study Group. *Int J Artif Organs*. 1994;17(4):195-202.

Kuriyama S, Tomonari H, Yoshida T, Kawaguchi Y, Sakai O. Reversal of anemia of erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. *Nephron*. 1997;77:176-185.

Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. *Am J Kidney Dis.* 1995;26(5):757-764.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchecker W, Villeval J. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. *Blood.* 2006;108(5):1652-1660.

Lai KN, Lui SF, Leung JCK, Law E, Nicholls MG. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. *Nephron.* 1991;57:394-400.

Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. *Oncogene.* 2005;24:4442-4449.

Lamas JM, Alonso M, Sastre F, García-Trío G, Saavedra J, Palomares L. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements-a randomized study. *Nephrol Dial Transplant.* 2006;21:2851-2858.

Lamperi S, Carozzi S, Icardi A. Improvement of erythropoietin in uremic patients on CAPD. *The International Journal of Artificial Organs.* 1983;6(4):191-194.

Lamping DL, Rowe P, Black N, Lessof L. Development and validation of an audit instrument: the prostate outcomes questionnaire. *British Journal of Urology.* 1998;82:49-62.

Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. *Am J Nephrol.* 2005;25:400-410.

Laupacis A. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. *Seminars in Nephrology.* 1990;10(2):11-19.

Laupacis A. A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. *Transplantation Proceedings.* 1991;23(2):1825-1826.

Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. *Nephron.* 1992;60:302-306.

Laupacis A, Wong C, Churchill D, The Canadian Erythropoietin Study Group. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. *Controlled Clinical Trials*. 1991;12:168S-179S.

Laville M. New strategies in anaemia management: ACORD. *Acta Diabetol*. 2004;41:S18-S22,

Lazarus HM, Goodnough LT, Goldwasser E, Long G, Arnold JL, Strohl KP. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting. *Bone Marrow Transplantation*. 1992;10:71-75.

Lee DB, David BN. Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation. *American Journal of Kidney Diseases*. 1991;4(1):54-56.

Lee GSL. Medical problems in dialysis patients awaiting renal transplantation. *Annals of the Academy of Medicine*. 1991;20(4):519-523.

Lee Y, Koo J, Kim J, Park I, Joo M, Yoon J, et al. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial. *American Journal of Kidney Diseases*. 2009;53(5):815-822.

Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, et al. A comparison between once-weekly and twice-or-thrice weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study. *Nephrol Dial Transplant*. 2008;23(10):3240-3246.

Leikis MJ, Kent AB, Becker GJ, McMahon LP. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. *Nephrology*. 2004;9:153-160.

Leikis M, McKenna MJ, Petersen AC, Kent AB, Murphy KT, Leppik A, et al. Exercise performance falls over time in patients with chronic kidney disease despite maintenance of hemoglobin concentration. *Clin J Am Soc Nephrol*. 2006;1:488-495.

Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. *American Journal of Kidney Diseases*. 2009;53(3)(Suppl 3):S4-S16.

Levin A. Predicting outcomes in CKD: the importance of perspectives, populations and practices. *Nephrol Dial Transplant*. 2009;24:1724-1726.

Levin A. Understanding recent haemoglobin trials in ckd: methods and lesson learned from CREATE and CHOIR. *Nephrol Dial Transplant*. 2007;22:309-312.

Levin A, Beaulieu. TREAT: implications for guideline updates and clinical care. *American Journal of Kidney Diseases*. 2010;55(6):984-987.

Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. *American Journal of Kidney Diseases*. 2008;52(4):661-667.

Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, et al. Canadian randomized trial of hemoglobin maintenance to prevent of delay left ventricular mass growth in patients with ckd. *Am J Kidney Dis*. 2005;46(5):799-811.

Levin A, Hemmelgarn B, Culeton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines for the management of chronic kidney disease. *CMAJ*. 2008;179(11):1154-1162.

Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomized non-inferiority trial (MAXIMA). *Lancet*. 2007;370:1415-1421.

Levin RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. 2005;7:387-397.

Lewis NP, Macdougall IC, Willis N, Coles GA, Williams JD, Henderson AH. Effects of the correction of renal anaemia by erythropoietin on physiological changes during exercise. *European Journal of Clinical Investigation*. 1993;23:423-427.

Li W, Chu T, Huang J, Wu M, Wu K. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. *J Formos Med Assoc*. 2008;107(11):843-850.

Light JA, Metz S, Oddenino K, Simonis T, Strong DM, Reinmuth B, Kumar J, Biggers JA. Fresh versus stored blood in donor specific transfusion. *Transplantation Proceedings*. 1982;14(2):296-301.

Lillevang ST, Pedersen FB. Quality of life of hemodialysis patients before and after erythropoietin therapy. *Ugeskrift for Laeger*. 1990;152(41):2999-3002.

Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J. Recombinant human erythropoietin treatment in pre-dialysis patients. *Annals of Internal Medicine*. 1989;110:108-114.

- Lim VS, Kirchner PT, Fangman J, Richmond J, DeGowin RL. The safety and efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. *American Journal of Kidney Diseases*. 1989; 14(6):496-506.
- Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. *Kidney International*. 2004; 65:1802-1809.
- Lim CS, Vaziri ND. Iron and oxidation stress in renal insufficiency. *Am J Nephrol*. 2004;24:569-575.
- Lindeboom R, Holman R, Mmath, Dijkgraaf MGW, Sprangers MAG, Buskens E, et al. Scaling the sickness impact profile using item response theory: an exploration of linearity, adaptive use, and patient driven item weights. *Journal of Clinical Epidemiology*. 2004;57:66-74.
- Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. *Clin Nephrol*. 2005;63(5):327-334.
- Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. *Seminars in Thrombosis and Hemostasis*. 2010;36(5):537-549.
- Locatelli F, Baldamus CA, Villa G, Ganea A, deFrancisco AM. A rationale for an individualized administration frequency of epoetin β : a pharmacological perspective. *Nephrol Dial Transplant*. 2002;17[Suppl 6]:13-16.
- Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL. Once-weekly compared with three-times-weekly subcutaneous epoetin β : results from a randomized, multicenter, therapeutic-equivalence study. *American Journal of Kidney Diseases*. 2002;40(1):119-125.
- Locatelli F, Del Vecchio L, Casartelli D. Darbepoetin alfa and chronic kidney disease. *NEJM*. 2010;362(7):654-655.
- Locatelli F, Mann JFE, Aldigier J-C, Guajardo DS, Schmidt R, Van Vlem B, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. *Clinical Nephrology*. 2010;73(20):94-103.
- Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. *Kidney International*. 2001;60:741-747.

Locatelli F, Villa G, de Francisco ALM, Albertazzi A, Adroque HJ, Dougherty FC, Beyer U. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. *Current Medical Research and Opinion*. 2007;23(5):969-979.

Locatelli, F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, et al. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. *J Nephrol*. 2008;21:412-420.

London GM, Fabiani F, Marchais SJ, De Vernejoul M, Guerrin AP, Safar ME, et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. *Kidney International*. 1987;31:973-980.

López-Gómez JM, Portolés JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. *Kidney International*. 2008;74(Suppl 111):S75-S81.

Lu WX, Jones-Burton C, Zhan M, Salzberg DJ, Moore J Jr, Fink JC. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. *Nephron Clin Pract*. 2005;101(2):c79-86.

Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. *Blood*. 1994;84:1056-1063.

Lui SF, Chung WWM, Leung CB, Chan K, Lai, KN. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. *Clinical Nephrology*. 1990;33(1):47-51.

Lui SF, Law CB, Ting SM, Li P, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. *Clinical Nephrology*. 1991;36(5):246-251.

Lundin AP, Akerman MJ, Chesler RM, Delano BG, Goldberg N, Stein RA, Friedman EA. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. *Nephron*. 1991;58:315-319.

Lust SA, Subar M, Faris R, Lin W, Weaver J, Tully L. A retrospective review of erythrocyte stimulating agents (ESA) usage in pharmacy claims data. <http://ash.confex.com/ash/2009/webprogram/Paper24741.html>

Macdonald R. Red cell 2, 3-diphosphoglycerate and oxygen affinity. *Anaesthesia*. 1977;32:544-553.

Macdougall IC. CERA (Continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. *Current Hematology Reports*. 2005;4(6):436-440.

Macdougall IC. CREATE: new strategies for early anaemia management in renal insufficiency. *Nephrol Dial Transplant*. 2003;18(suppl2):ii13-ii16.

Macdougall IC. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. *Current Opinion in Investigational Drugs*. 2008;9(9):1034-1047.

Macdougall IC. Hyporesponsiveness to anemia therapy—what are we doing? *Peritoneal Dialysis International*. 2001;21(suppl 3):S225-S230.

Macdougall IC. Strategies for iron supplementation: oral versus intravenous. *Kidney International*. 1999;55(suppl 69):S61-S66.

Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. *J Am Soc Nephrol*. 1999;10(11):2392-2395.

Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, Williams JD. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. *Contrib Nephrol*. 1991;88:81-86;discussion 152-158.

Macdougall IC, Matcham J, Gray SJ. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. *Nephrol Dial Transplant*. 2003;18:576-581.

Macdougall IC, Roberts DE, Coles GA. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). *Clin Pharmacokinet*. 1991;20(2):99-113.

Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. *Lancet*. 1989;425-427.

Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (c.e.r.a.) in patients with chronic kidney disease. *Clin J Am Soc Nephrol*. 2006;1:1211-1215.

Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege A, Froissart M, Eckardt K. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. *NEJM*. 2009;361(19):1848-1855.

- Macdougall IC, Temple RM, Kwan JTC. Is early treatment of anaemia with epoetin- α beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. *Nephrol Dial Transplant*. 2007;22:784-793.
- Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG. A randomized controlled study of iron supplementation in patients treated with erythropoietin. *Kidney International*. 1996;50:1694-1699.
- Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. *Clin J Am Soc Nephrol*. 2008;3:337-347.
- Maeda H, Hitomi Y, Hirata R, Tohyama H, Suwata J, Kamata S, et al. The effect of phlebotomy on serum erythropoietin levels in normal healthy subjects. *International Journal of Hematology*. 1992;55:111-115.
- Mahmoud K, Sobh M, El-Shenawy F, Mostafa A, Abo El Magd M, et al. Effect of high-dose intravenous immunoglobulin on suppression of alloantibodies against HLA in highly sensitized transplant candidate. *Transplantation Proceedings*. 2004;36:1850-1852.
- Maiorca R, Cancarini GC, Brunori G, ZuOOni R, Camerini O, Manili L, Movilli E. Comparison of long term survival between hemodialysis and peritoneal dialysis. www.advancesinpd.com/adv96/pt2long18-96.html (printed 11/17/09)
- Management of anemia with intravenous methoxy polyethylene glycol-epoetin beta in patients on dialysis. *Nature Clinical Practice*. 2008;4(4):186.
- Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. *Clinical Nephrology*. 2007;67(3):140-148.
- Mansuri N, Sheikh IA, Al-Khader AA, Al-Shaikh AM, Huraib SO, Zazgornik J. Reversible uremic deafness: is it correlated with the degree of anemia? *Ann Otol Rhinol Laryngol*. 1997;106:391-393.
- Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. *Clinical Nephrology*. 1997;48(1):34-40.
- Marsden PA. Treatment of anemia in chronic kidney disease—strategies based on evidence. *NEJM*. 2009;361(21):2089-2090.

Marshall TA, Roberts RJ. In vitro and in vivo assessment of lipid peroxidation of infant nutrient preparations: effect of nutrition on oxygen toxicity. *Journal of the American College of Nutrition*. 1990;9(3):190-199.

Martín-Guerrero J, Camps-Valls G, Soria-Olivias E, Serrano-López AJ, Pérez-Ruixo J, Jiménez-Torres NV. Dosage individualization of erythropoietin using a profile-dependent support vector regression. *IEEE Trans Biomed Eng*. 2003;50(10):1136-1142.

Martin KJ. Epoetin delta in the management of renal anaemia: results of a 6-month study. *Nephrol Dial Transplant*. 2007;22:3051-3054.

Martin KJ. The first human cell line-derived erythropoietin, epoetin- δ (Dynepo®), in the management of anemia in patients with chronic kidney disease. *Clinical Nephrology*. 2007;68(1):26-31.

Massry SG. Pathogenesis of the anemia of uremia: role of secondary hyperparathyroidism. *Kidney International*. 1983;24(Suppl 16):S204-S207.

Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H. Working capacity is increased following recombinant human erythropoietin treatment. *Kidney International*. 1988;34:525-528.

McCarthy JT, Regnier CE, Loebertmann CL, Bergstrath EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran—a comparison of two products. *Am J Nephrol*. 2000;20:455-462.

McGonigle RJS, Husserl F, Wallin JD, Fisher JW. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. *Kidney International*. 1984;25:430-436.

McGonigle RJS, Wallin JD, Shaddock RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. *Kidney International*. 1984;25:437-444.

McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. *Kidney International*. 2004;66:801-805.

McKenna R, Lamblin C, Pochinco D, Dembinski I, Rush D, Jeffrey J, Grimm P, Nickerson P. Risk of development of anti-hla antibodies following blood transfusions in renal patients. *ASHI* 1998. <http://www.ashi-hla.org/docs/pubs/abstracts/abs98/ab98255.htm>

McKenna SP, Hunt SM, McEwen J. Weighting the seriousness of perceived health problems using Thurstone's method of paired comparisons. *International Journal of Epidemiology*. 1981;10(1):93-97.

McMahon LP, Dawborn JK. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. *Am J Nephrol.* 1990;10:404-408.

McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. *Am J Nephrol.* 1992;12:162-169.

McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner S, et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. *Nephrol Dial Transplant.* 1999;14:1182-1187.

McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. *Nephrol Dial Transplant.* 2000;15:1425-1430.

McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. *Blood.* 1990;76(9):1718-1722.

McVicar CM, Colhoun LM, Abrahams JL, Kitson CL, Hamilton R, Medina RJ, et al. Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy. *PLoS ONE.* 2010;5(7):e11870-e11870.

Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. *The Journal of the American Society of Hematology.* *Blood.* 1992;80(7):1639-1647.

Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C. Results from EuCLiD (European clinical dialysis database): impact of shifting treatment modality. *Int J Artif Organs.* 2002;25(11):1049-1060.

Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. *Nephrol Dial Transplant.* 2000;15[Suppl 3]: 14-18.

Meyer JW, Eichhorn K, Vetter K, Christen S, Schleusner E, Klos A, et al. Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well? *J Perinat Med.* 1995;23:99-109.

Michael B, Fishbane S, Coyne DW, Agarwal R, Warnock DG. Drug insight: safety of intravenous iron supplementation with sodium ferric gluconate complex. *Nature Clinical Practice Nephrology.* 2006;2(2):92-100.

Middleton D, Martin J, Douglas J, McClelland M. Transfusion of one HLA-DR antigen-matched blood to potential recipients of a renal allograft. *Transplantation*. 1994;58(7):845-848.

Milutinović S, Plavljančić D, Trkulja V. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study. *Fundamental & Clinical Pharmacology*. 2006;1-9.

Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, et al. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. *Clin J Am Nephrol*. 2009;4:552-559.

Mircescu G, Gârneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. *Nephrol Dial Transplant*. 2006;21(1):120-4. Epub 2005 Sep 6.

Mircescu G, Gârneată L, Ciocâlțeu A, Golea O, Gherman-Câaprioară M, Capsa D, et al. Once-every2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients. *Am J Kidney Dis*. 2006;48(3):445-455.

Mohan P, Murphy DM, Counihan A, Cunningham P, Hickey DP. The role of intraoperative heparin in cyclosporine treated cadaveric renal transplant recipients. *The Journal of Urology*. 1999;162:682-684.

Mohini R. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. *Seminars in Nephrology*. 1989;9(1)suppl 1:16-21.

Mokrzycki MH, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. *Kidney International*. 2001;59:1935-1942.

Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. *Pediatr Transplantation*. 2004;8:535-542.

Morris KP, Hughes C, Hardy SP, Matthews JNS, Coulthard MG. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help? *Nephrol Dial Transplant*. 1994;9:1299-1301.

Morris KP, Sharp J, Watson S, Coulthard MG. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. *Archives of Disease in Childhood*. 1993;69:580-586.

Morris KP, Skinner JR, Hunter S, Coulthard MG. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure. *Arch Dis Child*. 1993;68:644-648.

Muirhead N, Churchill DN, Goldstein M, Nadler SP, Posen G, Wong C. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. *Am J Nephrol*. 1992;12:303-310.

Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian erythropoietin study group). *Nephrol Dial Transplant*. 1992;7:811-816.

Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, et al. Guidelines for the clinical use of red cell transfusions. British Committee for Standards in Haematology, Blood Transfusion Task Force. *Br J Haematol*. 2001;13(1):24-31.

Nagaya H, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Hamaguchi K, et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. *Clin Exp Nephrol*. 2010;14:158-163.

Nakatsuka K, Hino M, Miki T, Nishizawa Y, Tabata T, Inoue T, Moril H. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus. *Diabetes Care*. 1990;13(11):1130-1131.

National Collaborating Centre for Chronic Conditions. Chronic Kidney Disease. National guidelines for early identification and management in adults in primary and secondary care. Royal College of Physicians. 2008.

National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 39: Anaemia management in people with chronic kidney disease. Issue date: September 2006.

National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 73: Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. Issue date: September 2008.

Ness PM. Transfusion medicine: an overview and update. *Clinical Chemistry*. 2000;46(8):1270-1276.

Neumayer H, Brockmöller J, Fritschka E, Roots I, Scigalla P, Wattenberg M. Pharmacokinetics of recombinant human erythropoietin after SC administration and in long term IV treatment in patients on maintenance hemodialysis. *Contributions to Nephrology*. 1989;76(1):131-142.

Neves PL, Morgado E, Faisca M, Carrasqueira H, Baptista A, Silva AP. Nutritional and inflammatory status influence darbepoetin dose in pre-dialysis elderly patients. *Int Urol Nephrol*. 2006;38(3-4):811-3. Epub 2006 Dec 7.

Niaudet P, Dudley J, Charbit M, Gagnadoux M, Macleay K, Broyer M. Pretransplant blood transfusions with cyclosporine in pediatric renal transplantation. 2000;14:451-456.

Nielsen OJ, Thaysen JH. Response to erythropoietin in anaemic haemodialysis patients. *Journal of Internal Medicine*. 1989;226:89-94.

Nightingale SC. Erythropoietin available for severe anemia in AIDS patients. *JAMA*. 1989;262(2):184.

Nissenson AR. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. *American Journal of Kidney Diseases*. 1991;18(suppl 1):24-33.

Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schleicher RB, Seligman PA. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. *Am J Kidney Dis*. 2003;42(2):325-330.

Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. *Am J Kidney Dis*. 2002;40(1):110-118.

Nissim JA. Plasma iron levels after the intravenous administration of different iron preparations. *J Physiol*. 1952;118(4):63P-64P.

Nissim JA. Plasma iron levels and urinary iron excretion after the intravenous administration of different iron preparations. *Brit J Pharmacol*. 1953;8:371-377.

Nissim JA. Toxic reactions after intravenous saccharated iron oxide in man. *Br Med J*. 1954 February 13; 1(4858): 352–356.

Nomoto Y, Kawaguchi Y, Kubota M, Tagawa H, Kubo K, Ogura Y, et al. A multicenter study with once a week or once every two weeks high dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. *Peritoneal Dialysis International*. 1994;14:56-60.

Nonnast-Daniel B, Creutzig A, Kühn K, Bahlmann J, Reimers E, Brunkhorst R, Caspary L, Koch KM. Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation. *Contr. Nephrol.* 1988;66:185-194.

Norman DJ, Fletcher L, Barry J. A randomized study of buffy coat transfusions in cadveric renal transplantation. *Transplantation Proceedings.* 1987;19(1):1967-1970.

Nowicki M, Kokot F, Kokot M, Bar A, Dulawa J. Renal clearance of endogenous erythropoietin in patients with proteinuria. *International Urology and Nephrology.* 1994;26(6):691-699.

Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. *Ann Thorac Surg.* 2007;84:1556-1563.

Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. *Lancet.* 2005;365:1570-1576.

Opelz G, Pfarr E, Engelmann A, Keppel E. Kidney graft survival rates in black cyclosporine-treated recipients. *Transplantation Proceedings.* 1989;21(96):3918-3920.

Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. *Transplantation.* 1997;63(7):964-967.

Ostrvica E, Mesic E, Ostrvica D, Delic J, Delic-Custendil S, Hukic F, et al. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta. *Med Arh.* 2010;64(1):4-6.

Otsuka M, Yuzawa K, Takada Y, Taniguchi H, Todoroki K, Fukao K, et al. Long-term results of donor-specific blood transfusion with cyclosporine in living related kidney transplantation. *Nephron.* 2001;88:144-148.

Ouzouni S, Kouidi E, Grekas D, Deligiannis A. Effects of intradialytic exercise training on health-related quality of life indices in haemodialysis patients. *Clinical Rehabilitation.* 2009;23:53-63.

Ozdemir FN, Sezer S, Akcay A, Arat Z, Turan M, Gulmus S, Kulah E, Haberal M. Panel reactive antibody positivity and associated HLA antibodies in Turkish renal transplant candidates. *Transplant Immunology.* 2004;12:185-188.

Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa. *Clin Pharmacokinet.* 2006;45(5):503-510.

Paganini EP, Eschbach JW, Lazarus JM, Van Stone JC, Gimenez LF, Graber SE. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. *American Journal of Kidney Diseases*. 1995;26(2):331-340.

Paganini EP, Latham d, Abdulhadi M. Practical considerations of recombinant human erythropoietin therapy. *American Journal of Kidney Diseases*. 1989;14(2)supp 1:19-25.

Painter P, Moore G, Carlson L, Paul S, Myll J, Phillips W, Haskell W. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. *Am J Kid Dis*. 2002;39(2):257-265.

Papatheofanis F, McKenzie RS, Mody SH, Suruki RY, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. *Current Medical Research and Opinion*. 2006;22(5):837-842.

Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. *American Journal of Therapeutics*. 2007;14:322-327.

Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin. *Kidney Int*. 2005;68(1):246-255.

Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, Goudevenos JA, Siamopoulos KC. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. *Cardiovasc Drugs Ther*. 2008;22:37-44.

Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. *J Am Soc Nephrol*. 2005;16:2180-2189.

Parfrey PS, Vavasour H, Bullock M, Henry S, Harnett JD, Gault MH. Development of a health questionnaire specific for end-stage renal disease. *Nephron*. 1989;52:20-28.

Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. *Nephrol Dial Transplant*. 2000;15:1827-1834.

Pascual J, Teruel JL, Marcén R, Liaño F, Moya JL, Jiménez M, Ortuño J. Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis. *International Journal of Artificial Organs*. 1992;15(6):349-353.

Pascual J, Teruel L, Moya JL, Liaño F, Jiménez-Mena M, Ortuño J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. *Clinical Nephrology*. 1991;35(6):280-287.

Patel TV. ACP Journal club. Darbepoetin decreased transfusions and fatigue, but increased adverse effects in patients with chronic kidney disease, diabetes, and anemia. *Ann Intern Med*. 2010;152(6):JC3-9.

Pavlović-Kentera V, Clemons GK, Trbojević S, Dimković N, Djukanović L. Erythropoietin and anemia in the progression of Balkan endemic nephropathy and other renal diseases. *Nephron*. 1990;54:139-143.

Perazella MA, Khan S. Increased mortality in chronic kidney disease: a call to action. *Am J Med Sci*. 2006;331(3):150-153.

Pérez-Olivia JF, Casanova-González M, García-García I, Porrero-Martin PJ, Valenzuela-Silva CM, Hernández-Montero T, et al. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. *BMC Nephrol*. 2005;23:6(1):5.

Pérez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA. Pharmacokinetics and pharmacodynamics of the erythropoietin mimetibody™ construct CNTO 528 in healthy subjects. *Clin Pharmacokinet*. 2009;48(9):601-613.

Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in ckd patients with anemia. *Clin J Am Soc Nephrol*. 2009;4:1731-1740.

Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in ckd patients with anemia. *Clin J Am Soc Nephrol*. 2010;5:598-606.

Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the renal research institute-ckd study. *Am J Kid Dis*. 2005;45(4):658-666.

Perrinet M, Décaudin B, Champs B, Heran I, Urbina MA, et al. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres. *Journal of Clinical Pharmacy and Therapeutics*. 2010;35:395-400.

Petrányi GG, Réti M, Harsányi V, Szabó J. Immunologic consequences of blood transfusion and their clinical manifestations. *Int Arch Allergy Immunol*. 1997;114:303-315.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *NEJM*. 2009;361(21):2019-2032.

Pfeffer MA, Burdmann EA, Chen C, Cooper ME, de Zeeuw D, Eckardt K, Ivanovich P, et al. Baseline characteristics in the trial to reduce cardiovascular events with aranesp therapy (TREAT). *American Journal of Kidney Diseases*. 2009;54(1):59-69.

Pfeifer AC, Timmer J, Klingmüller U. Systems biology of JAK/STAT signaling. *Essays Biochem*. 2008;45:109-120.

Phelan DL, Hibbett S, Wetter L, Hanto DW, Mohanakumar T. Recombinant erythropoietin: does it really effect sensitization? *Transplantation Proceedings*. 1991;23(1):409-410.

Pisoni RL, Bragg-Gresham JL, Fuller DS, Morgenstern H, Canaud B, Locatelli F, et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the dialysis outcomes and practice patterns study (DOPPS): associations with mortality, patient characteristics, and facility practices. *Am J Kidney Dis*. 2011;57(2):266-275.

Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F. Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). *Am J Kidney Dis*. 2004;44(1):94-111.

Plant P, McEwen J, Prescott K. Use of the Nottingham health profile to test the validity of census variables to proxy the need for health care. *Journal of Public Health Medicine*. 1996;18(3):313-320.

Polenakovic M, Sikole A. Is erythropoietin a survival factor for red blood cells? *J Am Soc Nephrol*. 1996;7:1178-1182.

Pollard WE, Bobbitt RE, Bergner M, Martin DP, Gilson BS. The sickness impact profile: reliability of a health status measure. *Medical Care*. 1976;14(2):146-155.

Pollok M, Bommer J, Gurland HJ, Koch KM, Schoeppe W, Scigalla P, Baldamus CA. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. *Contributions to Nephrology*. 1989;76:201-218.

Portolés JM, de Francisco AL, Górriz JL, Martínez-Castelao A, López-Gómez JM, Arias M, et al. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical perspective study. *Kidney International*. 2008;74(Suppl 111):S82-S87.

Potter DE, Portale AA, Melzer JS, Feduska NJ, Garovoy MR, Husing RM, Salvatierra O. Are blood transfusions beneficial in the cyclosporine era? *Pediatr Nephrol.* 1991;5:168-172.

Pour-Reza-Gholi F, Daneshvar S, Nafar M, Firouzan A, Farrokhi F, Einollahi B. Potential risk factors for hypersensitization reflected by panel-reactive antibodies in dialysis patients. *Transplantation Proceedings.* 2005;37:2936-2938.

Pouteil-Noble C, Betuel H, Raffaele P, Robert F, Dubernard JM, Touraine JL. The value of platelet transfusions as preparation for kidney transplantation. *Transplantation.* 1991;51(4):777-781.

Prieto L, Alonso J, Ferrer M, Antó M. Are results of the SF-36 health survey and the Nottingham health profile similar?: a comparison in COPD patients. *J Clin Epidemiol.* 1997;50(4):463-471.

Prieto L, Alonso J, Lamarca R. Classical test theory versus Rasch analysis for quality of life questionnaire reduction. *Health and Quality of Life Outcomes.* 2003;1:27.

Pritikin N. Optimal dietary recommendations: a public health responsibility. *Preventive Medicine.* 1982;11:733-739.

Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. *Clinical Nephrology.* 2005;64(2):113-123.

Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woolen SB, Zabaneh R, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. *Clinical Nephrology.* 2004;61(6):392-405.

Pussell BA, Walker R (Australian Renal Anaemia Group). Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare? *Nephrology.* 2007;12:126-129.

Qureshi BH. Consensus and controversies on HLA matching and crossmatching in transplantation. *Saudi J Kidney Dis Transplant.* 1997;8(2):138-144.

Rabiner SF. Uremic Bleeding. *Prog Hemost Thromb.* 1972;1:233-250.

Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. *Blood*. 1979;54(4):877-884.

Radtke HW, Erbes PM, Fassbinder W, Koch KM. The variable role of erythropoietin deficiency in the pathogenesis of dialysis anaemia. *Proc Eur Dial Transplant Assoc*. 1977;14:177-183.

Radtke HW, Frei U, Erbes PM, Schoeppe W, Koch KM. Improving anemia by hemodialysis: effect on serum erythropoietin. *Kidney International*. 1980;17:382-387.

Radtke HW, Rege AB, LaMarche MB, Bartos D, Bartos F, Campbell RA, Fisher JW. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. *J Clin Invest*. 1981;67:1623-1629.

Ramirez G, Bittle PA, Rabb HA, Ballester O, Bercu BB. Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patients. *Clinical Endocrinology*. 1995;43:167-174.

Rao S, Carter WB, Mapes DL, Kallich JD, Kamberg CJ, Spritzer KL, Hays RD. Development of subscales from the symptoms/problems and effects of kidney disease scales of the kidney disease quality of life instrument. *Clinical Therapeutics*. 2000;22(9):1099-1111.

Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. *JAMA*. 2004;292(13):1555-1562.

Ratajczak J, Majka M, Kijowski J, Baj M, Pan ZK, Marquez LA, Janowska-Wieczork A, Ratajczak MZ. Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. *British Journal of Haematology*. 2001;115:195-204.

Ravanan R, Udayaraj U, Steenkamp R, Ansell D. Chapter 5: Demographics and biochemistry profile of kidney transplant recipients in the UK in 2007: national and centre-specific analyses. *Nephron Clin Pract*. 2009;111 (Suppl. 1):c69-c96.

Reed A, Pirsch JD, Armburst MJ, Burlingham WJ, Knechtle SJ, D'Alessandro AM, Sollinger HW, Kalayoglu M, Belzer FO. A comparison of donor-specific and random transfusions in living-related renal transplantation and their effect on steroid withdrawal. *Transplantation Proceedings*. 1991;23(1):1321-1322.

Rege AB, Ohno Y, Barona J, Fisher JW. Inhibitors of erythroid colony forming cells in sera of azotemic patients with anemia of renal disease. *Proc Dialysis Transplant Forum*. 1978;8:189-193.

Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. *Nephrol Dial Transplant*. 2010;1-8.

Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. *Blood Reviews*. 1997;11:233-242.

Reisaeter AV, Leivestad T, Albrechtsen D, Holdaas H, Hartmann A, Sódal G, Flatmark A, Fauchald P. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients. *Transplantation*. 1995;60(3):242-248.

Reissmann KR, Nomura T, Gunn RW, Brosius F. Erythropoietin response to anemia or erythropoietin injection in uremic rats with or without functioning renal tissue. *Blood*. 1960;16:1411-1423.

Rejman ASM, Grimes AJ, Cotes PM, Mansell MA, Joekes AM. Correction of anaemia following renal transplantation: serial changes in serum immunoreactive erythropoietin, absolute reticulocyte count and red-cell creatin levels. *British Journal of Haematology*. 1985;61:421-431.

Relative mortality and epoetin alfa dose among hemodialysis patients. *American Journal of Kidney Diseases*. 2008;51(5):865-867.

Remuzzi G, Ingelfinger JR. Correction of anemia-payoffs and problems. *NEJM*. 2006;355(20):2144-2146.

Revicki DA. Relationship between health utility and psychometric health status measures. *Medical Care*. 1992;30(5):MS274-MS282.

Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. *Am J Kidney Diseases*. 1995;25(4):548-554.

Richardson D, Ford D, Gilg J, Williams AJ. UK renal registry 11th annual report: chapter 9 haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analysis. *Nephron Clin Pract*. 2009;111(suppl 1):c149-183.

Riegersperger M, Sengoelge G, Köller M, Grossmann N, Benesch T, Sunder-Plassmann G. Anemia in patients with Wegener's granulomatosis. *Clinical Nephrology*. 2007;67(3):149-156.

Rijk Y, Raaijmakers R, van de Kar N, Schröder C. Intraperitoneal treatment with darbepoetin for children on peritoneal dialysis. *Pediatr Nephrol*. 2007;22:436-440.

- Ripamonti V, Racca V, Calvo MG, Castiglioni P, Ferratini M. Angiotensin-converting enzyme inhibitors slow recovery from anemia following cardiac surgery. *Chest*. 2006;130:79-84.
- Robertson, BC, Curtin C. Effects of EPO therapy on backfiltration of dialysate in high flux dialysis. *ASAIO Transactions*. 1990;36:M447-M452.
- Rocha JL, Gentil MA, Gili M, Gil L, Cabello V, Bernal G. Continuous intravenous intradialysis versus intravenous postdialysis erythropoietin therapy in chronic haemodialysis patients: a randomized, controlled, crossover study. *Nephrol Dial Transplant*. 1998;13:89-92.
- Roche A, Macdougall IC, Walker RG. Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres. *Current Medical Research & Opinion*. 2009;25(12):2971-2976.
- Roe DJ, Harford AM, Zager PH, Wiltbank TB, Kirlin L, Della Valle A, Van Wyck DB. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents. *American Journal of Kidney Diseases*. 1996;28(6):855-860.
- Roger SD, Levin A. Epoetin trials: randomized controlled trials don't always mimic observational data. *Nephrol Dial Transplant*. 2007;22(3):684-686.
- Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, et al. Effects of early and late intervention with epoetin α on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. *J Am Soc Nephrol*. 2004;15:148-156.
- Roger SD, Stewart JH, Harris DCH. Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common. *Nephron*. 1991;58:33-36.
- Roger SD, Suranyi MG, Walker RG. A randomized, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease. *Current Medical Research and Opinion*. 2008;24(8):2181-2187.
- Roman RMB, Lobo PI, Taylor RP, Goodkin DA, Labrecque J, Powers KL, Bolton WK. Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin. *J Am Soc Nephrol*. 2004;15:1339-1346.
- Ross RP, McCrea JB, Besarab A. Erythropoietin response to blood loss in hemodialysis patients is blunted but preserved. *ASAIO Journal*. 1994;40:M880-M885.

Rossert J, Levin A, Roger SD, Hörl WH, Fouqueray B, Gassmann-Mayer C, et al. Effect of early correction of anemia on the progression of CKD. *Am J Kidney Diseases*. 2006;47(5):738-750.

Rotaecche RS. Is CERA therapy every 2-4 weeks worse than usual EPO therapy 1-3 times per week? *Nefrologia*. 2008;28(Suppl 2):28-29.

Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. *Am J Kidney Dis*. 1994;24(5):777-784.

Ryan MH, Heavner GA, Brigham-Burke M, McMahon F, Shanahan MF, Gunturi SR, Sharma B, Farrell FX. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. *International Immunopharmacology*. 2006;6:647-655.

Salmonson T. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin. *Scandinavian Journal of Urology and Nephrology*. 1990;Suppl 129:1-66.

Salmonson T, Danielson BF, Grahnén A, Wikström B. Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. *Journal of Internal Medicine*. 1990;228:53-57.

Salmonson T, Danielson BG, Wikström B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. *Br J Clin Pharmacol*. 1990;29:709-713.

Saltissi D, Coles GA, Napier JAF, Bentley P. The hematological response to continuous ambulatory peritoneal dialysis. *Clinical Nephrology*. 1984;22(1):21-27.

Samtleben W, Baldamus CA, Bommer J, Grützmacher P, Nonnast-Daniel B, Sciagalla P, Gurland HJ. Indications and contraindications for recombinant human erythropoietin treatment. *Contrib Nephrol*. 1989;76:193-218.

Sander HW, Conigliari MF, Masdeu JC. Antecubital phlebotomy complicated by lateral antebrachial cutaneous neuropathy. *NEJM*. 1998;339:2024.

Santoro A, Canova C. Anemia and erythropoietin treatment in chronic kidney diseases. *Minerva Urol Nefrol*. 2005;57:23-31.

Santos AE, Shalansky KF, Jastrzebski JP. Management of anemia in erythropoietin-resistant hemodialysis patients. *Annals of pharmacotherapy*. 2003;37(12):1768-1773.

Sautner T, Gnant M, Banhegyi C, Wamser P, Götzinger P, Steininger R, Mühlbacher F. Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. *Transplant Int.* 1992;5[Suppl 1]:S116-S120.

Sav T, Tokgoz B, Sipahioglu M, Deveci M, Sari I, Oymak O, Utas C. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? *Renal Failure.* 2007;29:423-426.

Schaller R, Sperschneider H, Thieler H, Dutz W, Hans S, Voigt D, et al. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial. *Artificial Organs.* 1994;18(8):552-558.

Schärer K, Klare B, Braun A, Dressel P, Gretz N. Treatment of renal anemia by subcutaneous erythropoietin in children with preterminal chronic renal failure. *Acta Paediatr.* 1993;82(11):953-958.

Schellekens H. Assessing the bioequivalence of biosimilars. *Drug Discovery Today.* 2009;14(9/10):495-499.

Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Pansa A, Diamantidis CJ, Fink JC. Erythropoietin-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. *Kidney-International.* 2011;Mar;49 (advance on-line publication).

Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. *Nature Biotechnology.* 2006;24(6):613-614.

Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. *Leukemia.* 2008;22:87-95.

Schiesser D, Binet I, Tsinalis D, Dickenmann M, Keusch G, Schmidli M, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. *Nephrol Dial Transplant.* 2006;21:2841-2845.

Schiffel H. Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis. *Eur J Med Res.* 2007;12:26-33.

Schiller GJ, Berkman SA. Hematologic aspects of renal insufficiency. *Blood Reviews.* 1989;3:141-146.

- Schmidt B, Ward RA. The impact of erythropoietin on hemodialyzer design and performance. *Artificial Organs*. 1989;13(1):35-42.
- Schmitt CP, Nau B, Brummer C, Rosenkranz J, Schaefer F. Increased injection pain with darbepoetin- α in paediatric dialysis patients. *Nephrol Dial Transplant*. 2006;21:3520-3524.
- Schmitz SA, Taupitz M, Wagner S, Coupland SE, Gust R, Nikolova A, Wolf KJ. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques. *Investigative radiology*. 2002;37(7):405-411.
- Schollmeyer P, Lubrich-Birkner I, Steinhauer HB. Effect of recombinant human erythropoietin on anemia and dialysis: efficiency in patients undergoing CAPD. 1990;87:95-104.
- Schuster SJ, Koury ST, Bohrer M, Salceda S, Caro J. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. *British Journal of Haematology*. 1992;81:153-159.
- Schwartz AB, Kahn SB, Kelch B, Kim KE, Pequignot E. RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy. *Clinical Nephrology*. 1992;38(5):283-289.
- Schwartz AB, Kelch B, Terzian L, Prior J, Kim KE, Pequignot E, Kahn SB. One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. *American Society for Artificial Internal Organs*. 1990;36(3):M691-696.
- Schwartz AB, Prior JE, Mintz GS, Kim KE, Kahn SB. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin. *Transplantation Proceedings*. 1991;23(2):1827-1830.
- Scigalla P. Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. *Contrib Nephrol*. 1991;201-214.
- Scigalla P. Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients. *Contrib Nephrol*. 1990;82:55-64.
- Scornik JC, Pfaff WW, Howard RJ, Fennell RS, Ramos E, Peterson JC, Neiberger R. Increased antibody responsiveness to blood transfusions in pediatric patients. *Transplantation*. 1994;58(12):1361-1365.

Sekili S, McCay PB, Li X, Zughuib M, Sun J, Tang L, Thornby JI, Bolli R. Direct evidence that the hydroxyl radical plays a pathogenetic role in myocardial "stunning" in the conscious dog and demonstration that stunning can be markedly attenuated without subsequent adverse effects. *Circ Res.* 1993;73:705-723.

Sezer S, Özdemir FN, Turan M, Güz G, Haberal A, Kaya S, Bilgin N. Comparison of panel reactive antibody levels with clinical and laboratory parameters in end-stage renal disease patients. *Transplantation Proceedings.* 1998;30:844-845.

Sezer S, Özdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. *Artificial Organs.* 2002;26(4):366-370.

Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the choices for healthy outcomes in caring for end-stage renal disease (CHOICE) study. *Am J Kidney Dis.* 2010;56(2):348-358.

Shand BI, Buttimore AL, Hurrell MA, Wells JE, Inkster IA, Bailey RR, et al. Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: a prospective placebo-controlled study. *Nephron.* 1993;64:53-57.

Sharma AD, Sreeram G, Erb T, Grocott HP, Slaughter TF. Leukocyte-reduced blood transfusions: perioperative indications, adverse effects, and cost analysis. *Anesth Analg.* 2000;90:1315-1323.

Shigematsu T, Takami H, Shimizu T, Shimoyama H, Kim S, Hirose S, et al. Efficacy of once-weekly intravenous administration of epoetin- β as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study. *Therapeutic Apheresis and Dialysis.* 2008;12(6):469-474.

Shinaberger JH, Miller JH, Gardner PW. Erythropoietin alert: risks of high hematocrit hemodialysis. *Trans Am Soc Artif Intern Organs.* 1988;34:179-184.

Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, et al. Erythropoietin couples hematopoiesis with bone formation. *PLoS ONE.* 2010;5(5):1-14. Accessed via www.plosone.org (e10853)

Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasiliou EC, Tselepis AD. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. *Am J Kidney Dis.* 2006;48(2):242-249.

Sikole A, Efrernov DG, Dinovski A, Efremov GD, Polenakovic M. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin. *Nephron.* 1993;65:482-484.

Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. *Artificial Organs*. 17(12):977-984.

Sikole A, Stojanovic A, Polenakovic M, Petrusevska G, Sadikario S, Saso R, Jovanovski M. How erythropoietin affects bone marrow of uremic patients. *Am J Nephrol*. 1997;17:128-136.

Silverstein SB, Rodgers GM. Parenteral iron therapy options. *American Journal of Hematology*. 2004;76:74-78.

Silverstein DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. *J Am Coll of Cardiol*. 2001;37:1775-1780.

Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? *Curr Opin Nephrol Hypertens*. 2010;19:420-424.

Singh AK, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M, Reddan D. Anaemia of CKD—the CHOIR study revisited. *Nephrol Dial Transplant*. 2007;22:1806-1810.

Singh AK, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. *NEJM*. 2006;355:2085-2098.

Singh NP, Aggarwal L, Singh T, Anuradha S, Kohli R. Anaemia, iron studies and erythropoietin in patients of chronic renal failure. *JAPI*. 1999;47(3):284-290.

Sintonen H. The 15D instrument of health-related quality of life: properties and applications. *Ann Med*. 2001;33:328-336.

Sirken G, Raja R, Rizkala AR. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. *Clinical Nephrology*. 2006;66(5):348-356.

Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. *Nephrol Dial Transplant*. 2000;15:1207-1211.

Sjajeem FA, Akeel N, Alfi A, Harbi A, Tarif N, Souqiyyeh MZ. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudia Arabia. *Saudi J Kidney Dis Transplant*. 2006;17(3):365-372.

Sklar AH. Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin. *NEJM*. 2010;339(27):2023.

Smith WB, Dowell JA, Pratt RD. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. *Clinical Therapeutics*. 2007;29(7):1368-1380.

Sobota JT. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. *Contrib Nephrol*. 1989;76:166-78.

Sobota JT. The role of recombinant human erythropoietin in homologous transfusion avoidance. *Contrib Nephrol*. 1991;88:334-350.

Sohmiya M, Kakiba T, Kato Y. Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. *European Journal of Endocrinology*. 1998;139:367-370.

Solomon SD, Uno H, Lewis EF, Eckardt K, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and Type 2 diabetes. *NEJM*. 2010;363(12):1146-1155.

Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. *Am J Nephrol*. 2008;28:280-289.

St. Peter WL, Lewis MJ, Macres MG. Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of Epogen in hemodialysis patients. *Am J Kidney Dis*. 1998;32(3):470-474.

St. Peter WL, Manley HJ, Sullivan S. Managed care to medicare: sharing the burden of chronic kidney disease. *Supplement to Journal of Managed Care Pharmacy*. 2007;13(9):s1-s24.

Stansfield SA, Roberts R, Foot SP. Assessing the validity of the SF-36 general health survey. *Quality of Life Research*. 1997;6:217-224.

Stockenhuber F, Kurz RW, Geissler K, Jahn C, Hinterberger W, Balcke P, Lechner K. Recombinant human erythropoietin activates a broad spectrum of progenitor cells. *Kidney International*. 1990;37:150-156.

Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, Meisl ThF, Balcke P. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. *Nephron*. 1991;59:399-402.

Stojcheva-Taneva OO, Polenakovic MH. Autonomic neuropathy in hemodialysis patients treated with recombinant human erythropoietin. *Int J Artif Organs*. 1996;19:574-577.

Stone WJ, Graber SE, Krantz SB, Dessypris EN, O'Neil VL, Olsen NJ, Pincus TP. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. *Am J Med Sci*. 1988;296(3):171-179.

Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. *Nephrol Dial Transplant*. 2001;16(5):967-974.

Strippoli GF. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. *Trials*. 2010;11:70.

Strippoli GFM, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD003967. DOI: 10.1002/14651858.CD003967.pub2.

Sturm B, Laggner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron. *Kidney International*. 2005;67:1161-1170.

Sturm B, Goldenberg H, Scheiber-Mojdehkar. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. *Eur J Biochem*. 2003;270:3731-3738.

Subpoena information in Amgen SEC 10-K Annual Report (filed 2/25/2011) and 10-Q quarterly Reports (filed 5/7/2010, 8/9/2010).

Sudhaker Rao D, Shih M, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. *NEJM*. 1993;328:171-175.

Sulowicz W, Locatelli F, Ryckelynck J, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. *Clin J Am Soc Nephrol*. 2007;2:637-646.

Summerfield GP, Gyde OHB, Forbes AMW, Goldsmith HJ, Bellingham AJ. Haemoglobin concentration and serum erythropoietin in renal dialysis and transplant patients. *Scand J Haematol.* 1983;30:389-400.

Sun CH, Ward HJ, Paul WL, Koyle MA, Yanagawa N, Lee DB. Serum erythropoietin levels after renal transplantation. *N Engl J Med.* 1989;321:151-157.

Sundal E, Businger J, Kappeler A. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. *Nephrol Dial Transplant.* 1991;6:955-965.

Sunder-Plassmann, Hörl WH. Importance of iron supply for erythropoietin therapy. *Nephrol Dial Transplant.* 1995;10:2070-2076.

Sunder-Plassmann, Hörl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. *Nephrol Dial Transplant.* 1996;11:1797-1802.

Suzuki M, Hirasawa Y, Hirashima K, Arakawa M, Odaka M, Ogura Y, et al. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. *Contributions to Nephrology.* 1989;76:179-92; discussion 212-218.

Swain RA, Kaplan B, Montgomery E. Iron deficiency anemia. *Post Graduate Medicine.* 1996;100(5):181-193.

Szczzech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. *Kidney Int.* 2008;74(6):791-798.

Szczzech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. *Kidney Int.* 2010;77(3):239-246.

Szczzech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. *Ann Intern Med.* 1998;128:817-826.

Ter Wee PM, deKoter Y, van der Veer O, van Vliet MH. Immediate pain sensation is less with subcutaneous epoetin- β compared to subcutaneous darbepoietin- α . *Clinical Nephrology.* 2009;72(3):177-180.

Tan A. Recombinant human erythropoietin (rHuEPO): quality of life and other considerations. *J Cannt.* 1990:13-4.

Tarng D, Huang T. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. *Nephrol Dial Transplant*. 1998;13:2867-2872.

Taylor JE, Belch JJF, Fleming W, Macter RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. *Clinical Nephrology*. 1994;41(5):297-302.

Taylor JE, Belch JJF, McLaren M, Henderson IS, Stewart WK. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. *Kidney International*. 1993;44:182-190.

Taylor JE, Henderson IS, Stewart WK, Belch JJF. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. *Lancet*. 1991;338:1361-1362.

Taylor JE, McLaren M, Mactier RA, Henderson IS, Stewart WK, Belch JJ. Effect of dialyzer geometry during hemodialysis with cuprophane membranes. *Kidney Int*. 1992;42(2):442-7.

Taylor JE, Henderson IS, Mactier RA, Stewart WK. Effects of withdrawing erythropoietin. *BMJ*. 1991;302:272-273.

Teehan BP, Benz RL, Sigler MH, Brown JM. Early intervention with recombinant human erythropoietin therapy. *Seminars in Nephrology*. 1990;10(2):28-34.

Teehan BP, Krantz S, Stone WA, Graber SE, Abraham P, Dauer A, et al. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. *American Journal of Kidney Diseases*. 1991;18(1):50-59.

Teplan V, Schück O, Knotek A, Hajny J, Horáčková M, Kvapil M. Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet: Czech multicenter study. *Am J Kidney Dis*. 2003;41(S1):S26-S30.

Teplan V, Schück O, Knotek A, Hajny J, Horáčková M, Skibová J, Malý J. Effects of low-protein diet supplemented with ketoacids and erythropoietin in chronic renal failure: a long-term metabolic study. *Annals of Transplantation*. 2001;6(1):47-53.

Terasaki P. Factors influencing cadaver kidney transplantation outcome in the cyclosporine era. *Clinical Transplants*. 1988:131-145.

Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. *American Journal of Transplantation*. 2004;4(3):438-443.

- Ternes N, Scheiber-Mojdehkar B, Landgraf G, Goldenberg H, Sturm B. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran-a comparative in vitro study with liver cells and macrophages. *Nephrol Dial Transplant*. 2007;22:2824-2830.
- Thanakitcharu P, Siriwiwatanakul N. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia. *J Med Assoc Thai*. 2007;90(12):2574-2586.
- Thilly N, Boini S, Loos-Ayav C, Kessler M, Briancon S, Frimat L. Factors associated with anemia among incident pre-dialysis patients managed within a french care network. *Clin Nephrol*. 2007;67(2):81-8.
- Thitiarchakul S, Tasanarong A. 12-week clinical effects of erythropoietin Espogen™ in end stage renal patients undergoing hemodialysis. *J Med Assoc Thai*. 2007;90(4):636-642.
- Thomas MC, Maclsaac R, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes. *Diabetes Care*. 2003;26(4):1164-1169.
- Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietin regimens using a computerized decision-support system: a randomized clinical study. *J Am Soc Nephrol*. 2005;16:1463-1470.
- Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol*. 2006;17:2034-2047.
- Topf JM. CERA: third generation erythropoiesis-stimulating agent. *Expert Opin. Pharmacother*. 2008;9(5):839-849.
- Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. *Health Services Research. Health Serv Res*. 1972 Summer;7(2):118-133.
- Trachsler J, Glück Z, Dickenmann M, Gauthier T, Brünisholz M, Martin P-Y, Burnier M, Wahl C, Wüthrich RP. Parameters for successful monthly extended dosing of darbepoetin- α in patients undergoing hemodialysis. *Clinical Nephrology*. 2009;71(6):697-702.
- Trembecki J, Kokot F, Wiecek A, Marcinkowski W, Rudka R. Improved sexual function in haemodialyzed males with chronic renal failure treated with erythropoietin (rHuEPO). *Przegląd Lekarski*. 1995;52(9):462-466.

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, and U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: February 2006 draft guidance . Health Qual Life Outcomes. 2006;4:79.

U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, and U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: December 2009. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf>.

Udayaraj U, Tomson CR, Gilg J, Ansell D, Fogarty D. UK renal registry 11th annual report: chapter 6 Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales, and northern Ireland: national and centre-specific analyses. Nephron Clin Pract. 2009;111(s1):c97-111.

Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. 1992;51:76-89.

Usberti M, Gerardi G, Bufano G, Tira P, Micheli A, Albertini A, et al. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis. 2002;40(3):590-599.

US Renal Data System, USRDS 2009 Annual Data Report: Atlas of chronic kidney disease in the united states, National Institute of Health, National Institute of Diabetes & Digestive & Kidney Disease, Bethesda, MD, 2009.

Van Campenhout A, Van Campenhout C, Lagrou A, Manuel-y-Keenoy B. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes. Biometals. 2008;21:159-170.

Van der Meer P, Lokk DJ, Januzzi JL, Bruggink-Andre de la Porte PW, Lipsic E, van Wijngaarden J, et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. European Heart Journal. 2008.

Van der Putten K, Van der Baan FH, Schellekens H, Gaillard CAJM. Hemoglobin variability in patients with chronic kidney disease in the Netherlands. Int J Artif Organs. 2009;32:787-793.

Van Dyke DC, Layrissse M, Lawrence JH, Garcia JF, Pollycove M. Relation between severity of anemia and erythropoietin titer in human beings. Blood. 1961;18:187-201.

Van Iperen CE, Gaillard CAJM, Kraaijenhagen RJ, Braam BG, Marx JJM, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. *Critical Care Medicine*. 2000;28(8):2773-2779.

Van Stone JC. Who should receive recombinant human erythropoietin? *Seminars in Nephrology*. 1989;9(1) suppl 2:3-7.

Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. *Nephrol Dial Transplant*. 2004;19:561-565.

Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. *Kidney International*. 2005;68:2846-2856.

Vanrenterghem Y, Bárány P, Mann JFE, Kerr PG, Wilson J, Baker NF, Gray SJ. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. *Kidney International*. 2002;62:2167-2175.

Vanrenterghem Y, Waer M, Roels L, Coosemans W, Christaens M, Opelz G. A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. *Transplant International*. 1994;(Suppl 1):S243-S246.

Vaziri ND, Ritchie C, Brown P, Kaupke J, Atkins K, Barker S, Hyatt J. Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients. *Trans Am Soc Artif Intern Organs*. 1989;35:505-508.

Vaziri ND, Kaupke CJ, Barton CH, Gonzalez E. Plasma concentration and urinary excretion of erythropoietin in adult nephritic syndrome. *American Journal of Medicine*. 1992;92:3540.

Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. *Seminars in Nephrology*. 2004;24:469-473.

Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. *Am J Nephrol*. 1992;12:68-72.

Vigano G, Benigni A, Medogni D, Mingardi G, Mecca G, Remuzzi G. Recombinant human erythropoietin to correct uremic bleeding. *Am J Kidney Dis*. 1991;18(1):44-49.

Vincent J, Spapen H, Creteur J, Piagnerelli M, Hubloue I, Dilloer M, et al. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. *Crit Care Med*. 2006;34(6):1661-1667.

Virof JS, Janin G, Guillaumie J, Michel P, Dubot P, Chevet D, Rifle G. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? *Am J Kidney Dis.* 1996;28(3):400-408.

Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai C, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. *NEJM.* 2008;359:242-251.

Walker RG, Strippoli GF. A pegylated epoetin in anaemia of renal disease: non-inferiority for an unvalidated surrogate. *Lancet.* 2007;370(9596):1395-1396.

Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W. Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. *Kidney International.* 1987;31:1205-1209.

Wallner SF, Kurnick JE, Ward HP, Vautrin R, Alfrey AC. The anemia of chronic renal failure and chronic diseases: in vitro studies of erythropoiesis. *Blood.* 1976;47(4):561-569.

Wallner SF, Vautrin RM, Kurnick JE, Ward HP. The effect of serum from patients with chronic renal failure on erythroid colony growth in vitro. *J Lab Clin Med.* 1978;92(3):370-375.

Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. *Vox Sanguinis.* 2010;98:2-11.

Wann-Hansson C, Klevsgård R, Hagell P. Cross-diagnostic validity of the Nottingham health profile index of distress (NHPD). *Health and Quality of Life Outcomes.* 2008;6:47.

Ward HJ, Sun CH, Paul WL, Koyle MA, Yanagawa N, Lee DBN. Erythropoietin in renal transplant recipients: studies based on recombinant human erythropoietin radioimmunoassay. *Transplantation Proceedings.* 1989;21(1):2041-2042.

Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). *Medical Care.* 1992;30(6):473-483.

Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. *The American Journal of Medicine.* 1990;89:432-435.

Weber WW. Pharmacogenetics: from description to prediction. Clin Lab Med. 2008;28:499-511.

Weiner DE, Miskulin DC. Anemia management in chronic kidney disease: bursting the hemoglobin bubble. Ann Intern Med. 2010;153:53-55.

Weinhandl ED, Peng Y, Gilbertson DT, Bradbury BD, Collins AJ. Hemoglobin variability and mortality: confounding by disease severity. Am J Kidney Dis. 2011;57(2):255-265.

Weiss LG, Clyne N, Fihlho JD, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β : results from a randomized controlled multicentre trial. Nephrol Dial Transplant. 2000;15:2014-2019.

Weiss G, Goodnough LT. Anemia of chronic disease. NEJM. 2005;352:1011-1023.

Wells AW, Llewelyn CA, Casbard A, Johnson AJ, Amin M, Ballard S, et al. The EASTR study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service. Transfusion Medicine. 2009;19:315-328.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland G. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4278.

Williams AJ, Ford D, Casula A, Tomson CR. UK renal registry 11th annual report: chapter 8 adequacy of haemodialysis in UK renal centres in 2007: national and centre-specific analyses. Nephron Clin Pract. 2009;111(suppl 1): c141-c147.

Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25(3):433-439.

Wizemann V, Brune T, Kramer W, Schäfer R, Schütterle G. Recombinant human erythropoietin expressed in C-127 mouse cells: efficacy, side-effects and cardiovascular actions. Nephrol Dial Transplant. 1991;Suppl 2:122-125.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Current Medical Research and Opinion. 2008;24(3):625-637.

Wolff M, Jelkmann W. Erythropoiesis and erythropoietin levels in renal transplant recipients. Klin Wochenschr. 1991;69:53-58.

Wood DM, Thomson AH, Lawes M, Jones AL, Dargan PI. Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child. *The Drug Monit.* 2005;27(4):405-408.

Woodburn KW, Schatz PJ, Fong K-L, Beaumier P. Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide™ administration in cynomolgus monkeys. *International Journal of Immunopathology and Pharmacology.* 2010;23(1):121-129.

Wrighton NC, Balasubramanian P, Barbone FP, Kashyap AK, Farrell FX, Jolliffe LK, Barrett RW, Dower WJ. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. *Nature Biotechnology.* 1997;15:1261-1265.

Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. *J Am Soc Nephrol.* 1999;10:1309-1316.

Yagil Y. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. *Isr J Med Sci.* 1997;33:36-44.

Yamazaki T, Kanzaki M, Kamidono S, Fujisawa M. Effect of erythropoietin on Leydig cell is associated with the activation of Stat5 pathway. *Molecular and Cellular Endocrinology.* 2004;213:193-198.

Yang S, Kuo P, Wang J, Lin M, Su S. Quality of life and its determinants of hemodialysis patients in Taiwan measured with WHOQOL_BREF (TW). *Am J Kid Dis.* 2005;46(4):635-641.

Yee J, Besarab A. Iron sucrose: the oldest iron therapy becomes new. *American Journal of Kidney Diseases.* 2002;40(6):1111-1121.

Yu AW, Leung CB, Li PKT, Lui SF, Lai KN. Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha. *The International Journal of Artificial Organs.* 1998;21(6):341-343.

Yu JM, Shord SS, Cuellar S. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia. *J Oncol Pharm Pract.* 2010;1-6.

Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. *Kidney International.* 2004;66:144-156.

Zachée P, Ferrant A, Daelemans R, Coolen L, Goossens W, Lins RL, Couttenye M, De Broe ME, Boogaerts MA. Oxidative injury to erythrocytes, cell rigidity the splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment. *Nephron*. 1993;65:288-293.

Zadražil J, Horák P, Horčíčka V, Zahálková J, Štrébl P, Hruby M. Endogenous erythropoietin levels and anemia in long term renal transplant recipients. *Kidney Blood Press Res*. 2007;30:108-116.

Zanen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, de Jong GMT. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. *Nephrol Dial Transplant*. 1996;11:820-824.

Zappacosta AR, Caro J, Erslev A. Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. *The American Journal of Medicine*. 1982;72:53-57.

Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? *CMAJ*. 2008;179(4):333-337.

Zehnder C. Erythropoietin treatment: influence of haemoglobin concentration on dialyser creatinine clearance in haemodialysed patients. *Nephron*. 1989;51:424-425.

Zehnder C, Blumberg A. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration. *Nephron*. 1991;57:485-486.

Zehnder C, Blumberg A. The treatment of anemia of hemodialysis patients. *Schweiz Med Wochen*. 1990;120(7):217-220.

Zeier M, Jones E, Ritz E. Autosomal dominant polycystic kidney disease-the patient on renal replacement therapy. *Nephrol Dial Transplant*. 1996;11[Suppl 6]:18-20.

Zhang Y, Thamer M, Cotter D, Kaufmann J, Hernán MA. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. *Clin J Am Soc Nephrol*. 2009;4:638-644.

Zwezdaryk KJ, Coffelt SB, Figueroa YG, Liu J, Phinney DG, LaMarca HL, et al. *Experimental Hematology*. 2007;35:640-652.

[Back to Top](#)